## Table of Contents

### Sunday 9 July 2017
- Poster Session 1 ................................................................. 8:00-8:30
- Oral Abstracts ............................................................................. 9:00-10:00
- Oral Posters .............................................................................. 10:30-12:00
- Poster Viewing ........................................................................... 12:00-14:00
- Oral Abstracts ............................................................................. 14:30-15:30
- Oral Posters .............................................................................. 15:30-17:00
- Hot Topics Symposium ................................................................. 18:00-19:00
- Poster Session 1 ........................................................................ 17:00-17:30

### Monday 10 July 2017
- Poster Session 2 ......................................................................... 8:00-8:30
- Oral Abstracts ............................................................................. 9:00-10:00
- Oral Posters .............................................................................. 10:30-12:00
- Poster Session 2 ......................................................................... 13:00-14:00

### Tuesday 11 July 2017
- Poster Session 3 ......................................................................... 8:00-8:30
- Oral Abstracts ............................................................................. 9:00-10:00
- Oral Posters .............................................................................. 10:30-12:00
- Oral Abstracts ............................................................................. 14:30-15:30
- Oral Posters .............................................................................. 15:30-17:00
- Poster Session 3 ......................................................................... 17:00-17:30

### Wednesday 12 July 2017
- Poster Session 4 ......................................................................... 8:00-8:30
- Oral Abstracts ............................................................................. 9:00-10:00
- Oral Posters .............................................................................. 10:30-12:00
- Poster Viewing .......................................................................... 12:00-14:00
## SATURDAY 8 JULY 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.30 - 12.00</td>
<td>Individual Meetings 1: CMTR and INC</td>
</tr>
<tr>
<td>12.00 - 13.30</td>
<td>PNS Board Meeting 1</td>
</tr>
<tr>
<td>12.00 - 13.30</td>
<td>Lunch</td>
</tr>
<tr>
<td>14.00 - 18.00</td>
<td>Education Course</td>
</tr>
<tr>
<td>18.00 - 20.00</td>
<td>PNS Opening Ceremony</td>
</tr>
<tr>
<td>20.00 - 20.30</td>
<td>Put up Posters for Poster Session 1</td>
</tr>
</tbody>
</table>

## SUNDAY 9 JULY 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.30 - 8.30</td>
<td>Clinical Trial Updates</td>
</tr>
<tr>
<td></td>
<td>Coffee + Poster Viewing</td>
</tr>
<tr>
<td></td>
<td>Poster Session 1 (see end of Sunday for poster titles)</td>
</tr>
</tbody>
</table>
8.30 - 9.00
Plenary 1: Elior (Ori) Peles - RP Bunge Lecture
MOLECULAR ASPECTS OF THE FORMATION/MAINTENANCE OF THE NODE OF RANVIER

9.00 - 10.00
Oral Abstracts

9.00
O1_1
A NOVEL CMT2P MISSENSE MUTATION IN THE RING DOMAIN OF LRSAM1 IMPAIRS NUCLEAR TRANSLOCATION OF RNA-BINDING PROTEINS
Jun Li
(1) Hu B, (1) Arpag S, (2) Zuchner S, (1) Li J. (1) Department of Neurology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA; (2) Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.

9.15
O1_2
A RAT MODEL OF CMT2A DEVELOPS A PROGRESSIVE NEUROPATHY
Steven Scherer
(1) Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; (2) PsychoGenics, Tarrytown, NY, USA; (3) California Institute of Technology, Pasadena, CA, USA; (4) Renovo Neural Inc, Cleveland, OH, USA; (5) University of Wisconsin, Madison, WI, USA; (6) HumanFirst Therapeutics LLC, Silver Spring, MD, USA

9.30
O1_3
TRANSCRIPTIONAL AND TRANSLATIONAL PROFILING AND PRECLINICAL TESTING IN GARS/CMT2D MOUSE MODELS.
Robert Burgess
Burgess RW1,2, Morelli, KH1,2, Spaulding EL1,2, and Seburn KL.1 1The Jackson Laboratory, Bar Harbor, Maine, 04609 USA. 2The Graduate School of Biomedical Science and Engineering, University of Maine, Orono, ME 04469 USA.

9.45
O1_4
RALGTPASES CONTROL SCHWANN CELL’S REPAIR FUNCTION AFTER NERVE INJURY BY CONTROLLING LAMELLIPODIA FORMATION
Jorge Galino

10.00 - 10.30
Coffee
## Oral Posters

### OP1_1
**Nodes of Ranvier in Skin Biopsies of Patients with Diabetes Mellitus**

Claudia Sommer  
(1) Department of Neurology, University Hospital Würzburg, Würzburg, Germany, (2) Endocrinology and Diabetes Unit, Department of Medicine I, University Hospital Würzburg, Würzburg, Germany

### OP1_2
**Altered Potassium Channel Distribution and Composition in Myelinated Axons Suppresses Hyperexcitability Following Injury**

Margarita Calvo  
(1) Pontificia Universidad Catolica de Chile, Santiago, Chile; (2) Wolfson CARD, Kings College London, UK (3) NDCN Oxford University, UK (4) UT Health Science Center, San Antonio, TX, USA

### OP1_3
**N-Methyl-D-Aspartate Receptor (NMDA-R) Activated Cell-Signaling in Response to Glutamate in Schwann Cells**

Wendy Campana  
Campana WM1,3, Mantuano E2,4, Azmoon P2, Henry K1, Shibayama M1, Kim J1, Pizzo D2, Banki M2, Gonias SL2. Departments of 1Anesthesiology and 2Pathology and the 3Program in Neurosciences, University of California, San Diego School of Medicine, La Jolla, CA, USA; 4Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

### OP1_4
**Mild ERK/MAPK Activation in Adult Schwann Cells Negatively Affects Axon Survival, Myelin Stability and Small Fibres Reinnervation After Nerve Injury.**

Ilaria Cervellini  
(1) Cervellini I, (1) Galino J, (1) Zhu N, (2) Birchmeier C, (1) Bennett DL. (1) NDCN University of Oxford, Oxford, UK; (2) Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.

### OP1_5
**Autoantibodies to Nodal Isoforms of Neurofascin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy**

Emilien Delmont  
(1, 2)Delmont E, (2)Manso C, (3)Querol L, (4)Cortese A, (4)Berardinelli A, (2)Belghazi M, (5)Malissart P, (5)Labauge P, (5)Taieb G, (6)Yuki N, (3)Illa I, (1)Attarian S, (2)Devaux J. (1)Referral Center for ALS and Neuromuscular Diseases, La Timone University Hospital, Aix-Marseille University, France. (2)Aix-Marseille Université, CNRS, CRN2M-UMR7286, Marseille, France. (3)Neuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. (4)IRCCS, C. Mondino National Neurological Institute, Pavia, Italy. (5)Department of Neurology, Gui de Chauliac Hospital, Montpellier University Hospital Center, Montpellier, France. (6)Department of Neurology, Mishima Hospital, Niigata, Japan.

### OP1_6
**Anti-NFASC155 IgG4 Affect Paranode Structure in Animal Models**

Jerome Devaux  
(1) Manso C, (2) Querol L, (1) Mekaouche M, (2) Illa I, (1) Devaux J. (1) Aix-Marseille Université, CNRS, CRN2M-UMR7286, Marseille, France; (2) Neuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
OP1_7 MUTATIONAL BURDEN ANALYSIS IN INHERITED PERIPHERAL NEUROPATHIES
Dana Bis

OP1_8 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES POTENTIAL GENETIC MODIFIERS IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
Feifei Tao
(1) Tao F, (1) Beecham G, (1) Blanton S, (1) Abreu L, Inherited Neuropathy Consortium, (2) Baas F, (3) Choi BO, (4) Pareyson D, (5) Reilly M, (6) Shy M, (1) Zuchner S. (1) Dr. J.T. MacDonald Department for Human Genetics, Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA; (2) Department of Genome Analysis, Academic Medical Centre, Amsterdam, The Netherlands; (3) Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; (4) Department of Clinical Neurosciences, C. Besta Neurological Institute, Milan, Italy; (5) MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK; (6) Department of Neurology, University of Iowa, Iowa City, Iowa, USA.

OP1_9 LECITHIN LONG TERM THERAPY AMELIORATE DISEASE PROGRESSION IN A RAT MODEL OF CHARCOT MARIE TOOTH DISEASE 1A
Tamer Abdelaal
1) Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany.2) University Medical Center Göttingen, Department of Clinical Neuropathology, Göttingen, Germany 3) 2University Medical Center Göttingen, Department of Clinical Neurophysiology, Göttingen, Germany

OP1_10 FUNCTIONAL VALIDATION OF NON-CODING VARIANTS OF GJB1 IN PATIENTS WITH CMTX1
Andrea Cortese
Cortese A (1), Manole A (2), Simone R (3), Ashokkumar B (2), Tomaselli PJ (1), Rossor AM (1), Laura M (1), Polke H (4), Poh R (4), Houlden H (2), Reilly MM (1). (1) MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, Queen Square, London, UK (2) Department of Molecular Neuroscience, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. (3) Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK. (4) Department of Neurogenetics, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, London, UK.

OP1_11 DEVELOPMENT AND PILOT TESTING OF A FUNCTIONAL OUTCOME MEASURE FOR ADULTS WITH CHARCOT MARIE TOOTH NEUROPATHY (CMT-FOM)
David Herrmann
Eichinger KJ(1), Burns J (2), Cornett K(2), Bacon C(3), Shepherd M(4), Mountain J(1), Sowden J(1), Shy R(5), Shy ME(3), Herrmann DN(1)

OP1_12 A MULTICENTRE RETROSPECTIVE STUDY OF CHARCOT-MARIE-TOOTH DISEASE TYPE 4B (CMT4B)
Davide Pareyson
SCHWANN CELL-SPECIFIC DELETION OF THE ENDOSONAL PI 3-KINASE VPS34 LEADS TO DELAYED RADIAL SORTING OF AXONS, ARRESTED MYELINATION, AND ABNORMAL ERBB2-ERBB3 TYROSINE KINASE SIGNALING.

Fred Robinson
Anne M. Logan1,2, Anna E. Mammel1,3, Danielle C. Robinson1,2, Andrea L. Chin1, Alec F. Condon1,2, and Fred L. Robinson1,4. 1 Jungers Center for Neurosciences Research, Department of Neurology, Oregon Health & Science University, Mail code L623, Portland, Oregon, 97239, U.S.A.; 2 Neuroscience Graduate Program, Oregon Health & Science University, Portland, Oregon, 97239, U.S.A.; 3 Cell, Developmental & Cancer Biology Graduate Program, Oregon Health & Science University, Portland, Oregon, 97239, U.S.A.; 4 Vollum Institute, Oregon Health & Science University, Portland, Oregon, 97239, U.S.A.

LIMITED SCHWANN CELL DIFFERENTIATION AS A PROTECTIVE MECHANISM IN CMT1B NEUROPATHY WITH ACTIVATED UNFOLDED PROTEIN RESPONSE

Francesca Florio
(1) Florio F, (1) Scapin C, (1) Ferri C, (2) Feltri M L, (2) Wrabetz L, (1) D’Antonio M. (1) (1) Myelin Biology Unit, San Raffaele Scientific Institute, Milan, Italy; (2) HJKRI-University of Buffalo, NY, USA 14203.

OPTIMIZING GENE EXPRESSION ANALYSIS IN CMT1A SKIN BIOPSIES.

John Svaren
(1) Svaren J, (1) Moran JJ, (2) Wu X, (2) Gutmann L, (2) Shy M

12.00 - 14.00 Lunch + Poster Viewing

12.00 - 14.00 Poster Viewing

14.00 - 14.30 Plenary 2: Illa Isabel - AK Asbury Lecture
CLINICAL ASPECTS AND NEW ANIMAL MODELS OF AUTO-IMMUNITY TO NODAL COMPONENTS

14.30 - 15.30 Oral Abstracts

TREATMENT RELATED FLUCTUATIONS AND ACUTE-ONSET CIDP IN THE IGOS COHORT

Carina Bunschoten
(1) Bunschoten C, (1) Miry F, (2) Vytopil M, (1) van Doorn PA, (1,3) Jacobs BC, the IGOS Consortium.  (1) Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands; (2) Department of Neurology, Lahey Hospital & Medical Center, Burlington, USA; (3) Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.
PARANODAL DISSECTION IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY WITH ANTI-NEUROFASCIN 155 AND ANTI-CONTACTIN 1 ANTIBODIES

Haruki Koike,1 Masato Kadoya,2 Ken-ichi Kaida,2 Shohei Ikeda,1 Yucichi Kawagashira,1 Masahiro Iijima,1 Daisuke Kato,3 Hidenori Ogata,4 Ryo Yamasaki,4 Noriyuki Matsukawa,3 Jun-ichi Kira,4 Masahisa Katsuno,1 and Gen Sobue 1,5 1Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan 2 Division of Neurology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan. 3 Department of Neurology and Neuroscience, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan 4 Department of Neurology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan 5Research Division of Dementia and Neurodegenerative Disease, Nagoya University Graduate School of Medicine, Nagoya, Japan.

ANTI-GM1 ANTIBODY MEDIATED MODELS OF AXONAL AND DEMYELINATING GBS IN GLYCOSYLTRANSFERASE-MODIFIED TRANSGENIC MICE.

Rhona McGonigal
McGonigal R1, Yao D1, Barrie JA1, Crawford C 1, Willison HJ1. 1University of Glasgow, Glasgow, United Kingdom

INVESTIGATION OF SERUM ANTIBODIES AGAINST GLYCOLIPIDS AND GLYCOLIPID COMPLEXES IN IMMUNE-MEDIATED NEUROPATHIES BY COMBINATORIAL GLYCOARRAY

Susumu Kusunoki
Kusunoki S, Morikawa M, Kuwahara M, Ueno R, Samukawa M, Hamada Y. Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

INTERLEUKIN 10 DEFICIENCY PARADOXICALLY PROTECTS FROM SPONTANEOUS AUTOIMMUNE PERIPHERAL NEUROPATHY IN A MOUSE MODEL OF CIDP

Collin-Jamal Smith
(1) Smith C, (2) Trout D, (3) Montgomery S, (4) Howard J, (5) Su M. (1) University of North Carolina at Chapel Hill, Chapel Hill, USA; (2) University of North Carolina at Chapel Hill, Chapel Hill, USA; (3) University of North Carolina at Chapel Hill, Chapel Hill, USA; (4) University of North Carolina at Chapel Hill, Chapel Hill, USA; (5) University of North Carolina at Chapel Hill, Chapel Hill, USA.

Ca(2+)-DEPENDENT ANTI-GQ1B ANTIBODY IN FISHER SYNDROME: DETECTION AND INSIGHT INTO THE MOLECULAR MECHANISM.

Atsuro Chiba
Chiba A, Uchibori A, Gyohda A. Kyorin University, Tokyo, Japan.

JAPANESE ECULIZUMAB TRIAL FOR GUILLAIN- BARRÉ SYNDROME (JET-GBS)

Satoshi Kuwabara
Department of Neurology, Chiba University, Chiba, Japan.
ANTIBODIES TO NEUROFASCIN155 IN CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY: DIAGNOSTIC UTILITY OF A CONVENTIONAL ASSAY

Kenichi Kaida
(1) Kaida K, (1) Kadoya M, (2) Koike H, (2) Takazaki H, (3) Ogata H, (1) Moriguchi K, (4) Shimizu J, (5) Nagata E, (5) Takizawa S, (6) Chiba A, (3) Yamasaki R, (3) Kira J-i, (2) Sobue G, (1) Ikewaki K. (1) National Defense Medical College, Tokorozawa, Japan; (2) Nagoya University Graduate School of Medicine, Nagoya, Japan ; (3) Kyushu University, Fukuoka, Japan; (4) University of Tokyo, Tokyo, Japan; (5) Tokai University School of Medicine, Isehara, Japan; (6) Kyorin University, Tokyo, Japan

CLINICAL AND PATHOLOGICAL FEATURES IN FOUR PATIENTS WITH ANTI-NEUROFASCIN 155 IGG4 ANTI-BODY-POSITIVE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

Motoi Kuwahara
(1) Kuwahara M, (2) Oka N, (3) Ogata H, (1) Suzuki H, (1) Yanagimoto S, (1) Sadakane S, (1) Fukumoto Y, (1) Yamana M, (1) Yuhara Y, (1) Yoshikawa K, (1) Morikawa M, (1) Kawai S, (3) Kira J, (1) Kusunoki S. (1) Department of Neurology, Kindai University Faculty of Medicine, Osaka, Japan; (2) Department of Neurology, National Hospital Organization Minami-Kyoto Hospital, Kyoto, Japan; (3) Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

FREQUENCY AND ACTIVATION STATUS OF MYELOID CELLS IN THE GUILLAIN-BARRÉ SYNDROME

Ruth Huizinga
Wouter van Rijs, Willem Jan Fokkink, Anne Tio-Gillen, Maarten Brem, Bart Jacobs and Ruth Huizinga. Departments of Immunology and Neurology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands.

ANTI-FGFR3 ANTIBODIES AND SENSORY-NEUROPATHY. A FRENCH PROSPECTIVE STUDY.

Jean-Christophe Antoine
Tholance Y,1 Rosier C,1 F Bouhour,2 Psimaros D,3 Kuntzer T,4 Taieb G,5 Créange A,6 Delmont E,7 Camdessanché JP,1 Antoine JC.1 1 University Hospital, Saint-Etienne, France; 2 University Hospital, Lyon, France; 3 University Hospital, Paris, France; 4 University Hospital, Lausanne, Switzerland; 5 University Hospital, Montpellier, France; 6 University Hospital, Creteil, France ; 7 University Hospital, Marseille, France.

EVALUATION OF DERMAL NERVE FIBERS IN CIDP NODO-PARANODOPATHY PATIENTS

Raffaella Lombardi
(1) Lombardi R, (2) Devaux J, (3) Cortese A, (1) Dacci P, (4) Benedetti L, (4) Demichelis C, (1) Lauria G. (1) IRCCS Foundation “Carlo Besta” Neurological Institute, Milan, Italy; (2) Aix-Marseille Université, Marseille, France; (3) IRCCS C. Mondino National Neurological Institute, Pavia, Italy; (4) University of Genova and IRCCS AOU San Martino-IST, Genova, Italy

IN VIVO IMAGING OF EPIDERMAL NERVE FIBERS

Gang Zhang
Gang Zhang, Pradip Ghosh, Jianxin Lin, Sameera Ghauri, and Kazim A. Sheikh; Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
OP2_10
INTERNATIONAL SECOND IMMUNOGLOBULIN DOSE IN PATIENTS WITH GUILLAIN-BARRÉ SYNDROME WITH POOR PROGNOSIS (I-SID GBS), A PROSPECTIVE OBSERVATIONAL STUDY.
Christine Verboon
(1) Verboon C, (1) van den Berg B, (2) Cornblath DR, (1) Walgaard C, (3) Gorson KC, (4) Lunn MP, (5) Hartung HP, (6) Steyerberg EW, (6) Lingsma H, (1, 7) Jacobs BC, (1) van Doorn PA, the IGOS Consortium. (1) Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands (2) Department of Neurology, Johns Hopkins University, Baltimore, USA (3) Department of Neurology, Tufts University School of Medicine, Boston, USA (4) MRC Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London, UK (5) Department of Neurology, Heinrich Heine Universität, Düsseldorf, Germany (6) Department of Public Health, Erasmus Medical Centre, Rotterdam, The Netherlands (7) Department of Immunology, Erasmus Medical Centre, Rotterdam, The Netherlands

OP2_11
FUNCTIONAL AND MORPHOLOGICAL CONSEQUENCES OF CELLULAR AND HUMORAL RESPONSES IN TREATMENT-NAIVE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: A COMBINED SONOGRAPHIC AND NERVE CONDUCTION STUDY
HS Goedee
(1,2) Goedee HS, (1,2) van der Pol WL, (1-3) Herraets IJT, (3) van Asseldonk JTH, (3) Visser LH, (1,2) van den Berg LH. (1) Department of Neurology, UMC Utrecht, Utrecht, The Netherlands (2) Brain Center Rudolf Magnus, Department of Neuroscience, UMC Utrecht, Utrecht, The Netherlands (3) Department of Neurology and Clinical Neurophysiology, St. Elisabeth Hospital, Tilburg, The Netherlands

OP2_12
RANDOMIZED CONTROLLED TRIAL OF ORAL FINGOLIMOD IN CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (FORCIDP TRIAL): PRIMARY AND SECONDARY OUTCOMES
Richard Hughes

OP2_13
EXPANDED B-CELL RECEPTOR CLONES ARE PRESENT IN PERIPHERAL BLOOD SAMPLES IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Gwen van Lieverloo
(1, 2) van Lieverloo G, (2) Musters A, (1) Adrichem M, (2) Esveldt R, (2) Dooresnpleet M, (2) Klarenbeek P, (1) van Schaik I, (2) de Vries N, (1) F. Eftimov (1) Academic Medical Center, Department of Neurology, Amsterdam, the Netherlands (2) Academic Medical Center/University of Amsterdam, Department of Clinical Rheumatology and Immunology, Amsterdam, the Netherlands

OP2_14
REGULATORY B CELL FREQUENCIES INCREASE AFTER IVIG THERAPY IN INFLAMMATORY NEUROPATHIES.
Ana Maria Siles
Siles AM 1,2, Assylbekova D1,2, Diaz-Manera J1,2, Rojas-Garcia R1,2, Cortes E1,2, Gallardo E1,2, Illa I1,2, Querol L1,2. 1 Neuromuscular Diseases Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona (Spain); 2 Centro para la Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid (Spain).

OP2_15
DEVELOPMENT OF A SUBACUTE ANTI-GANGLIOSIDE ANTIBODY-MEDIATED MOUSE MODEL OF GBS
Madeleine Cunningham
(1) Cunningham ME, (1) Yao D, (1) Meehan GR, (1) Barrie JA, (1) Willison HJ. (1) University of Glasgow, Glasgow, United Kingdom
Coffee + Poster Viewing

Hot Topics Symposium

18.00 - 18.15
**SUBCUTANEOUS IMMUNOGLOBULIN FOR MAINTENANCE TREATMENT IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP), A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL: THE PATH STUDY**

Ivo van Schaik
(1) van Schaik IN, (2) Bril V, (3) van Geloven N, (4) Hartung H-P, (5) Lewis RA, (6) Sobue G, (7) Lawo J-P, (7) Mielke O, (7) Durn BL, (8) Cornblath DR, (9) Merkies ISJ and on behalf of the PATH study group. (1) Department of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; (2) Department of Medicine (Neurology), University Health Network, University of Toronto, Toronto, Canada; (3) Department of Biostatistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands; (4) Department of Neurology, Heinrich Heine University, Düsseldorf, Germany; (5) Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; (6) Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan; (7) CSL Behring, Marburg, Germany and King of Prussia, PA, USA; (8) Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; (9) Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands.

18.15 - 18.30
**Thalidomide therapy for POEMS syndrome: a multicenter, randomized, double blind, placebo controlled trial with long-term extension study**

Sonoko Misawa
(1) Misawa S, (2) Sato Y, (2) Katayama K, (1) Sekiguchi Y, (1) Amino H, (1) Suichi T, (1) Kuwabara S, and J-POST trial study group. (1) Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan;  (2) Clinical Research Center, Chiba University Hospital, Chiba, Japan

18.30 - 18.45
**EFFECT OF PATISIRAN ON NERVE FIBER DENSITY AND AMYLOID CONTENT IN SKIN: RESULTS FROM PHASE 2 OPEN LABEL EXTENSION (OLE) STUDY IN hATTR AMYLOIDOSIS**

Michael Polydefkis
18.45  MRI QUANTIFICATION OF INTRAMUSCULAR FAT ACCUMULATION IN CMT1A: FOUR YEAR FOLLOW UP DATA

Jasper Morrow
(1) Evans ME, (1) Morrow JM, (2) Wastling S, (2) Sinclair CDJ, (3) Fischmann A, (2) Shah S, (2) Emira AK, (1) Hanna MG, (2) Youser TA, (2) Thornton JS, (1) Reilly MM. (1) MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK; (2) Neuroradiological Academic Unit, UCL Institute of Neurology, London, UK; (3) University of Basel Hospital, Basel, Switzerland

19.00 - 20.00  Sponsor Symposia 1: Alnylam and Grifols

19.00 - 20.00  Poster Session 1

P1_1  ANATOMICAL AND NEUROPHYSIOLOGICAL INVESTIGATIONS IN QUADRILATERAL SPACE SYNDROME

Micaela Pauni
(1,3) Bendersky M, (2) Ranaletta M, (3) Postan D (2), (1) Pauni M, (3) Tanoira I, (1) Poitevin L (1) Normal Anatomy Department, School of medicine, University of Buenos Aires, Argentina; (2) Pediatric Neurology Department, Hospital Italiano de Buenos Aires, Argentina; (3) Orthopedics and Traumatology Department, Hospital Italiano de Buenos Aires, Argentina.

P1_2  STOP NEUROMA: SURGICAL TREATMENT OF SYMPTOMATIC NEUROMA

Marietta Bertleff
Bertleff, PhD, MD, MScBA

P1_3  THE RELATIONSHIP BETWEEN MEDIAN SENSORY CONDUCTION OF MEDIAN NERVE AND ULNAR NERVE IN PATIENTS WITH CARPAL TUNNEL SYNDROME

Gulnihal Kutlu
(1) Unal Y, (2) Ozturk DA, (3) Emir GK, (4) Tosun K, (5) Kutlu G (1) Mugla Sitki Kocman University Faculty of Medicine, Department of Neurology, Mugla, Turkey (2) Mugla Sitki Kocman University Faculty of Medicine, Department of Neurology, Mugla, Turkey (3) Mugla Sitki Kocman University Faculty of Medicine, Department of Neurology, Mugla, Turkey (4) Mugla Sitki Kocman University Faculty of Medicine, Department of Biostatistics, Mugla, Turkey (5) Mugla Sitki Kocman University Faculty of Medicine, Department of Neurology, Mugla, Turkey

P1_4  PAIN-RELATED SEP AFTER SELECTIVE A-DELTA- AND C-FIBER STIMULATION IN PATIENTS WITH NEUROPATHIC PAIN AND ITS POST-TREATMENT CHANGES

Sagiri Iose

P1_5  USEFULNESS OF VARIOUS ULTRASONOGRAPHIC FINDINGS IN CARPAL TUNNEL SYNDROME

Hee Ju Kim
(1) Kim HJ, (2) Hyun JK, (3) Kim TU. (1) Dankook University, Cheonan, South Korea (2) Dankook University, Cheonan, South Korea (3) Dankook University, Cheonan, South Korea.
DOPPLER ULTRASONOGRAPHY FINDING BETWEEN PRE- AND POST- OPERATION IN CARPAL TUNNEL SYNDROME

Yasufumi Sekiguchi, Shin-ichi Kikuchi, Shin-ichi Konno and Miho Sekiguchi

THE RELATIONSHIP BETWEEN CENTRAL AORTIC SYSTOLIC PRESSURE, PERIPHERAL BLOOD PRESSURE AND SYMPTOMATIC IN PATIENTS WITH AUTONOMIC DYSFUNCTION

Julia Ng

DEFINITION AND DIAGNOSIS OF SMALL FIBER NEUROPATHY (SFN): RECOMMENDATIONS FROM THE BRAZILIAN ACADEMY OF NEUROLOGY

Francisco Gondim

PHASE 1 BIOEQUIVALENCY STUDIES OF NEUROPATHIC PAIN MEDICATIONS

ZAFER SEZER

ULTRASOUND FINDING IN ACUTE DIABETIC LUMBOSACRAL RADICULOPLEXUS NEUROPATHY

Jae Young An

OCCURRENCE OF DIABETIC FOOT BY NCS-SEVERITY OF DIABETIC NEUROPATHY: A 5-YEAR PROSPECTIVE OBSERVATION

Masayuki Baba

MITOCHONDRIAL OXODICARBOXYLATE CARRIER DEFICIENCY: METABOLIC MODELLING IDENTIFIES DISEASE MECHANISM

Veronika Boczonadi

RATS BRED FOR LOW AND HIGH RUNNING CAPACITY MAY OFFER A NEW MODEL OF INFLAMMATORY PAIN

Michael Cooper
P1_14  CAPILLARY DYSFUNCTION IN THE DEVELOPMENT OF DIABETIC PERIPHERAL NEUROPATHY IN ANIMAL MODELS
Anete Dudele
(1,2) Dudele A, (1) Gutiérrez Jiménez E, (1) Iversen NK, (3) Frische S, (2,4) Jensen TS, (1,5) Østergaard L. (1) Center for Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark; (2) International Diabetic Neuropathy Consortium, Aarhus University, Aarhus, Denmark; (3) Department of Biomedicine, Aarhus University, Aarhus, Denmark; (4) The Danish Pain research Centre, Aarhus University Hospital, Aarhus, Denmark; (5) Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark.

P1_15  MEDIAN NERVE ULTRASOUND MORPHOLOGY CADAVER SCREENING
Anna Grisold
Hamscha U1, Grisold A2, Grisold W3, Meng S1,4
1 Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria
2 Department of Neurology, Medical University of Vienna, Vienna, Austria
3 Ludwig Boltzmann Institute for Experimental und Clinical Traumatology, Vienna, Austria
4 Department of Radiology, Kaiser Franz Joseph Hospital, Vienna, Austria

P1_16  CHARACTERIZING IN VITRO MODELS OF TYPE 2 DIABETIC PERIPHERAL NEUROPATHY
Marc Leal Julià
(1,2) Leal-Julià M, (2) Pagès G, (1,3,4) Casas C, (1,2,5,6) Chillón M, (1,2,4) Bosch A 1Neurociències Institute, UAB, 2Biochemistry and Molecular Biology Department, UAB, 3Cell Biology, Physiology and Immunology Department, UAB, 4Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CiberNed), Instituto de Salud Carlos III, 5Institut Català de Recerca i Estudis Avançats (ICREA), 6Unitat Mixta UAB-VHIR, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain.

P1_17  IN VITRO EFFECTS OF PURE GLYPHOSATE VS. GLYPHOSATE-BASED HERBICIDE ON PERIPHERAL NERVOUS SYSTEM MYELINATION
Leon-Phillip Szepanowski
(1) Szepanowski LP, (1) Szepanowski F, (1) Kleinschnitz C, (1) Stettner M. (1) Department of Neurology, University Hospital Essen, Essen, Germany

P1_18  CHARACTERIZATION OF THE DENDRITIC ARBOR AND THE SPINAL CHANGES THAT POSTNATAL MOTONEURONS SUFFER AFTER A PERIPHERAL NERVE INJURY
Esther Udina
(1) Arbat-Plana A, (2) Rotterman TM, (1) Navarro X, (2) Alvarez FJ, (1) Udina E1. (1) Institute of Neurosciences, Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Bellaterra, Spain; (2) Department of Physiology, Emory University, Atlanta, Georgia 30322.

P1_19  THE FORGOTTEN CELL TYPE IN NEUROPATHIC PAIN: SATELLITE GLIAL CELLS
Sara B. Jager
(1) Jager SB, (2) Denk F, (1) Richner M, (1) Goncalves N, (1) Pallesen LT, (2) McMahon S, (1) Vægter CB (1) Department of Biomedicine, Aarhus University, Aarhus, Denmark (2) King’s College London, London, United Kingdom

P1_20  NEUROTOXICITY OF PACLITAXEL: IMPACT OF NANOPARTICLE - AND SOLVENT - BASED FORMULATION
Ines Klein
(1)(2) Klein I, (1)(2) Bobylev I, (1)(2) Lehmann HC. (1) University Hospital Cologne, Cologne, Germany; (2) Center for Molecular Medicine Cologne (CMMC), Cologne, Germany.
P1_21  ELECTRICAL STIMULATION AS A CONDITIONING LESION FOR PROMOTING PERIPHERAL NERVE REGENERATION

Jenna-Lynn Senger
(1)JL Senger, (1)KM Chan, (1)JL Olson, (1)CA Webber. (1)University of Alberta, Edmonton Canada

P1_22  OBESITY ATTENUATES EPIDERMAL NERVE FIBERS IN THE DISTAL LIMB

Gigi Ebenezer
(1) Gigi J Ebenezer, (2) Shaun Truelove, (3) Michael Polydefkis (1) Neurology, Johns Hopkins University, Baltimore, MD, USA; (2)Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

P1_23  IMAGING OF THE LOWER CRANIAL NERVES (LCN) IN THE EXTRACRANIAL COURSE

Anna Grisold
Grisold W, Ludwig Boltzmann Institute for Experimental und Clinical Traumatology, Vienna, Austria; Finsterer J, Department of Neurology, Krankenanstalt Rudolfstiftung, Vienna, Austria; Meng S, Department of Radiology, Kaiser Franz Josef Hospital, Vienna, Austria, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria

P1_24  THE FUNCTIONAL IMPACT OF PERIPHERAL MYELIN PROTEIN 2 (PMP2) FOLLOWING Demyelination In Vitro And Vivo

Mark Stettner

P1_25  MARKED DECREMENT IN CMAP AMPLITUDE FOLLOWING PROLONGED EXERCISE IN SECONDARY HYPOKALEMIC PARALYSIS

Sung-Yeon Sohn
Sohn S-Y1, Lee SJ1, Hong JH2, Kim DK3. 1Department of Neurology, Eulji University Hospital, Daejeon, Republic of Korea; 2Department of Endocrinology, Eulji University Hospital, Daejeon, Republic of Korea; 3Department of Urology, Eulji University Hospital, Daejeon, Republic of Korea.

P1_26  THE FUNCTIONAL ROLE OF CONNEXINS IN PERIPHERAL MYELINATED FIBERS

Marianthi Tympanidou
Tympanidou M1, Kagiava A1, Kleopa KA1,2. (1) Neuroscience Laboratory and (2) Neurology Clinics, Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.

P1_27  FACIAL DIPLEGIA WITH BILATERAL FACIAL NERVE ENHANCEMENT AT 3T-MRI AND ANTI-GANGLIOSIDE ANTIBODIES

Marta Ruiz

P1_28  NEWLY DEVELOPED WALDENSTROM MACROGLOBULINEMIA DURING IMMUNOMODULATORY TREATMENT FOR ANTI-MAG ANTI-SULFATIDE CIDP

Valeria Serban
Serban V.
P1_29  LENALIDOMIDE-RESPONSIVE ANTI-MAG NEUROPATHY

Amro Stino
(1) Stino A, (2) Efebra Y; (1) Ohio State University Dept of Neurology, Columbus, USA, (2) Ohio State University Division of Hematology, Columbus, USA

P1_30  NEUROPATHY AND PRIMARY HEADACHES DO NOT AFFECT THE SAME SUBGROUPS OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)

Francisco Gondim
Leitão AMF1, 2; Araújo DF1; Marques H2; Pamplona L2,3; Gondim FAA2,4. 1Department of Anatomy, Universidade Federal do Ceará, Brazil; 2Unicristus, Fortaleza, Brazil; 3Department of Public Health, Universidade Federal do Ceará, Brazil; 4Department of Internal Medicine, Fortaleza, Brazil.

P1_31  THE ROLE OF IMMUNOGLOBULIN G FC-GAMMA RECEPTOR POLYMORPHISMS IN THE PATHOGENESIS OF GUILLAIN-BARRÉ SYNDROME IN BANGLADESH

Shoma Hayat
(1,2,3) Hayat S, (1) Babu MG, (1) Jahan I, (1) Rahman I, (3) Mahmud I, (2) Hassan Z, (1) Islam Z. (1)Laboratory Sciences and Services Division, International Centre for Diarrheal Disease Research (icddr,b), Dhaka, Bangladesh; (2)Department of Physiology and Molecular Biology, Bangladesh University of Health Sciences; Dhaka, Bangladesh; (3)Department of Biochemistry and Molecular Biology, University of Dhaka; Dhaka, Bangladesh.

P1_32  FUNCTIONAL FAS/FASL PROMOTER POLYMORPHISMS ASSOCIATED WITH INCREASED RISK OF NERVE DAMAGE IN GUILLAIN–BARRÉ SYNDROME IN BANGLADESH

Zhahirul Islam
(1) Jahan I, (2) Khalid MM, (1) Ahammad RU, (1) Shahnewaj, (3) Mohmmad QD, (1) Islam Z. (1)Laboratory Sciences and Services Division, International Centre for Diarrheal Disease Research (icddr,b), Dhaka, Bangladesh; (2) Department of Biochemistry, Erasmus University Medical Centre, Rotterdam, The Netherlands; (3) National Institute of Neurosciences and Hospital, Sher-e-Bangla Nagar, Agargaon, Dhaka, Bangladesh.

P1_33  RITUXIMAB IN INTRACTABLE CIDP

Bill Jacobsen

P1_34  THE BURDEN AND JOURNEY OF PATIENTS WITH CIDP: A CASE-CONTROL ANALYSIS

Girishanthy Krishnarajah
(1) Krishnarajah S, (2) Divino V, (1) Mallick R, (2) DeKoven M. (1) CSL Behring, King of Prussia, PA, USA; (2) QuintilesIMS, Fairfax, VA, USA.

P1_35  CORNEAL CONFOCAL MICROSCOPY IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHIES

Inn Lee
(1) Lee I, (2) Petropoulos JN, (3) Hartung HP, (1) Kleinschnitz CK, (4) Malik RA, (3) Kieseier BC, (1) Stettner M. (1) Department of Neurology, University Hospital Essen, Essen, Germany; (2) Centre for Endocrinology & Diabetes, Institute of Human Development, Faculty of Medical & Human Sciences, CMFT & University of Manchester, UK; (3) Department of Neurology, Medical Faculty, Heinrich-Heine-University, Dusseldorf, Germany; (4) Weil Cornell Medical College in Qatar, Education City, Doha, Qatar.
NEUROPATHY AND PRIMARY HEADACHES DO NOT AFFECT THE SAME SUBGROUPS OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)

Antonio Miguel Leitao
Leitao AMF1, 2; Araújo DF1; Marques H2; Pamplona L2,3; Gondim FAA,2,4. 1Department of Anatomy, Universidade Federal do Ceará, Brazil; 22Christus Universitary Center, Fortaleza, Brazil; 3Department of Public Health, Universidade Federal do Ceará, Brazil; 4Department of Internal Medicine, Fortaleza, Brazil.

ACUTE DEMYELINATING POLYNEUROPATHY RESEMBLING GUILLAIN-BARRE SYNDROME IN A PATIENT TAKING THE SLIMMING PRODUCT PURA ALEGRÍA®

Alicia Alonso-Jiménez
(1, 2) Alonso-Jiménez A, (3) Belvis-Nieto R, (1, 2) Diaz-Manera J, (1, 2) Illa I, (1, 2) Querol L. (1) Neuromuscular Diseases Unit. Neurology department. Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain (2) Centro para la Investigación Biomédica en Red para Enfermedades Raras, CIBERER, Madrid, Spain (3) Neurology department. Hospital Universitario Dexeus, Barcelona, Spain

ERAMUS GUILLAIN-BARRÉ SYNDROME RESPIRATORY INSUFFICIENCY SCORE IN JAPANESE PATIENTS

Hiroshi Amino

COEXISTENCE OF ACUTE DISSEMINATED ENCEPHALOMYELITIS AND GUILLAIN-BARRÉ SYNDROME WITH IG G ANTI-GT1A ANTIBODY POSITIVITY

Jong Seok Bae
(1) Lee JY, (2) Yoo JH, (3) Kang DK, (4) Bae JS. (1) Department of Neurology Hallym University, Seoul, Korea; (2) Department of Neurology Hallym University, Seoul, Korea; (3) Department of Neurology Hallym University, Seoul, Korea.

A COMPARISON OF CLINICAL AND ELECTROPHYSIOLOGICAL PROFILES IN POEMS SYNDROME AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

Seol-Hee Baek
(1) Baek S-H, (2) Byun JM, (3) Kim I, (4) Choi K, (5) Choi S-J, (5) Kwun K, (5) Shin J-Y, (5) Sung J-J, (6) Hong Y-H. (1) Department of Neurology, Korea University Anam Hospital, Seoul, Korea; (2) Department of Internal Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea; (3) Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; (4) Department of Neurology, Konkuk university medical center, Seoul, Korea; (5) Department of Neurology, Seoul National University Hospital, Seoul, Korea; (6) Department of Neurology, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea

INVESTIGATION OF THE VARIATION OF MOTOR CONDUCTION VELOCITY BY USING HOPF’S COLLISION TECHNIQUE IN CIDP PATIENTS

Jan Buermann
(1) Buermann J, (1) Singh P, (2) Rapp D, (1) Fassbender K, (1) Dillmann U. (1) Department of Neurology, Medical University of the Saarland, Homburg, Germany; (2) Institute for Medical Biometry, Epidemiology and Medical Informatics, Medical University of the Saarland, Homburg, Germany.

TOTAL COMPOUND MUSCLE ACTION POTENTIAL DURATION: A NEW USEFUL ELECTROPHYSIOLOGICAL MEASURE FOR EARLY GBS DIAGNOSIS

Giorgio Capoccitti
Capoccitti G1, Giannini F1, Ginanneschi F1, Casali S1, Insana L1, Rossi A1. 1 University of Siena, Siena, Italy
P1_43  CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY ASSOCIATED WITH LYMPHOMA: MONOCENTRIC STUDY.

Cécile Cauquil

P1_44  CONTRIBUTION OF PLEXUS MRI IN CIDP WITHOUT EFNS PNS DEFINITE ELECTROPHYSIOLOGICAL CRITERIA

Guillaume Fargeot

P1_45  SEMI-AUTOMATED MUSCLE MRI-VOLUMETRY FOR MYOPATHY AND NEUROPATHY PATIENTS

Burkhard Gess
(1) Müller M, Dohrn M, Romanzetti S, Reetz K, Gess B. (1) University RWTH Aachen, Department of Neurology, Aachen, Germany

P1_46  TREATMENT OF PARAPROTEINAEMIC NEUROPATHIES – A SINGLE-CENTRE AUDIT

Robert Hadden
(1, 3) Cruz-Veláquez G, (1) Mahdi-Rogers M, (2) Kazmi M, (1) Hadden RDM. (1) Neurology Department and (2) Haematology Department, King’s College Hospital, London, UK; (3) Department of Neurology, University Hospital Miguel Servet, Zaragoza, Spain.

P1_47  GUILLAIN BARRÉ SYNDROME IN A HO CHI MINH CITY, VIETNAM HOSPITAL

Nokia Hoang Tien Trong
(1) Hoang T.T.N, (2) Umapathi T.

P1_48  SUBACUTE INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY WITH TREATMENT-RELATED FLUCTUATIONS

Yoon-Ho Hong
Hong YH1, Choi SJ2, Yoon BN3, Sohn SY4, Baek SH2, Choi K2, Park KH5, Kwon KH2, Sung JJ2. 1Seoul National University-Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea; 2Seoul National University Hospital, Seoul, Korea; 3Inha University Hospital, Incheon, Korea; 4Eulji University Hospital, Daejeon, Korea; 5Gyeongsang National University Medical School, Jinju, Korea.

P1_49  MARKERS AND INTENSIVE THERAPIES FOR GUILLAIN- BARRÉ SYNDROME WITH POOR PROGNOSIS: A RETROSPECTIVE STUDY IN JAPAN

Yuko Yamagishi
(1) Yamagishi Y, (1) Suzuki H, (2) Sonoo M, (3) Kuwabara S, (4) Yokota T, (5) Nomura K, (6) Chiba A, (7) Kaji R, (8) Kanda T, (9) Kaida K, (10) Ikeda S, (11) Mutoh T, (12) Kira J, (13) Takashima H, (14) Matsu M, (15) Nishiyama K, (16) Sobue G, (1) Kusunoki S. (1) Department of Neurology, Kindai University, Osaka-sayama, Japan; (2) Teikyo University, Tokyo, Japan; (3) Chiba University, Chiba, Japan; (4) Tokyo Medical and Dental University, Tokyo, Japan; (5) Saitama Medical Center, Saitama Medical University, Saitama, Japan; (6) Kyorin University, Mitaka, Japan; (7) Tokushima University, Tokushima, Japan; (8) Yamaguchi University, Ube, Japan; (9) National Defense Medical College, Tokorozawa, Japan; (10) Shinshu University, Matsumoto, Japan; (11) Fujita Health University School of Medicine, Toyoake, Japan; (12) Kyushu University, Fukuoka, Japan; (13) Kagoshima University, Kagoshima, Japan; (14) Kanazawa Medical University, Kahoku-gun, Japan; (15) Kitazato University, Sagamihara, Japan; (16) Nagoya University, Nagoya, Japan.
P1_50  CHANGES OF SERUM IGG DIMER LEVELS AFTER TREATMENT WITH IVIG IN GUILLAIN-BARRÉ-SYNDROME
34204
Martin K. R. Svacina
Department of Neurology, University Hospital Cologne, Cologne, Germany; (2) Department of Neurology,
University of Texas, Houston, USA.

P1_51  COMPARISON OF TWO-YEAR RESPONSE TO LENALIDOMIDE OR PERIPHERAL BLOOD STEM-CELL TRANSPLANTATION IN PATIENTS WITH POEMS
34864
Mariangela Bianco
Bianco M (1), Terenghi F(1), Gallia F(1), Nozza A (2), Scarale A (1), Fayourmi MZ (1), Giannotta C(1), Morenghi E
(3), Nobile-Orazio E (1). (1)Department of Medical Biotechnology and Translational Medicine, Milan University,
Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Center; (2) Department of
Medical Oncology and Hematology, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy; (3) Biostatistic
Unit, Humanitas Clinical and Research Centre, Rozzano, Milan

P1_52  CLINICOPATHOLOGICAL FEATURES AMONG CIDP SUBTYPES
35156
Shohei Ikeda
of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan; (2) Research Division of Dementia
and Neurodegenerative Disease, Nagoya University Graduate School of Medicine, Nagoya, Japan.

P1_53  NEUROLOGICAL COMPLICATIONS IN MIDDLE EAST RESPIRATORY SYNDROME
34195
Jee-Eun Kim
(3) Choi JP*. (1) Department of Neurology, Seoul Medical Center, Seoul, Republic of Korea; (2) Division of
Pulmonology and Critical Care Medicine, Department of Internal Medicine, Seoul Medical Center, Seoul, Republic
of Korea; (3) Division of Infectious Diseases, Department of Internal Medicine, Seoul Medical Center, Seoul,
Republic of Korea.

P1_54  NEUROPATHY IN RHEUMATOID ARTHRITIS: VASCULITIC OR IMMUNE-MEDIATED NEUROPATHY
34722
Masaki Kobayashi
Kobayashi M, Takeuchi M, Suzuki M, Kitagawa K Department of Neurology, Tokyo Women’s Medical University,
Tokyo, Japan

P1_55  PLEXIC MRI AND POSITRON EMISSION TOMOGRAPHY (PET) MERGE: A NEW TOOL FOR THE INVESTIGATION OF PERIPHERAL NERVES ?
35544
Celine Labeyrie
(1) Adams D

P1_56  NEUROFASCIN ANTIBODIES IN AUTOIMMUNE, GENETIC AND IDIOPATHIC NEUROPATHIES.
35116
Eric Lancaster
P1_57 43466
AFTERDISCHARGES FOLLOWING M WAVES IN PATIENTS WITH VOLTAGE-GATED POTASSIUM CHANNELS ANTIBODIES
Jingwen Niu
Niu JW1, Guan HZ1, Cui LY1, Guan YZ1, Liu MS1. 1The Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

P1_58 35058
INFLUENCE OF BASELINE NEUROLOGIC SEVERITY ON DISEASE PROGRESSION AND THE ASSOCIATED DISEASE-MODIFYING EFFECTS OF TAFAMIDIS IN TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY
Leslie Amass

P1_59 35337
PRELIMINARY RESULTS FOR CHARCOT-MARIE-TOOTH PATIENT-REPORTED SURVEY
Kenneth Attie
(1) Moore A, (1) Ekins S, (1) Tockarshewsky T, (2) Nguyen TQ, (2) Miller B, (2) Glasser CE, (2) Attie KM, (2) Johnson K, (3) Statland JM, (4) Ramchandren S, (5) Walk D, (6) Nussbaum J. (1) Hereditary Neuropathy Foundation, New York, USA; (2) Acceleron Pharma, Cambridge, USA; (3) University of Kansas Medical Center, Kansas City, USA; (4) University of Michigan, Ann Arbor, USA; (5) University of Minnesota, Minneapolis, USA; (6) ProHealth & Fitness New York, USA

P1_60 35333
CHARCOT MARIE TOOTH DISEASE ASSOCIATED WITH AGENESIS OF THE CORPUS CALLOSUM: A HETEROGENEOUS ENTITY?
Hamid Azzedine
(1) Institute of Neuropathology, Uniklinik-REWTH, Aachen, Germany  (2) ICM, la Pitié-Salpêtrière Hospital, Paris, France.  (3) Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia  (4) Service of Neurology, Ben Aknoun hospital, Algiers, Algeria  (5) Division of Clinical Neurophysiolooy, Department of Neuroscience, Prince Sultan Medical City, Riyadh, Saudi Arabia  (6) Kush Eye Center, Omdurman, Sudan  (7) Institute of Endemic Diseases Faculty of Medicine, University of Khartoum, Sudan  (8) Department of Physiology, Faculty of Medicine, University of Khartoum, Sudan  (9) Service of Neurophysiology, Ben Aknoun hospital, Algiers, Algeria.  (10) Division of Pediatric Neurology, College of Medicine, King Saud University, Riyadh, Saudi Arabia

P1_61 31149
THE GENE MUTATION OF CHINESE PROBANDS WITH CHARCOT-MARIE-TOOTH DISEASE
Dongsheng Fan
Liu X, Fan D. Department of Neurology, Peking University Third Hospital, Beijing, China

P1_62 35085
DUPLICATION OF MYELIN PROTEIN ZERO CAUSING EARLY ONSET CHARCOT MARIE TOOTH DISEASE TYPE 1B
Shawna Feely
(1) Feely SME, (1) Saade D, (1) Shy ME. (1) University of Iowa Carver College of Medicine.

P1_63 34955
CLINICAL AND MAGNETIC RESONANCE IMAGING FEATURES OF THREE NOVEL MUTATIONS IN THE BICD2 GENE
Marina Frasquet
(1,2) Frasquet M, (3) Lupo V, (1,4) Mas F, (2) Vilchez R, (1,5) Chumillas MJ, (3) Espinós C, (1,5,6) Sevilla T. (1) Hospital Universitari i Politécnic La Fe, Valencia, Spain; (2) Instituto de Investigación Sanitaria La Fe, Valencia, Spain; (3) Centro de Investigación Príncipe Felipe, Valencia, Spain; (4) ERESA, Valencia, Spain; (5) Centro de Investigación Biomédica en enfermedades raras (CIBERER); (6) Departamento Medicina Universitat de Valencia, Valencia, Spain.
1. GAIT IN CHILDREN AND ADOLESCENTS WITH CHARCOT-MARIE-TOOTH DISEASE: A CASE CONTROLLED STUDY OF GAIT IN DIFFERENT FOOTWEAR CONDITIONS
   - Rachel Kennedy
   - (1,2,3) Kennedy R, (1,3) Carroll K, (2) Paterson K, (1,2,3) Ryan MM, (2,3) McGinley JL
   - (1) The Royal Children's Hospital, Parkville, Australia
   - (2) The University of Melbourne, Parkville, Australia
   - (3) The Murdoch Childrens Research Institute, Parkville, Australia

2. IMPAIRED MOTOR AXON EXCITABILITY IN A MOUSE MODEL OF CMT1A
   - Christian Krarup
   - (1) Alvarez S, (2) Klein D, (2) Martini R, (1,3) Moldovan M, (1,3) Krarup C
   - (1) Center for Neuroscience, University of Copenhagen, Denmark
   - (2) Neurology, Developmental Neurobiology, University Hospital Würzburg, Germany
   - (3) Department of Clinical Neurophysiology, Rigshospitalet, Copenhagen, Denmark

3. TARGETED NEXT-GENERATION SEQUENCING (NGS) PANELS IN CMT: A RETROSPECTIVE COMPARATIVE STUDY IN UK AND US TERTIARY REFERRAL CENTRES
   - Andrea Cortese
   - Cortese A (1), Phetteplace J (2), Polke J (3), Poh R(3), Houlden H (4), Rosser AM(1), Laura’ M (1), Shy ME (2), Reilly MM (1)
   - (1) MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, Queen Square, London, UK
   - (2) Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, IA
   - (3) Department of Neurogenetics, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, London, UK
   - (4) Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK

4. IS PMP22 DUPLICATION THE ONLY COPY NUMBER VARIATION (CNV) RESPONSIBLE FOR CHARCOT-MARIE-TOOTH DISEASE? NEW CNV DISCOVERED USING COV'COP
   - Anne-Sophie Lia
   - (1) Miressi F, (1) Derouault P, (1,2) Dzugan H, (3) Cintas P, (1,2) Magdelaine C, (1,2) Sturtz F, (4) Merillou S, (1,2)
   - Lia AS. (1) EA6309 – Université de Limoges, Limoges, France
   - (2) Service de Biochimie et Génétique Moléculaire - CHU de Limoges, Limoges, France
   - (3) Service de Neurologie et d'explorations fonctionnelles - CHU de Toulouse, Toulouse, France
   - (4) UMR7252-XLIM – Université de Limoges, Limoges, France

5. CHARCOT-MARIE-TOOTH DISEASE TYPE 1C: CLINICAL AND ELECTROPHYSIOLOGICAL FINDINGS FOR THE C.334G>A (P.GLY112SER) LITAF/SIMPLE MUTATION
   - Nivedita Jerath
   - *Nivedita U. Jerath MD, MS 1 and Michael E. Shy MD 1
   - 1Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, IA

6. EXTREME VARIABILITY IN DISEASE SEVERITY IN A FAMILY WITH A NOVEL EGR2 MUTATION
   - Shawna Feely
   - (1) Feely SME, (1) Saade D, (1) Shy ME
   - (1) University of Iowa Carver College of Medicine

7. MUTATION SPECTRUM IN A TURKISH CHARCOT-MARIE-TOOTH DISEASE COHORT
   - Ayse Candayan
   - Candayan A1, Atkinson D2, Durmus Tekce H3, Parman Y3, Jordanova A2, Battaloglu E1
   - 1Bogazici University Department of Molecular Biology and Genetics, Istanbul, Turkey
   - 2Antwerp University, Center for Molecular Neurology, Antwerp, Belgium
   - 3Istanbul University, Istanbul Medical School, Istanbul, Turkey
P1_71  SCREENING OF HINT1 MUTATIONS ASSOCIATED WITH RECESSIVE AXONAL NEUROPATHY IN A BRAZILIAN COHORT
Pedro José Tomaselli  
Rocha AM, Tomaselli PJ (1), Gouvea SP (2), Figueiredo FB (2), Lourenço CM (1), Marques W Jr (1, 2) (1) Division of Neuromuscular Diseases, Department of Neurosciences and Behaviour Sciences, Clinical Hospital of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. (2) Neurogenetics, Department of Neurosciences and Behaviour Sciences, University of São Paulo, Ribeirão Preto, Brazil.

P1_72  CHARCOT-MARIE-TOOTH DISEASE ASSOCIATED WITH DEAFNESS AND/OR SCOLIOSIS: NEW MUTATIONS DISCOVERED IN SH3TC2 GENE
A Lunati  
(1) Lunati A, (1) Lerat J, (1,2) Dzugan H, (2) Rego M, (1,2) Magdelaine C, (4) Bieth E, (4) Calvas P, (5) Cintas P, (6) Gilbert-Dussardier B, (7) Goizet C, (8) Journel H, (9) Magy L, (10) Toutain A, (11) Urtizberea J, (1,2) Sturtz F, (1,2) Lia AS. (1) Service de Biochimie et Génétique Moléculaire - CHU de Limoges, Limoges, France ; (2) EA6309 - Université de Limoges, Limoges, France ; (3) Service Oto-rhino-laryngologie - CHU de Limoges, Limoges, France ; (4) Service de Génétique Médicale - CHU de Toulouse, Toulouse, France ; (5) Service de Neurologie et d'explorations fonctionnelles - CHU de Toulouse, Toulouse, France ; (6) Service de Génétique Médicale - CHU de Poitiers, Poitiers, France ; (7) Service de Neurogénétique - CHU de Bordeaux, Bordeaux, France ; (8) Service de Génétique Médicale - Centre hospitalier Bretagne Atlantique, Vannes, France ; (9) Service de Neurologie - CHU de Limoges, Limoges, France ; (10) Service de Génétique Médicale - CHU de Tours, Tours, France ; (11) Centre de référence Neuromusculaire - Hôpital marin, Hendaye, France.

P1_73  AUTOSOMAL RECESSIVE MME MUTATIONS BROADEN THE CLINICAL PHENOTYPE ASSOCIATED WITH CMT2T
Vincenzo Lupo  
Lupo V1,2, Frasquet M3,4, Sánchez-Monteagudo A1,2, Barreiro M3, Alberti MA5, Casasnovas C5, Quintáns B4,6,7, Camacho A8, Domínguez C8, Sedano MJ9, Pelayo AL9, Pardo J10, Sobrino T10, Sobrido MJ4,6,7, Sevilla T3,4, Espinós C1,2. 1Centro de Investigación Príncipe Felipe, Valencia, Spain; 2INCLIVA & IIS La Fe Rare Diseases Joint Units, Valencia, Spain; 3Hospital Universitari i Politècnic La Fe, Valencia, Spain; 4CIBER of Rare Diseases (CIBERER); 5Hospital Bellvitge, Barcelona, Spain; 6Instituto de Investigaciones Sanitarias (IDIS), Santiago de Compostela, Spain; 7Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain; 8Hospital 12 de Octubre, Madrid, Spain; 9Hospital Universitario Marqués de Valdecilla, Santander, Spain; 10Hospital Clínico Universitario Santiago de Compostela, Santiago de Compostela, Spain.

P1_74  UPDATING THE CLASSIFICATION OF CMT AND RELATED NEUROPATHIES. RESULTS OF AN INTERNATIONAL SURVEY
Laurent Magy  
Õunpuu S1,2, Pogemiller K1, Acsadi G2,3, and Pierz K1,2,4. 1Center for Motion Analysis, Connecticut Children’s Medical Center, Farmington, CT, USA 2School of Medicine, University of Connecticut, Farmington, CT, USA 3Division of Neurology, Connecticut Children’s Medical Center, Farmington, CT, USA 4Division of Orthopaedics, Connecticut Children’s Medical Center, Farmington, CT, USA
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1_76</td>
<td>DIAGNOSTIC CHALLENGES IN AMYLOID NEUROPATHIES</td>
<td>Michael Polydefkis, Sarah Neuhaus, Leana Doherty, Gigi J Ebenezer</td>
</tr>
<tr>
<td>P1_78</td>
<td>FUNCTIONAL CONSEQUENCES OF HIP DYSPLASIA IN PAEDIATRIC CHARCOT-MARIE-TOOTH DISEASE</td>
<td>Leanne Purcell, (1,2) Purcell L, (1,2) Wojciechowski E, (1,2) Gibbons P, (1,3) Jamil K, (1,2) Menezes, M, (1,2) Burns J. (1) Sydney Children's Hospitals Network (Randwick and Westmead), New South Wales, Australia (2) University of Sydney, New South Wales, Australia (3) Universiti Kebangsaan, Kuala Lumpur, Malaysia</td>
</tr>
<tr>
<td>P1_79</td>
<td>PREDICTING AMBULATORY AID NEED WITH DISEASE PROGRESSION IN CHARCOT-MARIE-TOOTH DISEASE</td>
<td>Sindhu Ramchandren, Ramchandren S1, Moore J2, Hornyak JE1; on behalf of the Inherited Neuropathy Consortium (NCT 01193075). 1University of Michigan, Ann Arbor, MI, USA; 2A. T. Still University SOMA, Mesa, AZ, USA</td>
</tr>
<tr>
<td>P1_80</td>
<td>CMT2B2 IN CZECH PATIENTS WITH DIFFERENT GLAUCOMA PHENOTYPES AND THREE NOVEL SBF2 MUTATIONS, ONE OF THEM DE-NOVO.</td>
<td>Pavel Seeman, (1) Seeman P, (1) Laššuthová P, (1) Neupauerová J, (2) Mazanec R, (3) Senderek J (1) Dept of Pediatric Neurology, 2nd Medical Faculty, Charles University, Prague, Czech Republic; (2) Dept of Neurology, 2nd Medical Faculty, Charles University, Prague, Czech Republic (3) Friedrich Baur Institute, Ludwig – Maximilian University, Munich, Germany.</td>
</tr>
<tr>
<td>P1_81</td>
<td>QUANTITATIVE MUSCLE ULTRASOUND AS A BIOMARKER IN CHARCOT-MARIE-TOOTH NEUROPATHY</td>
<td>Nortina Shahrizaila, (1,2) Shahrizaila N, (1) Noto Y, (3) Simon NG, (1) Huynh W, (1) Shibuya K, (1) Matamala JM, (1) Dharmadasa T, (1) Devenney E, (4) Kennerson ML, (4) Nicholson GA, (1) Kiernan MC (1) Brain and Mind Centre, University of Sydney, Camperdown, Australia (2) Department of Neurology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia (3) St Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia (4) ANZAC Research Institute and Sydney Medical School, University of Sydney, Sydney, Australia</td>
</tr>
<tr>
<td>P1_82</td>
<td>CHARACTERISTIC OF RECOVERY FROM MUSCLE FATIGUE IN CHARCOT-MARIE-TOOTH PATIENTS WITH ELECTROMYOGRAPHIC STUDY (THIRD REPORT)</td>
<td>Toshinori Shimoi, (1) SHIMOI T., (2) Yamada T. (1) International University of Health and Welfare, Tochigi, Japan, (2) CMT Japan, Tokyo, Japan</td>
</tr>
</tbody>
</table>
P1_83  IS IT RELEVANT TO KEEP THE DEJERINE-SOTTAS SYNDROME AS AN ENTITY IN THE 21st CENTURY?
Jean-Michel Vallat
(1) Vallat JM, (2) MD (Department of Neurology, CHU Limoges, France), Magy L, MD PhD (Department of Neurology, CHU Limoges, France), (3) Mathis S, MD PhD (Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux, France).

P1_84  CHARCOT-MARIE-TOOTH DISEASE TYPE-2 ASSOCIATED WITH TWO MISSSENSE MUTATION IN MME GENE
Elisa Vegezzi
(1) Vegezzi E, (2) Cortese A, (1) Callegari I, (2) Rossor AM, (3) Houlden H, (2) Reilly MM. (1) Neuroscience Consortium, University of Pavia, Monza Policlinico and Pavia Mondino, Italy; (2) MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, Queen Square, London, UK; (3) Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

P1_85  3D PRINTING ANKLE-FOOT ORTHOSES FOR CHILDREN WITH CMT: A REVIEW OF THE LITERATURE
Elizabeth Wojciechowski
(1,2) Wojciechowski E, (1) Chang A, (1,2) Cheng T, (1,2) Little D, (1,2) Menezes MP, (2) Hogan S, (1,2) Burns J. (1) University of Sydney, New South Wales, Australia; (2) Sydney Children’s Hospitals Network (Randwick and Westmead), New South Wales, Australia.

P1_86  THE EFFECTS OF A PHYSICAL THERAPY PROGRAM ON BALANCE, MOBILITY, AND QUALITY OF LIFE IN PATIENTS WITH CHARCOT-MARIE-TOOTH PERIPHERAL NEUROPATHY: A RETROSPECTIVE REPORT
James Nussbaum
(1) James Nussbaum. (1) ProHealth & Fitness New York, NY

P1_87  A SENSITIVE MEASURE OF VIBRATION SENSE IN THE CMTNSv2
Chelsea Bacon
Bacon C(1), Feely SME(1), Shy ME(1)

P1_88  MRI FAT FRACTION OF TIBIALIS ANTERIOR MUSCLE CORRELATES WITH DISABILITY IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A.
Joachim Bas
(1) Bas J, (1, 2) Delmont E, (3) Le Troter A, (1) Fatehi F, (1, 5) Salort-Campana E, (1) Sévy A, (1) Verschueren A, (1, 5) Pouget J, (4) Lefebvre MN, (1) Grapperon AM, (3) Bendahan D, (1, 5) Attarian S. (1) Reference Center for Neuromuscular Diseases and ALS, La Timone University, Aix-Marseille University, Marseille, France (2) Aix-Marseille University, UMR 7286, Medicine Faculty, Marseille, France (3) CRMBM, CNRS, La Timone University Hospital, Aix-Marseille University, Marseille, France (4) CIC-CPCET, La Timone University Hospital, Aix-Marseille University, Marseille, France (5) Aix-Marseille University, Inserm, GMGF, Marseille, France

P1_89  LONGITUDINAL MODELING OF DISEASE-PROGRESSION IN TRANSTHYRETIN FAMILIAL POLYNEUROPATHY WITH TAFAMIDIS
Martin Boucher
(1) Boucher M, (2) Riley S, (1) Harnisch L. (1) Pfizer Inc, Sandwich, UK; (2) Pfizer Inc, Groton, CT, USA
CARDIAC SCINTIGRAPHY IS A USEFUL TOOL FOR THE DIAGNOSIS, PROGNOSIS AND PRE-SYMPTOMATIC EARLY DETECTION OF FAMILIAL AMYLOIDOsis ASSOCIATED NEUROPATHIES

Tayla Romão

MONDAY 10 JULY 2017

7.30 - 8.00
Clinical Trial Updates
Coffee + Poster Viewing

Poster Session 2 (see end of Monday for poster titles)

8.30 - 9.00
Plenary 3: Jeff Milbrandt - JW Griffin Lecture
METABOLIC SUPPORT OF AXONS BY SCHWANN CELLS

9.00 - 10.00
Oral Abstracts

CONSERVED BIOENERGETIC SIGNATURE IN PERIPHERAL NERVE OF BKS-DB/DB AND HIGH FAT DIET MICE WITH NEUROPATHY

Lucy Hinder
Hinder LM, Backus C, Hayes JM, Feldman EL. University of Michigan, Ann Arbor, MI, USA

MUTATION IN GLYCyl-tRNA SYNTHETASE IMPAIR MITOCHONDRIAL METABOLISM IN NEURONS

Veronika Boczonadi
Boczonadi V, (2) Meyer K, (3,4) Gonczarowska-Jorge H, (1) Bartsakoulia M, (1,3) Roos A, (1) Bansagi B, (3) Zahedi RP, (5) Talim B, (6) Bruni F, (2,7) Kaspar B,(1) Lochmüller H, (8) Boycott KM, (1) Müller JS, (1) Horvath R. (1)JWMDRC, WTCMR, IGM, Newcastle University, Newcastle upon Tyne, UK , (2) RINCH, Columbus, Ohio USA; (3)Leibniz-Institute für Analytische Wissenschaften -ISAS- e.V., Dortmund, Germany;(4)CAPES Foundation, Brazil; (5) Department of Pediatrics, Hacettepe University Children's Hospital, Ankara, Turkey; (6) DBBB,University of Bari Aldo Moro, Bari, Italy; (7) Department of Neuroscience, The Ohio State University, Columbus; (8) Department of Genetics, CHEO, University of Ottawa, Ottawa, Canada
9.30 O4_3 CRITICAL ROLE FOR MONOCARBOXYLATE TRANSPORTER (MCT1) IN DEVELOPING AND REGENERATING PERIPHERAL NERVES
Brett Morrison
Jha MK, Russell K, Lee Y, Rothstein JD, Morrison BM. Departments of Neurology and Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore MD, USA

9.45 O4_4 MUSCARINIC RECEPTOR SIGNALING CONSTRAINS AXONAL OUTGROWTH BY AUGMENTING DISSOLUTION OF THE CYTOSKELETON IN ADULT SENSORY NEURONS
Mohammad Golam Sabbir
Sabbir MG1, Calcutt NA2 and Fernyhough P1, 3. 1Division of Neurodegenerative Disorders, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada, 2Department of Pathology, University of California San Diego, California USA and 3Dept of Pharmacology & Therapeutics, University of Manitoba, MB, Canada.

10.00 - 10.30 Coffee

10.30 - 12.00 Oral Posters

OP3_1 34974 DISTAL SENSORIMOTOR POLYNEUROPATHY FOLLOWING 13 YEARS OF TYPE 2 DIABETES ASSESSED BY THE MICHIGAN NEUROPATHY SCREENING INSTRUMENT QUESTIONNAIRE. A PROSPECTIVE STUDY, THE ADDITION DENMARK STUDY.
Signe Toft Andersen
Andersen S T1,2, Witte D R1,3, Dalsgaard EM1, Andersen H2,4, Nawroth P5, Flemming T5, Jensen T M6, Finnerup N B2,7, Jensen T S2,7, Lauritzen T1, Charles M1,2

OP3_2 34962 TREATMENT INDUCED NEUROPATHY OF DIABETES MELLITUS IS UNCOMMON IN A GENERAL DIABETES MELLITUS COHORT
Jasmine Koh
(1)Koh SJ, (2)Wong SHJ, (2)Loh KW, (3)Chng YSK, (3)Pawa C, (4)Ei MA, (2)Lee BJH, (5)Subramaniam T, (1)T. Umapathi. (1) National Neuroscience Institute, Singapore; (2) Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; (3) Yong Loo Lin School of Medicine, National University Singapore, Singapore; (4) Tan Tock Seng Hospital, Singapore; (5) Khoo Teck Puat Hospital, Singapore.

OP3_3 35284 DIFFERENTIAL EFFECT OF SATURATED AND UNSATURATED FATTY ACIDS ON MITOCHONDRIAL TRAFFICKING IN DORSAL ROOT GANGLION SENSORY NEURONS
Amy Rumora
(1) Rumora AE, (1) Hayes JM, (1) LoGrasso G, (1) Haidar J, (1) Dolkowski J, (2) Lentz SI, and (1) Feldman EL. (1) Department of Neurology, University of Michigan, Ann Arbor, MI 48109 USA; (2) Department of Internal Medicine, Division on Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48105 USA

OP3_4 35083 RESPONSIVENESS OF CORNEAL CONFOCAL MICROSCOPY TO DIABETIC NEUROPATHY PROGRESSION
Gordon Smith
Smith AG, Thurgood B, Revere C, Hauer P, Aperghis A, Singleton JR University of Utah, Salt Lake City, Utah, USA
GENOMIC ANALYSIS REVEALS FREQUENT TRAF7 MUTATIONS IN INTRANEURAL PERINEURIOMAS

Michelle Mauermann

IMPAIRMENT OF AUTOPHAGY AS A POSSIBLE PATHOMECHANISM FOR CMT CAUSING MUTATIONS IN HSPB1

Mansour Haidar
Haidar M1, De Winter V1, Asselbergh B1, Bouhy D1, Timmerman V1. 1 Peripheral Neuropathy Research Group, VIB, University of Antwerp, Antwerp, Belgium

CHARCOT–MARIE–TOOTH DISEASE TYPE 2G REDEFINED BY A NOVEL MUTATION IN LRSAM1

Paulius Palaima

GENETIC HETEROGENEITY OF MOTOR NEUROPATHIES

Boglarka Bansagi
(1) Bansagi B, (1) Griffin H, (2) Whittaker R, (3) Antoniadi T, (1) Evangelista T, (2) Miller J, (3) Greenslade M, (3) Forester N, (1) Duff J, (1) Bradshaw A, (4) Kleinle S, (1) Boczonadi V, (1) Steele H, (5) Ramesh V, (1,6) Franko E, (1) Pyle A, (1) Lochmüller H, (1,7) Chinnery PF, (1) Horvath R. (1) MRC Centre for Neuromuscular Diseases and John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK; (2) Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK; (3) Bristol Genetics Laboratory, Pathology Sciences, North Bristol NHS Trust, Southmead Hospital, Bristol, UK; (4) Medical Genetic Center, Munich, Germany; (5) Department of Paediatric Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Foundation Hospitals NHS Trust, Newcastle upon Tyne, UK; (6) Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; (7) Department of Clinical Neurosciences, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK

A BREED-PREVALENT CANINE MODEL OF LATE ONSET PERIPHERAL NEUROPATHY

Susannah Sample
FUNCTIONAL IMPLICATIONS OF HAND IMPAIRMENT IN PEDIATRIC CHARCOT-MARIE-TOOTH DISEASE TYPE 1

Timothy Estilow

Estilow T1, Glanzman AM1, Burns J2 Cornett KMD2, Menezes MP2, Shy R3, Moroni I4, Foscan M4, Pagliano E4, Pareyson D4, Laura M5, Bhandari T6, Muntoni F6, Reilly MM5, Finkel RS7, Sowden J8, Eichinger K8, Herrmann DN8, Shy ME9, Yum SW10 and Ramchandren S;11 on behalf of the Inherited Neuropathies Consortium 1The Children’s Hospital of Philadelphia, Philadelphia, USA; 2University of Sydney & Children’s Hospital at Westmead, Sydney, Australia; 3Carver College of Medicine, Department of Pediatrics, University of Iowa, Iowa City, USA; 4IRCCS Foundation, Carlo Besta Neurological Institute, Milan, Italy; 5MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, UK; 6UCL Institute of Child Health & Great Ormond Street Hospital, London, UK; 7Neuromuscular Program, Division of Neurology, Nemours Children’s Hospital, Orlando, USA; 8Department of Neurology, University of Rochester, Rochester, NY, USA; 9 Carver College of Medicine, Department of Neurology, University of Iowa, Iowa City, USA; 11The Children’s Hospital of Philadelphia, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, PA, USA 11Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA

DISEASE PROGRESSION IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A: A LONGITUDINAL STUDY USING RASCH ANALYSIS-BASED WEIGHTED CMT NEUROPATHY SCORES

Vera Fridman

(1) Fridman V, (1) Sillau S., on behalf of the (2) Inherited Neuropathies Consortium (INC). (1) University of Colorado Hospital, Aurora, CO, USA, (2) University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

INTRATHECAL GENE THERAPY IN DIFFERENT MUTANT MOUSE MODELS OF CMT1X

Alexia Kagiava

Kagiava A1, Karaioskis C1, Richter J2, Tryfonos C2, Lapatithis G1, Sargiannidou I1, Christodoulou C2, Kleopa KA1,3. 1Neuroscience Laboratory, 2Department of Molecular Virology and 3Neurology Clinics, Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.

ROLE OF X-BOX BINDING PROTEIN 1 (XBP1) IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1B

Thierry Touvier

(1) Touvier T, (1) Ferri C, (1) Mastrangelo R, (2,3) Glimcher L, (4,5,6) Wrabetz L, (1) D’Antonio M. (1) Myelin Biology Unit, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, DIBIT, Milan, Italy, (2) Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, USA, (3) Department of Medicine, Harvard Medical School, Boston, USA, (4) Hunter James Kelly Research Institute and Departments of (5) Biochemistry and (6) Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, USA.

RANDOMISED TRIAL OF PROGRESSIVE RESISTANCE EXERCISE FOR CHILDHOOD CHARCOT-MARIE-TOOTH DISEASE

Joshua Burns

(1,2) Burns J, (1) Sman AD, (1) Cornett KMD, (1,2) Wojciechowski E, (1) Walker T, (1,2) Menezes MP, (1) Mandarakas MR, (1,2) Rose KJ, (1,2) Bray P, (2) Sampaio H, (2,3) Farrar M, (1) Refshauge KM, (1) Raymond J for the FAST Study Group. (1) University of Sydney, New South Wales, Australia; (2) Sydney Children’s Hospitals Network (Randwick and Westmead), New South Wales, Australia; (3) University of New South Wales, Sydney, Australia.
**OP3_15**  
NOCICEPTIN/ORPHANIN FQ OPIOID PEPTIDE (NOP) RECEPTOR EXPRESSION IN PACHYONYCHIA CONGENITA (PC)

Baohan Pan  
(1) Baohan Pan, (2) Wolfgang Schröder, (2) Ruth Jostock, (3) Mary Schwartz, and (1) Michael Polydefkis  
(1) Department of Neurology, The Johns Hopkins University SOM, Baltimore, USA; (2) Translational Science & Intelligence (WS) and In-vitro Biology & Biomarker Research Unit (RJ), Grünenthal GmbH, Aachen, Germany; (3) Pachyonychia Congenita Project. Salt Lake City, USA.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00 - 14.00</td>
<td>PNS Business Meeting</td>
</tr>
<tr>
<td>12.00 - 14.00</td>
<td>Lunch + Poster Viewing</td>
</tr>
<tr>
<td>14.00 - 18.00</td>
<td>Individual Meetings 2: Diabetes, CMTR and INC</td>
</tr>
<tr>
<td>18.00 - 19.00</td>
<td>Sponsor Symposia 2: Pfizer and Kedrion</td>
</tr>
<tr>
<td>19.00 - 20.00</td>
<td>Junior Reception and New Members</td>
</tr>
<tr>
<td>20.00 - 20.30</td>
<td>Put up Posters for Poster Session 3</td>
</tr>
<tr>
<td>Poster Session 2</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td></td>
</tr>
</tbody>
</table>
| **P2_1**  
34310  
A QUALITY IMPROVEMENT STRATEGY: ULNAR NERVE CONDUCTION STUDY OF THE FIRST DORSAL INTEROSSEOUS MUSCLE  
Elie Naddaf  
Anandan C, Litchy WJ, Laughlin RS, Leep Hunderfund AN, Naddaf E. Mayo Clinic, Rochester, USA. |
| **P2_2**  
34917  
PAIN AND ANXIETY WITH ELECTRODIAGNOSTIC PROCEDURES  
Mamatha Pasnoor  
Pasnoor M, Veerapaneni K, Murphy R, Statland JM, Kimple D, Hamasaki A, Glenn MD, Herbelin L, Barohn RJ, Jawdat O, Dimachkie MM. The Univeristy of Kansas Medical Center, Kansas City, KS, USA |
| **P2_3**  
33999  
THE APPLICABILITY OF CORNEAL CONFOCAL MICROSCOPY IN SMALL FIBER NEUROPATHY  
Maurice Sopacua  
Sopacua M(1), Hoeijmakers JGJ(1), Dickman MM(1), Nuijts RMMA(1), Merkies ISJ(2), Faber CG(1). (1) Maastricht University Medical Center, Maastricht, the Netherlands; (2) St. Elisabeth Hospitaal, Willemstad, Curaçao. |
| **P2_4**  
34915  
DULOXETINE IN CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY.  
Roser Velasco  
(1,2) Velasco R, (1) Besora S, (3) Santos C, (1) Sala R, (1) Izquierdo C, (1) Simó M, (1,3) Gil-Gil M, (3) Jiménez L, (3) Pardo B, (3) Calvo M, (3) Palmero R, (4) Clapés V, (1,2) Bruna J. (1) Neuro-Oncology Unit, Department of Neurology, University Hospital of Bellvitge- Catalan Institute of Oncology, L’Hospitalet, Barcelona, Spain. (2) Institute of Neurosciences, Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Bellaterra, Spain. (3) Department of Medical Oncology, Hospital Duran i Reynals, Catalan Institute of Oncology, L’Hospitalet, Barcelona, Spain. (4) Department of Clinical Hematology, Hospital Duran i Reynals, Catalan Institute of Oncology, L’Hospitalet, Barcelona, Spain. |
| **P2_5**  
35126  
CHANGES IN PAIN THRESHOLD BY SKIN TEMPERATURE: A STUDY BY INTRAEPIDERMAL ELECTRICAL STIMULATION  
Chieko Suzuki  
SUZUKI C1, BABA M1, KON T1, FUNAMIZU Y1, UENO T1, HAGA R1, NISHIJIMA H1, ARAI A1, NUNOMURA J1, TOMIYAMA M1. 1Department of Neurology, Aomori Prefectural Central Hospital, Aomori, JAPAN. |
| **P2_6**  
35074  
STRESS-INDUCED MECHANICAL ALLODYNIA, BLADDER HYPERSENSITIVITY, AND ANHEDONIA IN AN ANXIETY-PRONE MOUSE STRAIN  
Pau Yen Wu  
(1) Pau Yen Wu, (2) Xiaofang Yang, (3) Julie A. Christianson (4) Douglas E. Wright (1)(2)(3)(4) University of Kansas Medical Center, Kansas City, USA |
| **P2_7**  
34751  
NOSOCOMIAL TREATMENT-INDUCED NEUROPATHY OF DIABETES MELLITUS (TIND)?  
Benjamin Jun Hwee Lee  
(1) Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (2) National Neuroscience Institute, Singapore, Singapore |
P2_8 THE AXONAL PROPERTIES IN PREDIABETIC PATIENTS
34608 Yi-Chen Lin
(1) Lin Y, (2) Sung J, (3) Chang T, (4) Jowy T. (1) Department of Neurology, Taipei Municipal Wanfang Hospital, Taipei, Taiwan; (2) Department of Neurology, Taipei Municipal Wanfang Hospital, Taipei, Taiwan; (3) Department of Neurology, Taipei Municipal Wanfang Hospital, Taipei, Taiwan; (4) Department of Neurology, Taipei Municipal Wanfang Hospital, Taipei, Taiwan

P2_9 AUTONOMIC NERVE FIBER INVOLVEMENT IN CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
31105 Ying Liu
Johns Hopkins School of Medicine, Baltimore, USA

P2_10 ADIPOSE-NERVE SIGNALING IN PERIPHERAL NEUROPATHY
35439 Faye Mendelson
Hinder LM, Mendelson F, Backus C, Feldman EL

P2_11 THE RELATIONSHIP BETWEEN CENTRAL AORTIC SYSTOLIC PRESSURE AND PERIPHERAL BLOOD PRESSURE IN PATIENTS WITH POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME
35356 Brandon Ng
Ng CJB, Ng JPH; Tay LB, T, Umapathi

P2_12 VENTRAL ABDOMINAL SENSORY LOSS IS COMMON IN LENGTH DEPENDENT SENSORIMOTOR PERIPHERAL NEUROPATHY
31101 Benn E Smith
Mayo Clinic in Arizona, Scottsdale, AZ, USA

P2_13 HIGH FAT FED FEMALE MICE DEVELOP PERIPHERAL NEUROPATHY DESPITE NORMAL SYSTEMIC INSULIN SIGNALING
35217 Phillipe O'Brien
(1) Hayes JM, (1) O'Brien PD, (1) Backus C, and (1) Feldman EL (1) Department of Neurology, University of Michigan, Michigan, USA

P2_14 SENSORY AXONAL DYSFUNCTION IN THE PAINFUL DIABETIC POLYNEUROPATHY
34526 Tsui-san Chang
1) Chang TS, (1,2) Lin CS, (3,4) Tani J, (1,4) Sung JY. (1) School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; (2) University of New South Wales, Sydney, Australia; (3) Taipei Medical University and National Health Research Institutes, Taipei, Taiwan; (4) Wan Fang Hospital, Taipei, Taiwan.

P2_15 STRUCTURAL AND FUNCTIONAL TESTS OF NEUROPATHY IN DIABETES
35056 Christopher Gibbons
(1) Gibbons C, (1) Garcia J, (1) Casasola M, (1) Freeman R. (1)Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
P2_16  SENSORY SMALL FIBERS IMPLICATION ON INFLAMMATION REGULATION DURING SKIN PRESSURE ULCER DEVELOPMENT IN MICE

Flavien  Bessaguet
(1) Bessaguet F, (1) Sturtz F, (1,2) Magy L, (1) Desmouliere A, (1) Bourthoumieu S and (1) Demiot C.  (1) EA 6309 - Myelin Maintenance & Peripheral Neuropathy, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France ; (2) Department of Neurology, Reference Center for Rare Peripheral Neuropathies, University Hospital of Limoges, Limoges, France.

P2_17  EFFECTS OF MONASTROL IN BORTEZOMIB INDUCED PERIPHERAL NEUROPATHY

Ilja  Bobylev
(1, 2) Bobylev I, (3) Peters D, (4) Vyas M, (2) Barham M, (1, 2) Klein I, (4) von Strandmann EP, (2) Neiss WF, (1, 2) Lehmann HC
(1) University Hospital of Cologne, Cologne, Germany; (2) University of Cologne, Cologne, Germany; (3) University of Düsseldorf, Düsseldorf, Germany; (4) Philipps University, Marburg, Germany

P2_18  DEXAMETHASONE REDUCES THE FOREING BODY RESPONSE TO PARYLENE-C INTRANEURAL IMPLANTS IN RATS

Natalia  de la Oliva
De la Oliva N1, Del Valle J1, Navarro X1. 1Institute of Neurosciences, Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Bellaterra, Spain

P2_19  ALTERNATIVES TO TRADITIONAL MICROSURGICAL NEURORRHAPHY FOR THE COAPTATION OF TRANSECTED PERIPHERAL NERVES

Erick  DeVinney
(1) DeVinney E, (2) Ducic I (1) AxoGen Clinical Sciences, Alachua, FL USA; (2) Washington Nerve Institute, McLean, VA USA

P2_20  ULNAR NERVE ENTRAPMENT IN MASSIVE MUSCLE FIBROSIS FOLLOWING INTRAMUSCULAR ANABOLIC STEROID INJECTIONS: A CASE REPORT

Vivian  Drory
(1) Fainmesser Y, (2,3) Dori A, (1,3) Drory VE  (1) Department of Neurology and Neuromuscular Service, Tel-Aviv Medical Center, Tel-Aviv, Israel; (2) Department of Neurology, Sheba Medical Center, Ramat Gan, Israel; (3) Sackler Faculty of Medicine, Tel Aviv University, Israel

P2_21  ENRICHMENT OF CHITOSAN TUBES WITH SKELETAL MUSCLE FIBRES TO IMPROVE PERIPHERAL NERVE REGENERATION

Benedetta Elena  Fornasari
(1,2) Fornasari BE, (1,2) Raimondo S, (1,2) Ronchi G, (3) Crosio A, (1) Budau CA, (1) El Soury M, (1,2) Muratori L, (4) Tos P, (3) Battiston B, (1,2) Geuna S, (1)Gambarotta G.
(1) Department of Clinical and Biological Sciences, University of Torino, Italy; (2) Neuroscience Institute Cavalieri Ottolenghi, Torino, Italy; (3) Microsurgery Unit, Health and Science City, CTO, Torino, Italy; (4) Hand Microsurgery and Surgery, Gaetano Pini Hospital, Milano, Italy.
<table>
<thead>
<tr>
<th>Presentation ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2_22</td>
<td>THE MODIFIED MULTIPLE POINT STIMULATION METHOD FOR MOTOR NUMBER UNIT ESTIMATION</td>
<td>Hachisuka Akiko, Senger J, Curran M, Chan K.M. (University of Alberta, Edmonton, Canada; Department of Rehabilitation and Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; Division of Plastic surgery, University of Alberta, Edmonton, Canada.)</td>
</tr>
<tr>
<td>P2_23</td>
<td>THE USE OF MAGNETIC RESONANCE NEUROGRAPHY IN PERIPHERAL NERVE SHEATH TUMORS</td>
<td>Jack MM1, Shah K1, Everist B1, Reyna J1, Hylton P1. (University of Kansas Medical Center, Kansas City, USA.)</td>
</tr>
<tr>
<td>P2_25</td>
<td>EFFECT OF NIFEDIPINE ON SURGICALLY ANASTOMIZED PERIPHERAL NERVE REGENERATION</td>
<td>Demir Ö., Yazıcı T. (University of Gaziosmanpaşa School of Medicine, Neurosurgery, Tokat, Turkey; Kent Hospital, Neurosurgery, Giresun, Turkey)</td>
</tr>
<tr>
<td>P2_26</td>
<td>NEPRILYSIN IS NOT INVOLVED IN REGENERATION AND RE-MYELINATION AFTER NERVE INJURY</td>
<td>Cervellini I, Galino J, Zhu N, Bao Lu, Bennett DL. (NDCN, University of Oxford, Oxford, UK; Harvard Medical School, Boston, Massachusetts.)</td>
</tr>
<tr>
<td>P2_27</td>
<td>LYSOPHOSPHATIDIC ACID CONTRIBUTES TO A SCHWANN CELL PHENOTYPE ASSOCIATED WITH PERIPHERAL NERVE INJURY</td>
<td>Szepanowski Fabian, Szepanowski LP, Kleinschnitz C, Kieseier BC, Stettner M. (Department of Neurology, Medical Faculty, University Duisburg-Essen, Essen, Germany; Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.)</td>
</tr>
<tr>
<td>P2_28</td>
<td>VECTOR-BORNE VIRAL INFECTIONS IN GUILLAIN BARRE SYNDROME PATIENTS</td>
<td>Okar SV, Ergunay K, Bekircan-Kurt CE, Erdem-Ozdamar S, Tan E. (Hacettepe University School of Medicine, Department of Neurology, Ankara TURKEY; Hacettepe University School of Medicine, Department of Medical Microbiology, Virology Unit, Ankara TURKEY; Hacettepe University School of Medicine, Neuromuscular Disease Research Laboratory, Ankara TURKEY)</td>
</tr>
</tbody>
</table>
QUALITY OF LIFE IN ANTI-MAG NEUROPATHY: EVALUATION OF DETERMINANTS IN A MULTICENTRE EUROPEAN SETTING

Fu Liong Hiew
(1) Regional Neuromuscular Clinic, Queen Elizabeth Hospital, University Hospitals of Birmingham, Birmingham, U.K; (2) Referral Centre for Neuromuscular Diseases and ALS, university hospital La Timone, 264 rue Saint-Pierre, 13005, Marseille, France; (3) Centre de Référence Maladies Neuromusculaires de l’Enfant et de l’Adulte Nantes-Angers, Centre Hospitalier Universitaire d’Angers, Angers, France; (4) Referral Centre for Neuromuscular Diseases and ALS, university hospital La Timone, 264 rue Saint-Pierre, 13005, Marseille, France, Aix-Marseille University, CNR2M, CNRS UMR 7286, Medicine Faculty, Marseille, France; (5) Centre de Référence Maladies Neuromusculaires de l’Enfant et de l’Adulte Nantes-Angers, Centre Hospitalier Universitaire d’Angers, Angers, France; (6) Referral Centre for Neuromuscular Diseases and ALS, university hospital La Timone, 264 rue Saint-Pierre, 13005, Marseille, France, Aix Marseille University - Inserm UMR S 910 Medical Genetics and Functional Genomics, Marseille, France; (7) Regional Neuromuscular Clinic, Queen Elizabeth Hospital, University Hospitals of Birmingham, Birmingham, U.K, School of Life and Health Sciences, Aston Brain Centre, Aston University, Birmingham, U.K.

SENSORY AXON EXCITABILITY IN MULTIFOCAL MOTOR NEUROPATHY

Maria Kovalchuk
1Department of Neuromuscular Disorders, University Medical Center Utrecht, the Netherlands. 2Department of Medical Technology and Clinical Physics, University Medical Centre Utrecht, the Netherlands.

ANTI-A DONOR SCREENING AND THE RISK OF HEMOLYTIC ANEMIA WITH HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN TREATMENT – A HOSPITAL-BASED COHORT STUDY IN THE US

Alphonse Hubsch
(1) Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany; (2) CSL Bering AG, Bern, Switzerland; (3) CSL Behring LLC, King of Prussia, USA; (4) CSL Bering GmbH, Marburg, Germany.

DE-NOVO SUBCUTANEOUS IMMUNOGLOBULIN G FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY. A SINGLE CENTRE EXPERIENCE OF 3 PATIENTS

Tim Lavin
(1) Greater Manchester Neurosciences Centre, Salford Royal Hospital, Manchester, United Kingdom

TERMINAL LATENCY INDEX (TLI) AND SENSORY ELECTROPHYSIOLOGY IN PARAPROTEINEMIC CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)

Anza Memon
FREQUENCY, PROGRESSION AND THERAPY OF ATYPICAL CIDP: DATA FROM THE ITALIAN DATABASE ON CIDP

Pietro Emiliano Doneddu

SWITCHING FROM IVIG TO FLEXIBLY-DOSED SCIG IN PATIENTS WITH CIDP AND MMN: CLINICAL AND PATIENT EXPERIENCE

Michael Cumberbatch

AN UP-TO-DATE REVIEW ON SWEATING DISTURBANCES IN GUILLAIN-BARRÉ SYNDROME

Rodrigo Conde

SENSORY GUILLAIN BARRE SYNDROME

Luciana Leon Cejas

DIFFERENTIATION POEMS AND CIDP BY TERMINAL LATENCY INDEX

Jie Lin

FIRST GLOBAL MULTIFOCAL MOTOR NEUROPATHY (MMN) QUALITY OF LIFE (QOL) PATIENT SURVEY IDENTIFIES NEEDS IN EDUCATION AND TREATMENT

Dominick V Spatafora
P2_40
INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENT-RELATED FLUCTUATIONS IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PATIENTS USING DAILY GRIP STRENGTH MEASUREMENTS (GRIPPER): STUDY DESIGN AND PROGRESS UPDATE

Timothy Walton
(1) Allen, J A, (2) Pasnoor, M, (3) Burns, T, (4) Ajroud-Driss, S, (5) Ney, J P, (6) Cook, A A, (7) Brannagan, III, T H, (8) Lawson, V H, (9) Kissel, J T, (10) Gorson, K C, (11) Lewis, R A, (12) Jensen, S, (13) Walton, T P. (1) Department of Neurology, University of Minnesota, Minneapolis, MN, USA and Department of Neurology, Northwestern University, Chicago, IL, USA; (2) Department of Neurology, Kansas University Medical Center, Kansas City, Kansas, USA; (3) Department of Neurology, University of Virginia, Charlottesville, Virginia, USA; (4) Department of Neurology, Northwestern University, Chicago, IL, USA; (5) Department of Neurology, Boston University Medical Center, Boston, MA, USA; (6) Neurology and Johns Creek, Johns Creek, GA, USA; (7) Department of Neurology, Columbia University Medical Center, New York, NY; (8) Department of Neurology, Dartmouth Geisel School of Medicine, Hanover, NH, USA; (9) Department of Neurology, Ohio State University, Columbus, OH, USA; (10) Department of Neurology, St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA, USA; (11) Department of Neurology, Cedars-Sinai, Los Angeles, CA, USA; (12) AxelaCare Health Solutions (BriovaRx Infusion Services), Lenexa, KS, USA; (13) AxelaCare Health Solutions (BriovaRx Infusion Services), Lenexa, KS, USA.

P2_41
INFLAMMATORY POLYRADICULOPATHY ASSOCIATED WITH SJOGREN’S SYNDROME

Byung-Nam Yoon
(1) Byung-Nam Y, (2) Yoon-Ho H, (3) Suk-Won A, (4) SeokJin C, (4) Jung-Joon S (1) Inha University Hospital, Incheon, Korea; (2) Seoul National University-Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea; (3) Joong Ang University Hospital, Seoul, Korea; (4) Seoul National University Hospital, Seoul, Korea

P2_42
FOLLOW-UP STUDY OF NERVE ULTRASOUND IN A PATIENT WITH PRIMARY NEUROLYMPHOMATOSIS

Jingwen Niu
Niu JW, Guan HZ, Cui LY, YANG YM, Liu MS. The Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

P2_43
A CURIOS CASE OF NUMBNESS, DIZZINESS, WETNESS, and DRYNESS – IS ROSS SYNDROME ON THE SPECTRUM OF SJOGREN NEUROPATHY?

Francy Shu
Shu F. University of California, Los Angeles, Medical Center, Los Angeles, California, USA

P2_44
PATTERN OF PERIPHERAL NEUROPATHY IN SJOGREN’S SYNDROME IN A TERTIARY CARE HOSPITAL FROM SOUTH INDIA

Yareeda Sireesha

P2_45
PERIPHERAL NERVE INVOLVEMENT IN CELIAC DISEASE: A NOVEL ASSOCIATION WITH A MULTIFOCAL ACQUIRED MOTOR AXONOPATHY (MAMA)

Miguel Oliveira Santos
Oliveira Santos M1,2, Ohana B1, de Carvalho M1,2. 1Institute of Physiology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal; 2Department of Neurology, Department of Neurosciences and Mental Heath, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
P2_46  IVIG CAN INDUCE A RENAL IMPAIRMENT IN PATIENTS AT RISK WITH DYSIMMUNE NEUROPATHIES
Sophie Puget
Puget S1, Paolantonacchi P2, Burlot L2 -1 LFB Biomédicaments; 2 LFB Biotechnologies, Les Ulis France

P2_47  CORRELATION BETWEEN ULTRA HIGH FREQUENCY ULTRASOUND (UHFUS) IMAGING AND HISTOLOGICAL FINDINGS OF SURAL NERVE IN CIDP
Angela Puma
Puma A1, Panicucci E1, Cambieri C1,2, Butori C3, Garibaldi M1, Soriani MH1, Desnuelle C1, Raffaelli C4 and Sacconi S1

P2_48  ACUTE TRANSIENT POLYNEURITIS ASSOCIATED WITH ZIKA VIRUS INFECTION
Tayla Romão

P2_49  A DESCRIPTION OF GUILLAIN-BARRÉ SYNDROME IN LAOS PEOPLE DEMOCRATIC REPUBLIC
Keosodsay Saysavath
Saysavath Keosodsay1, Somchit Vorachit2, T. Umapathi3

P2_50  OCTAGAM® FOR NEUROLOGICAL DISORDERS: FOCUS ON CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY – DATA FROM 3 OBSERVATIONAL STUDIES
Daniel Svorc
Octapharma Pharmazeutika Produktions.ges.m.b.H., Vienna, Austria

P2_51  SONOGRAPHIC NERVE ENLARGEMENT IN SARCOID PERIPHERAL NEUROPATHY - A CASE REPORT -
Yukiko Tsujii

P2_52  EFFICACY OF CYCLOPHOSPHAMIDE IN ANTI-CONTACTIN-1 ANTIBODIES ASSOCIATED TO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY AND MEMBRANOUS GLOMERULONEPHRITIS: A CASE REPORT
Elisa Vegezzi
(1) Vegezzi E, (2) Cortese A, (3) Zardini E, (4) Devaux J, (3) Franciotta D. (1) Neuroscience Consortium, University of Pavia, Monza Policlinico and Pavia Mondino, Italy; (2) MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, Queen Square, London, UK; (3) Department of General Neurology, C. Mondino National Institute of Neurology Foundation, IRCCS, Pavia, Italy; (4) Aix-Marseille Université, CNRS, CRN2M-UMR7286, 13344 Marseille cedex 15, Marseille, France.

P2_53  ATYPICAL MULTIFOCAL MOTOR NEUROPATHY WITH SCAPULAR WINGING
Cecilia Vidal
(1) Vidal C, (1) Bhatt N, (1) Agudelo C, (1) Mahapatra A, (1) Saporta MA. (1) Department of Neurology, University of Miami Miller School of Medicine, Miami, USA.

P2_54  CLINICAL, NEUROPHYSIOLOGICAL AND MRI FEATURES OF SENSORY NEUROPATHIES
Dongqing Zhu
(1) Zhu Dongqing, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China;
P2_55 35344  
EPIDEMIOLOGY OF GUILLAIN-BARRÉ SYNDROME IN DENMARK – THE INTERNATIONAL GBS OUTCOME STUDY IN A POPULATION BASED PERSPECTIVE  
Helle Al-Hakem  
Al-Hakem H(1), Sindrup SH (2), Dornonville de la Cour C (3), van den Berg B (4), Jacobs BC (4), Andersen H (1), Harbo T (1). 1. Department of Neurology, Aarhus University Hospital, Aarhus, Denmark. 2. Department of Neurology, Odense University Hospital, Odense, Denmark. 3. Department of Clinical Neurophysiology, Danish National Hospital, Copenhagen, Denmark. 4. Department of Neurology and Immunology, Erasmus Medical Centre, Rotterdam, The Netherlands.

P2_56 35097  
OVERALL DISEASE IMPACT OF CHRONIC INFLAMMATORY Demyelinating Polyneuropathy (CIDP)  
Ivana Basta  
Basta I, Peric S, Cobeljic M, Bjelica B, Bozovic I, Kacar A, Nikolic A, Rakocevic Stojanovic V, Stevic Z, Lavrnic D. Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade.

P2_57 35319  
PREVALENCE OF ANTI-NEUROFASCIN-155, ANTI-CONTACTIN-1 AND CONTACTIN-ASSOCIATED PROTEIN 1 ANTIBODIES IN CHRONIC INFLAMMATORY Demyelinating Polyradiculoneuropathy: A SEROLOGICAL MULTICENTER STUDY IN ITALY  
Ilaria Callegari  

P2_58 34019  
EFFICACY AND SAFETY OF THREE DIFFERENT DOSAGES OF IVIG (PANZYGA®) IN PATIENTS WITH CHRONIC INFLAMMATORY Demyelinating Poly(radiculo)neuropathy (ProCID STUDY) – DESIGN OF A PHASE 3 STUDY  
David Cornblath  
Cornblath DR1, van Doorn PA2, Hartung HP3, Katzberg HD4, Merkies ISJ5. 1Johns Hopkins University, Baltimore, USA; 2Erasmus University Medical Center, Rotterdam, The Netherlands; 3Heinrich Heine University, Düsseldorf, Germany; 4University of Toronto, Toronto, Canada; 5Maastricht University Medical Center, Maastricht, The Netherlands.
P2_59  
35089  
CONDUCTION BLOCKS AND PARESIS INDUCED BY PASSIVE TRANSFER OF ANTI-CONTACTIN-1 IGG OF PATIENTS WITH CIDP  
Kathrin Doppler  
Doppler K, Schuster Y, Weishaupt A, Sommer C University Hospital Würzburg, Department of Neurology, Würzburg, Germany

P2_60  
35215  
ANTI-GANGLIOSIDE COMPLEX ANTI-BODIES IN CHRONIC IMMUNE-MEDIATED NEUROPATHIES  
Kei Funakoshi  
Department of Neurology, Dokkyo Medical University

P2_61  
34282  
SELECTIVE IN VIVO REMOVAL OF PATHOGENIC ANTI-MAG AUTOANTIBODIES - A NOVEL TREATMENT OPTION FOR ANTI-MAG NEUROPATHY  
Pascal Hänggi  

P2_62  
35296  
GUILLAIN-BARRÉ SYNDROME IN BANGLADESH: PAST, PRESENT AND FUTURE PERSPECTIVE  
Zhahirul Islam  
Zhahirul Islam1, Mohammad B. Islam1,2, Israt Jahan1, Gulshan Ara1, Quazi D. Mohammad3

P2_63  
35308  
IMPROVING REVIEW PROCESSES FOR IVIG THERAPY: GETTING TO KNOW OUR AUNTS (AUSPICIOUSLY UNINTERPRETABLE NOTE TAKING) AND UNCLES (UNCERTAIN NEUROLOGICAL CLINICAL ENTITIES)  
Jonathan Katz  
(1) Katz, J (2) Levine, T (3) Dimachke, M (3) Barohn, R. (1) Forbes Norris Center, San Francisco, CA, USA (2) Phoenix Neurological Institute, Phoenix AZ, USA (3) Kansas University Medical Center, Kansas City KS, USA

P2_64  
35457  
ANTI-NFASC155 NEUROPATHY: A RELAPSING-REMITTING NEUROPATHY ?  
Thierry Kuntzer  
Kuntzer T1, Cuendet D1, Maulucci F1, Tsouni P1, Magot A2, Boucraut J3, Devaux J3, Attarian S4, Delmont E4, 1DCN, CHUV, Lausanne, Switzerland; 2Centre de Référence Maladies Neuromusculaires, Nantes-Angers, CHU de Nantes, Nantes, France; 3CNRS, CRN2M-UMR 7286, Université Aix-Marseille, Marseille, France; 4Centre de Référence maladies neuromusculaires et SLA, Hôpital La Timone, Marseille, France.

P2_65  
35212  
CD1A AND CD1E GENE POLYMORPHISMS ARE NOT ASSOCIATED WITH THE SUSCEPTIBILITY OF GUILLAIN–BARRÉ SYNDROME IN BANGLADESH  
Mohammad Imtiazur Rahman  
(1) Rahman IM, (1) Jahan IT, (1) Nahar S, (2) Khalid MM, (1) Jahan I, (1,3,4) Hayat S, (1) Islam Z. (1)Laboratory Sciences and Services Division, International Centre for Diarrheal Disease Research (icddr,b), Dhaka, Bangladesh; (2)Department of Biochemistry, Erasmus University Medical Centre, Rotterdam, The Netherlands; (3)Department of Physiology and Molecular Biology, Bangladesh University of Health Sciences; Dhaka, Bangladesh; (4) Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh

P2_66  
34847  
CLONICAL SYMPTOMS OF SUBACUTE MYELO-OPTICO NEUROPATHY ARE ELOCITED BY MYELOPATHY RATHER THAN PERIPHERAL NEUROPATHY  
Matsumoto A 1  
Matsumoto A 1 1Department of Neurology Keijinkai Jozanki Hospital Sapporo Japan
DO ANTI-MAG TITERS HAVE A GOOD CORRELATION WITH CLINICAL STATUS IN IgM ANTI-MAG NEUROPATHY?

Jean Neil
(1) Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France; (2) Department of Neurology, National Referral Center for Rare Neuromuscular Diseases, Pitié-Salpêtrière Hospital (AP-HP), Paris, France; (3) Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France

MONTH OF BIRTH AS A RISK FACTOR FOR GUILLAIN-BARRÉ SYNDROME

Stojan Peric
(1) Peric S, (1) Bjelica B, (1) Berisavac I, (2) Lukic S, (3) Babic M, (1) Jovanovic D, (4) Dominovic A, (2) Cvijanovic M, (1) Rakocavic Stojanovic V, (1) Lavrnic D, (1) Basta I. (1) Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia, (2) Neurology Clinic, Clinical Center Novi Sad, Novi Sad, Serbia, (3) Neurology Clinic, Clinical Center Banjaluka, Banaluka, Republic of Srpska, Bosnia and Herzegovina

FLAVIVIRUS ASSOCIATED GUILLAIN-BARRÉ SYNDROME IN SINGAPORE

Kalpana Prasad
(1) Prasad K, (1) Ohnmar O, (2) Teng A, (2) Cheng YJ, (1) T Umapathi. (1) National Neuroscience Institute, Singapore; (2) Yong Loo Lin School of Medicine, National University of Singapore, Singapore; (3) Yangon General Hospital, Yangon, Myanmar.

A PEDIATRIC SERIES OF GUILLAIN BARRÉ SYNDROME INCLUDED IN IGOS PROTOCOL. ARGENTINIAN EXPERIENCE.

Andrea Savransky
(1) Department of Neurology, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentine. (2) Department of Physical Therapy, Hospital de Pediatría J. P Garrahan, Buenos Aires, Argentine (3) Department of neurology. Britain Hospital, Buenos Aires Argentine.

PREDICTIVE FACTORS OF LONG-TERM DISABILITY IN CIDP

Emanuele Spina

QUANTITATIVE AUTONOMIC ASSESSMENT IN GUILLAIN-BARRÉ SYNDROME

Cheng-Yin Tan
(1) Tan CY, (1) Tan MP, (1) Yeoh KY, (1) Goh KJ, (1) Shahrizaila N. (1) Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

LYSOPHOSPHATIDYLCHOLINE - INDUCED ACUTE DEMYELINATION AGGRAVATES MOTOR AXON DYSFUNCTION IN A MOUSE MODEL OF CMT1B

Christian Krarup
(1) Alvarez S, (1,2) Krarup C, (1,2) Moldovan M (1) Center for Neuroscience, University of Copenhagen, Denmark; (2) Department of Clinical Neurophysiology, Rigshospitalet, Copenhagen, Denmark
P2_74 SCO2 MUTATIONS CAUSE AUTOSOMAL RECESSIVE CHARCOT-MARIE-TOOTH DISEASE
Dimah Saade
(1) Saade D, (2) Pereira C, (3) Shon E, (2) Moraes C, (4) Zuchner S, (1) Shy M, (4) Rebelo A. (1) Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, USA; (2) Department of Neurology, University of Miami, Miami, USA; (3) Department of Neurology, Columbia University Medical Center, New York, USA; (4) Dr. John T. Macdonald Foundation Department of Human Genetics, John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, USA

P2_75 AMINOACYL tRNA SYNTHETASE GENE MUTATIONS INCLUDING GARS, MARS AND YARS GENES IN KOREAN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE
Byung-Ok Choi, Ki Wha Chung, Sung-Chul Jung

P2_76 SPINO-BULBAR MUSCULAR ATROPHY COMBINED WITH CHARCOT-MARIE-TOOTH DISEASE: "DOUBLE TROUBLE" IN NEUROMUSCULAR DISORDERS
Kyomin Choi
(1) Choi K, (2) Choi SJ, (2) Kwon KH, (2) Ahn SH, (2) Kim JS, (2) Baek SH, (2) Shin JY, (2) Kim SM, (3) Hong YH, (2) Sung JJ. (1) Konkuk University Hospital, Seoul, Republic of Korea (2) Seoul National University Hospital, Seoul, Republic of Korea; (3) Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea

P2_77 AXONAL CMT WITH ATYPICAL PROXIMAL WEAKNESS CAUSED BY TRANSLATIONAL ELONGATION OF THE 3' UTR IN NEFH
Ki Wha Chung
(1) Nam DE, (2) Jung S-C, (3) Choi B-O, (1) Chung KW, (1) Kongju National University, Gongju, Korea; (2) Ewha Womans University School of Medicine, Seoul, Korea; (3) Sungkyunkwan University School of Medicine, Seoul, Korea

P2_78 COWCHOCK SYNDROME, 2 FAMILIAL CASES WITH A NEW MUTATION IN AIFM1 GENE.
Gerardo Jose Cruz Velasquez
(1, 3) Cruz-Velásquez G, (1) Mahdi-Rogers M, (2) Kazmi M, (1) Hadden RDM (1) Neurology Department and (2) Haematology Department, King’s College Hospital, London, UK; (3) Department of Neurology, University Hospital Miguel Servet, Zaragoza, Spain.

P2_79 CHARCOT-MARIE-TOOTH 2W. A NEW MUTATION?
Marcos de Freitas
(1) de Freitas M, (1) Dias J, (1) Vidal C, (1) Szklarz D, (1) Nascimento O, (2) Kok F (1) Federal Fluminense University, Niterói, Brazil, (2) São Paulo University, São Paulo, Brazil

P2_80 GENOTYPIC AND PHENOTYPIC PRESENTATION OF TRANSTHYRETIN-RELATED FAMILIAL AMYLOID POLYNEUROPATHY (TTR-FAP) IN TURKEY
Hacer Durmus
(1) Istanbul University, Istanbul Medical Faculty, Neurology Department, Istanbul, Turkey (2) Istanbul University, Istanbul Medical Faculty, Neurology Department, Istanbul, Turkey (3) Istanbul University, Istanbul Medical Faculty, Neurology Department, Istanbul, Turkey (4) Istanbul Bilim University, Medical Faculty, Neurology Department, Istanbul, Turkey (5) Istanbul University, Genetics Department, Institute of Experimental Medical Research (6) Istanbul University, Istanbul Medical Faculty, Department of Medical Genetics, Istanbul, Turkey (7) Istanbul University, Istanbul Medical Faculty, Neurology Department, Istanbul, Turkey (8) Istanbul University, Istanbul Medical Faculty, Neurology Department, Istanbul, Turkey (9) Istanbul University, Istanbul Medical Faculty, Neurology Department, Istanbul, Turkey

2017 PNS Annual Meeting programme 39
P2_81  SENSITIVITY TO CHANGE OF THE CHARCOT-MARIE-TOOTH NEUROPATHY SCORE (CMTNS) AND OVERALL NEUROPATHY LIMITATION SCALE (ONLS) IN A DATABASE OF FRENCH PATIENTS WITH CMT1A

Julie Foucquier

P2_82  CHARCOT-MARIE-TOOTH DISEASE: GENETIC SUBTYPES IN NORTHWESTERN SPAIN

Tania García-Sobrino
García-Sobrino T1, 2, Blanco-Arias Patricia2, 3, Vidal-Lijó M.P4, Quintáns Bea2, 3, Sobrido MJ2, 3, Pardo J1, 2. 1 Department of Neurology, Hospital Clínico, Santiago de Compostela, Spain; 2 Neurogenetics Research Group, Instituto de Investigaciones Sanitarias (IDIS), Santiago de Compostela, Spain; 3 Genomic Medicine Group (U711), Centre for Biomedical Network Research on Rare Diseases (CIBERER), Spain; 4 Department of Neurophysiology, Hospital Clínico, Santiago de Compostela. Spain

P2_83  GENE THERAPY ON RATS MODELS OF THE PERIPHERAL NEUROPATHY CHARCOT-MARIE-TOOTH

Helene Hajjar
(1) Hajjar H, (1) Gautier B, (1) Berthelet J, (1) Gonzalez E, (2) Gess B, (2) Young P (1) Tricaud N. (1) Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France; (2) Universitätsklinikum Münster, Klinik für Schlafmedizin und neuromuskuläre Erkrankungen, Münster, Germany

P2_84  CHARCOT MARIE TOOTH DISEASE TYPE 4C: NOVEL MUTATIONS, CLINICAL PRESENTATIONS, AND DIAGNOSTIC CHALLENGES OF AN ATYPICAL CMT

Nivedita Jerath
*Nivedita U. Jerath MD, MS 1, Ami Mankodi MD2, Thomas O. Crawford MD 3, Christopher Grunseich MD2, Hasna Baloui, PhD4, Chioma Nnamdi-Emeratom MD2, Alice B. Schindler MS2, Terry Heiman-Patterson MD5, Roman Chrast PhD4, and Michael E. Shy MD1 1 Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, IA, USA; 2Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA ; 3Department of Pediatric Neurology, Johns Hopkins University, Baltimore, MD, USA; 4Department of Neurosciences and Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; and 5Department of Neurology, Drexel University College of Medicine, Philadelphia, PA, USA.

P2_85  DIAGNOSTIC CHALLENGES IN THE MOLECULAR DIAGNOSIS OF CMT IN THE ERA OF NEXT GENERATION SEQUENCING (NGS)

Andrea Cortese
A Cortese A (1), Polke J (2), Poh R (2), Houlden H (3), Rosser AM (1), Laura’ M (1), Reilly MM (1) (1) MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, Queen Square, London, UK (2) Department of Neurogenetics, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, London, UK. (3) Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

P2_86  PERIPHERAL NEUROPATHIES IN METABOLIC MYOPATHY

Xi Jianying
Jianying X, Jie L, Kai Q, Sushan L, Wenhua Z, Chongbo Z, Jiahong L. Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
P2_87
REDUCED INTRAEPIDERMAL NERVE FIBER DENSITY IN PATIENTS WITH REM SLEEP BEHAVIOUR DISORDER
Istvan Katona*, (2) Wiebke Schrempf*, (3,4) Imis Dogan, (5) Verena v. Felbert, (2) Miriam Wienecke, (3,4) Julia Heller, (3) Andrea Maier, (2,6) Andreas Hermann, (2) Katharina Linse, (2) Moritz D. Brandt, (2) Heinz Reichmann, (3,4,7) Jörg B. Schulz, (3) Johannes Schiefer, (8) Wolfgang H. Oertel, (2,6,9,10) Alexander Storch, (1) Joachim Weis*, (3,4,7) Kathrin Reetz*, (1) Institute of Neuropathology, RWTH Aachen University, Pauwelsstr. 30, 52074 Aachen, Germany (2) Department of Neurology, Technische Universität Dresden, 01307 Dresden, Germany (3) Department of Neurology, RWTH Aachen University, Pauwelsstr. 30, 52074 Aachen, Germany (4) JARA – Translational Brain Medicine, Jülich and Aachen, Germany (5) Department of Dermatology and Allergology, RWTH Aachen University, 52074 Aachen, Germany (6) German Center for Neurodegenerative Diseases (DZNE) Dresden, 01307 Dresden, Germany (7) Institute of Neuroscience and Medicine (INM-11), Research Center Jülich GmbH, Wilhelm-Johnen-Straße, 52428 Jülich, Germany (8) Department of Neurology, Philipps University Marburg, German (9) Division of Neurodegenerative Diseases, Department of Neurology, Technische Universität Dresden, 01307 Dresden, Germany (10) Department of Neurology, University of Rostock, 18147 Rostock, German

P2_88
SURGICAL MANAGEMENT OF FOOT AND ANKLE DEFORMITIES IN CHARCOT MARIE TOOTH DISEASE: RESULTS OF A PROSPECTIVE STUDY
Matilde Laurá
(1) Laurá M, (1,2) Ramdharry G, (3) Singh D, (1) Kozyra D, (1) Skorupinska M, (1) Reilly M.M. (1) MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK, (2) School of Rehabilitation Sciences, St George’s University of London/ Kingston University, UK, (3) Royal National Orthopaedic Hospital, Stanmore, UK

P2_89
A RARE CASE OF NEUROFIBROMATOSIS PRESENTING WITH DEMYELINATING POLYNEUROPATHY
Hyung-Soo Lee
(1) Lee H-S, (2) Kim SM. (1) Presbyterian Medical Center, Jeonju, Korea; (2) Yonsei University College of Medicine, Seoul, Korea.

P2_90
ENHANCEMENTS TO THE RARE DISEASES CLINICAL RESEARCH NETWORK CONTACT REGISTRY FOR THE INHERITED NEUROPATHIES CONSORTIUM
Devon Marking
(1) Marking D, (2) Shy M, and members of the Inherited Neuropathies Consortium and Rare Diseases Clinical Research Network Data Management and Coordinating Center.

P2_91
A MPZ R98C CMT PATIENT PRESENTING A FLUCTUATING NEUROPATHY SUSCEPTIBLE TO TREATMENT
Wilson Marques Jr
Germano CSB, Onofre PTBN, Bordini EC, Gouvea S, Barreira AA, Marques W Jr. Division of Neuromuscular Diseases, Department of Neurosciences and Behaviour Sciences, Clinical Hospital of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.

P2_92
A NEW SYT2 MUTATION CAUSING PRESYNAPTIC NEUROMUSCULAR JUNCTION DYSFUNCTION AND DISTAL MOTOR NEUROPATHY (LEMS-CMT)
Nataly Montes-Chinea
(1) Montes-Chinea, NI, (1) Coutts, M, (1) Vidal C, (2) Courel, S, (2) Rebelo A, (2) Abreu L, (2) Zuchner S, (1,2) Saporta, MA. (1) Department of Neurology, University of Miami, Miami, USA, (2) Department of Human Genetics, University of Miami, Miami, USA
P2_93  CLINICAL AND PATHOLOGICAL FINDINGS IN FAMILIAL AMYLOIDOTIC POLYNEUROPATHY DUE TO TRANSTHYRETIN E61K
34990
Tatsufumi Murakami
(1) Murakami T, (2) Nishimura H, (1) Nagai T, (1) Hemmi S, (1) Kutoku Y, (1) Sunada Y. (1) Department of Neurology, and (2) Department of Pathology, Kawasaki Medical School, Kurashiki, Japan

P2_94  PREGNANCY, SLEEP, FATIGUE AND OTHER ITEMS IN CHARCOT-MARIE-TOOTH DISEASE: DATA FROM QUESTIONNAIRES LINKED TO THE ITALIAN CMT NATIONAL REGISTRY
35168
Davide Pareyson
(1) Pareyson D, (1) Calabrese D, (2) Santoro L, (2) Manganelli F, (3) Fabrizi GM, (4) Schenone A, (3) Cavallaro T, (4) Ursino G, (5) Previtali S, (6) Allegri I, (7,8) Padua L, (8) Pazzaglia C, (9) Quattrone A, (1) Villani F, (1) Pisciotta C, (10) Mazzeo A, (10) Vita G; for the Italian CMT Network. (1) IRCCS Foundation, "C. Besta" Neurological Institute, Milan; (2) Federico II University, Department of Neurosciences, Reproductive Sciences and Odontostomatology, Naples; (3) University of Verona, Department of Neurological, Biomedical and Motor Sciences, Verona; (4) University of Genoa, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal Infantile Sciences, Genoa; (5) Ospedale San Raffaele, Vita Salute San Raffaele University, Department of Neurology and INSPE, Milan; (6) A.O. di Parma, U.O. Neurologia, Parma; (7) Università Cattolica del Sacro Cuore, Rome; (8) Don Carlo Gnocchi Onlus Foundation, Department of Neuroscience, Milan; (9) Magna Graecia University, Department of Medical Sciences, Catanzaro; (10) University of Messina, Unit of Neurology, Department of Clinical and Experimental Medicine, Messina, Italy.

P2_95  CLINICAL AND GENETIC HETEROGENEITY IN CHARCOT-MARIE-TOOTH NEUROPATHY TYPE 2 PATIENTS FROM TURKEY
35175
Yesim Parman
(1) Parman Y, (1) Durmus H, (3) Deymeer F, (4) Oflazer-Serdaroğlu P, (5) Battaloglu E (1) Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey (2) Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey (3) Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey (4) Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey (5) Bogazici University, Istanbul, Turkey

P2_96  ARL6IP1 CAUSES CONGENITAL INSENSITIVITY TO PAIN, SELF-MUTILATION AND SPASTIC PARAPLEGIA
31147
Yann Pereon

P2_97  DETERMINING THE PATHOGENICITY OF NEWLY IDENTIFIED ATP7A VARIANTS USING PRIMARY FIBROBLASTS
34710
Gonzalo Perez-Siles
(1,2) Perez-Siles G, (1,2) Drew A, (1) Ellis M, (1) Kidambi M, (4) Takata R I, (4) Speck-Martins C E, (5) Hagerman K A, (5) Siskind C E, (5) Day J W, (6) Ginberg M, (1,2,3) Nicholson G, (1,2,3) Kennerson M L. (1) Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia; (2) Sydney Medical School, University of Sydney, Sydney, Australia; (3) Molecular Medicine Laboratory, Concord Repatriation General Hospital, Sydney, Australia; (4) Sarah Network Rehabilitation Hospitals, Brasilia, DF, Brazil; (5) Department of Neurology, Stanford Health Care, Stanford, CA, USA; (6) Pediatric Neuromuscular Unit, Wolfson Medical Center, Holon, Israel

P2_98  HOMOZYGOUS DUPLICATION OF PMP22: A CASE REPORT
34628
Janei Phetteplace
Phetteplace JE1, Saade D1, Bacon C1, Shy ME1. 1 University of Iowa Hospitals and Clinics, Iowa City, IA, USA
THE GERMAN CHARCOT-MARIE-TOOTH DISEASE NETWORK (CMT-NET): DISEASE SEVERITY AND PROGNOSTIC BIOMARKERS FROM BLOOD AND SKIN OF CMT1A PATIENTS

Thomas Prukop
Prukop T1,2,3, Garcia-Angarita N4, König LS4, Pieper D5, Dräger B5, Thiele S4, Hüttlemann D5, Schlotter-Weigel B4, Walter MC4, Young P5, and Sereda MW1,3. 1University Medical Center Göttingen, Department of Clinical Neurophysiology, Göttingen, Germany; 2University Medical Center Göttingen, Institute of Clinical Pharmacology, Göttingen, Germany; 3Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany; 4Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-Universität, Munich, Germany; 5Department of Sleep Medicine and Neuromuscular Disorders, University of Münster, Münster, Germany.

DEVELOPMENT OF BEST PRACTICE GUIDELINES FOR PAEDIATRIC CHARCOT-MARIE-TOOTH DISEASE

Joshua Burns
Yiu EM 1,2,3, Burns J 2,4,5, Menezes M P4,5, and Ryan MM 1,2,3 for the Paediatric CMT Best Practice Guidelines Consortium. 1 Royal Children’s Hospital Melbourne, Melbourne, Victoria, Australia; 2 Murdoch Childrens Research Institute, Melbourne, Victoria, Australia; 3 University of Melbourne, Melbourne, Victoria, Australia; 4University of Sydney, New South Wales, Australia ; 5 Sydney Children’s Hospitals Network (Randwick and Westmead), New South Wales, Australia

CHARCOT-MARIE-TOOTH NEUROPATHY MISDIAGNOSED AS CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY: A CASE SERIES.

Marta Ruíz
Ruiz M1 Campagnolo M1, Salvalaggio A1, Cacciavillani M2 , Taioli F3, Fabrizi GM3, Briani C1. 1Department of Neuroscience, Neurology Unit, University of Padova, Padova, Italy 2 Data Medica Group, EMG Unit, CEMES, Padova, Italy 3 Department of Neurological and Movement Sciences, University of Verona, Verona, Italy

NERVE ULTRASOUND, MRI NEUROGRAPHY AND DIFFUSION TENSOR IMAGING ANALYSIS REVEALED PECULIAR NERVE ABNORMALITIES IN FRIEDREICH’S ATAXIA.

Alessandro Salvalaggio
Salvalaggio A1, Coraci D2, Cacciavillani M3, Ruiz M1, Manganelli F4, Antenora A4, Filla A4, Santoro L4, Gasparotti R5, Padua L6, Briani C1 1 Department. of Neurosciences, University of Padova, Padova; 2 Board of Physical Medicine and Rehabilitation, Department of Orthopaedic Science, “Sapienza” University, Rome, Italy; 3 CEMES-EMG Lab, Data Medica Group, Padova; 4 Department of Neurosciences, Reproductive Sciences and Odontostomatontology, University Federico II of Naples, Naples, Italy; 5 Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia; 6 Department of Geriatrics, Neurosciences and Orthopaedics, Università Cattolica del Sacro Cuore, Rome, Italy

THE AIFM1 p.F210S MUTATION CAUSES AN APOPTOTIC FAILURE AND ACTIVATION OF SENESENT PROGRAM IN FIBROBLASTS DERIVED FROM PATIENT BIOPSIES

Paula Sancho
Sancho P1,2, Sánchez-Monteagudo A1,2, Collado-Padilla A1,2, Marco C3,4, Dominguez C5, Camacho A6, Knecht E2,4,7, Espinós E1,2,8*, Lupo V1,2,8. 1Unit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain; 2INCLIVA & IIS La Fe Rare Diseases Joint Units, Valencia, Spain; 3Unit of Structural Enzymopathology, Instituto de Biomedicina de Valencia, 4CIBER of Rare Diseases (CIBERER), Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain; 5Department of Neurology, Hospital 12 de Octubre, Madrid, Spain; 6Department of Neuropediatrics, Hospital 12 de Octubre, Madrid, Spain; 7Unit of Intracellular Protein Degradation, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain; 8Department of Genomics and Translational Genetics, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.
P2_104  SARM1 AND NAD INVOLVEMENT IN AXONAL DEGENERATION IN DEMYELINATING HEREDITARY NEUROPATHY CMT1A
Jens Schmidt
Schmidt J1, Gess B1. 1Uniklinikum RWTH Aachen, Germany

P2_105  IDENTIFICATION OF FIVE NOVEL MUTATIONS IN BRAZILIAN FAMILIES WITH X-LINKED CMT
Pedro José Tomaselli
Tomaselli PJ (1), Gouvea SP (2), Nyshyama KFS (2), Nicolau N Jr (2), Lourenço CM (1), Marques W Jr (1, 2) (1) Division of Neuromuscular Diseases, Department of Neurosciences and Behaviour Sciences, Clinical Hospital of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. (2) Neurogenetics, Department of Neurosciences and Behaviour Sciences, University of São Paulo, Ribeirão Preto, Brazil.

TUESDAY 11 JULY 2017

7.30 - 8.30  Clinical Trial Updates
            Coffee + Poster Viewing

            Poster Session 3 (see end of Tuesday for poster titles)

8.30 - 9.00  Plenary 4: Gary Lewin - PJ Dyck Lecture
            MECHANOTRANSDUCTION AND PAIN

9.00 - 10.00 Oral Abstracts

9.00  TRPV4-MEDIATED DISRUPTION OF CALCIUM SIGNALING AND MITOCHONDRIAL AXONAL TRANSPORT IN A DROSOPHILA MODEL OF CMT2C
O5_1  Brian Woolums

9.15  IMPLICATION OF RARE Nav1.7 VARIANTS IN PAINFUL DIABETIC NEUROPATHY
O5_2  Andreas Themistocleous
RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA RESULTS IN PAINFUL SMALL FIBRE NEUROPATHY

Margarita Calvo
(1) Calvo M, (2) Bennett DLH (1) Pontificia Universidad Catolica de Chile, Santiago, Chile; (2) NDCN Oxford University, UK

A RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY, SAFETY, AND TOLERABILITY OF LACOSAMIDE IN PATIENTS WITH GAIN-OF-FUNCTION NAV1.7 MUTATIONS-RELATED SMALL FIBER NEUROPATHY, THE LENSS STUDY.

Bianca de Greef
(1) de Greef BTA, (1) Geerts M, (1, 2) Faber CG1, Merkies ISJ,(1) Hoeijmakers JGJ. (1) Department of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands. (2) Department of Neurology, St. Elisabeth Hospital, Willemstad, Curaçao.

10.00 - 10.30
Coffee

10.30 - 12.00
Oral Posters

REVERSAL OF PAINFUL DIABETIC NEUROPATHY BY CONTROL OF NOCICEPTOR EXCITABILITY

Daniela Maria Menichella
Bhattacharyya, B. J. (1), Jayaraj, N.D. (1), Belmadani, A. (2), Ren, D. (2), Rathwell, C.A. (1), Hackelberg, S. (1), Miller, R.J. (2) and Menichella, D.M. (1). (1) Department of Neurology Northwestern University, Chicago, IL, USA, (2) Department of Pharmacology, Northwestern

SENSORY PHENOTYPE AND RISK FACTORS FOR PAINFUL DIABETIC NEUROPATHY: A CROSS SECTIONAL OBSERVATIONAL STUDY

Josef Bednarik
(1,2) Vickova E, (1,2) Raptopova J, (1,2) Srotova I, (3) Sommer C, (3) Üçeyler N, (4) Birklein F, (4) Rebhorn C, (5) Rittner HL, (1,2) Kovalova E, (1,2) Nekvapilova E, (6) Belobradkova J, (7) Olsovsky J, (8) Weber P, (9) Dusek L, (9) Jarkovsky J, (1,2) Bednarik J. (1) Central European Institute of Technology, Masaryk University, Brno, Czech Republic (2) Department of Neurology, University Hospital Brno Brno, Brno, Czech Republic (3) Department of Neurology, University of Würzburg, Germany (4) Department of Neurology, University Medical Center, Mainz, Germany (5) Department of Anesthesiology, Centre for interdisciplinary Pain Medicine, University Hospital Würzburg, Germany (6) Diabetologic Centre, Department of Internal Medicine and Gastroenterology, University Hospital Brno (7) Diabetologic Centre, St. Anne University Hospital, Brno, Czech Republic (8) Department of Internal Medicine, Geriatrics and Practical Medicine, University Hospital Brno, Brno, Czech Republic (9) Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic

PHYSIOLOGICAL CHARACTERIZATION OF NOCICEPTORS INNERVATING THE PLANTAR SKIN FOLLOWING NEUROPATHIC INJURY

Johannes Kühnemund
(1) Kühnemund J, (2) Wetzel C, (3) Bégay V, Moshourab R (4) & (5) Lewin GR. (1) MDC & BIH, Berlin, Germany; (2)(3),(5) MDC, Berlin, Germany; (4) Charité, Berlin, Germany
OP4_4  CHRONIC NON-FREEZING COLD INJURY RESULTS IN NEUROPATHIC PAIN DUE TO A SENSORY NEUROPATHY
Tom Vale
Vale TA, Themistocleous AC, Rice A, Symmonds M, Polydefkis M, Bennett DLH

OP4_5  EVALUATION OF MOLECULAR INVERSION PROBE VERSUS TruSeq® CUSTOM-NEXT GENERATION SEQUENCING METHODS TO IDENTIFY GENETIC VARIATIONS IN PAINFUL NEUROPATHIES- THE PROPANE STUDY
Rowida Almomani
Rowida Almomani1, Margherita Marchi2, Patrick Lindsey1, Maurice Sopacua3, Silvia Santoro 4, Hubert Smeets1, Giuseppe Lauria2, Filippo Martinelli Boneschi4, Sulayman Dib-Hajj5,6,7, Stephen G Waxman5,6,7, Ingemar S.J. Merkies3,8, Catharina G. Faber3, Monique M. Gerrits1; PROPANE Study Group

OP4_6  TRPV1 Expression in Human Peripheral Sensory Nerves and Relationship to Neuropeptides CGRP and SP
Baohan Pan
(1) Pan B, (2) Karlsson P, (1) Liu Y, (3) Caterina M, (1) Polydefkis M. (1) Department of Neurology, Johns Hopkins University, Baltimore, USA; (2) Danish Pain Research Center and Department of Clinical Medicine, Aarhus University Hospital, Denmark; (3) Department of Neurosurgery, Johns Hopkins University, Baltimore, USA.

OP4_7  SMALL FIBER NEUROPATHY CHARACTERIZATION IN THE SOD1G93A ALS MOUSE MODEL
Miguel Angel Rubio
Rubio MA1,2, Herrando-Grabulosa M2, Vilches JJ2, Navarro X2. 1 Neuromuscular Unit, Department of Neurology, Hospital del Mar. Barcelona, Spain; 2 Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences and CIBERNED, Universitat Autònoma de Barcelona, Bellaterra, Spain.

OP4_8  AN IN VIVO AND IN VITRO NEUROPHYSIOLOGICAL APPROACH TO ACUTE AND CHRONIC OXALIPLATIN-INDUCED PERIPHERAL NEUROTOXICITY
Paola Alberti
(1) Alberti P, (2) Lecci M, (1,2,3) Monza L, (2) Pastori V, (1) Fumgalli F, (1) Pozzi E, (2) Becchetti A, (4) Bostock H, (1) Cavaletti G. (1) School of Medicine and Surgery- PhD Program in Neuroscience - University of Milano-Bicocca, Monza, Italy; (2) Department of Biotechnology and Bioscience - University of Milano-Bicocca, Milan, Italy; (3) PhD program in Translational and Molecular Medicine (DIMET) - University of Milano-Bicocca, Milan, Italy; (4) University College London, London, London, U.K.

OP4_9  PROLONGED POST TETANIC POTENTIATION
Ludwig Gutmann
Gutmann L, Shy M

OP4_10  THE GENERATOR SITE IN ACQUIRED AUTOIMMUNE NEUROMYOTONIA
Miguel Oliveira Santos
Oliveira Santos M1,2, Swash M1,3, de Carvalho M1,2. 1Institute of Physiology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal; 2Department of Neurology, Department of Neurosciences and Mental Heath, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal; 3Departments of Neurology and Neuroscience, Barts and the London School of Medicine, Queen Mary University of London, United Kingdom.
OP4_11 33408 PHARMACOLOGICAL STIMULATION OF PHAGOCYTOSIS ENHANCES AMYLOID PLAQUE CLEARANCE; EVIDENCE FROM A TRANSGENIC MOUSE MODEL OF ATTR NEUROPATHY

Eleni Fella
(1) Fella E, (2) Sokratous K, (2) Papacharalambous R,(2) Kyriacou K, (3) Phillips J, (4) Sanderson S, (2) Panayiotou E, (2) Kyriakides T (1) The Cyprus School of Molecular Medicine, P.O.Box 23462, 1683 Nicosia, Cyprus; (2) The Cyprus Institute of Neurology & Genetics, P.O.Box 23462, 1683 Nicosia, Cyprus; (3) Donald P. Shiley Bioscience Center, San Diego State University, San Diego, California, United States of America; (4) Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, United States of America

OP4_12 35046 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF L-SERINE IN SUBJECTS WITH HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY TYPE 1 (HSAN1)

Vera Fridman
(1) Fridman, V, (2) Novak P, (1) David W, (1) Macklin EA, (1) McKenna-Yasek, D, Walsh K, (1) Oaklander AL, (2) Brown R, (3) Hornemann T, (1) Eichler F. (1) Massachusetts General Hospital, Boston, MA, USA, (2) University of Massachusetts Medical School, Worcester, USA, (3) University Hospital Zurich, Zurich, Switzerland.

OP4_13 34742 HUMAN IPSC DERIVED SENSORY NEURON MODEL OF HEREDITARY SENSORY NEUROPATHY TYPE 1 (HSN1)

Umaiyal Kugathasan
Kugathasan U1, Clark AJ2, Suriyanarayanan S3, Laurá M1, Wilson E1,4, Kalmar B4, Greensmith L1,4, Hornemann T3, Reilly MM1* and Bennett DLH2*. 1MRC Centre for Neuromuscular Diseases, London, UK; 2Neural Injury Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; 3Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; 4Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London, UK.

OP4_14 33405 THE ROLE OF COMPLEMENT IN ATTR AMYLOIDOSIS: A NEW THERAPEUTIC AVENUE?

Elena Panagiotou
(1) Panagiotou E, (2) Fella E, (1) Papacharalambous R, (1) Malas S, (3) Saraiva MJ, (1) Kyriakides T. (1) The Cyprus Institute of Neurology & Genetics, P.O.Box 23462, 1683 Nicosia, Cyprus; (2) The Cyprus School of Molecular Medicine, P.O.Box 23462, 1683 Nicosia, Cyprus; (3) Instituto de Inovação e Investigação em Saúde (I3S) and Neurobiologia Molecular-Instituto de Biologia Molecular (IBMC) - Universidade do Porto, 4200-135, Portugal

OP4_15 35075 NEUROPHYSIOLOGICAL FINDINGS IN ASYMPTOMATIC STAGE OF FAMILIAL AMYLOID NEUROPATHY: A CASE CONTROL STUDY

Guillemette Beaudonnet

12.00 - 14.00 Lunch + Poster Viewing
12.00 - 13.00  
Sponsor Symposia 3: CSL and Termuno BCT

TerumoBCT “Therapeutic Plasma Exchange in PNS Diseases: New Knowledge”

14.00 - 14.30  
Plenary 5: Michael Coleman - PK Thomas Lecture
THE CONTROL OF WALLERIAN DEGENERATION AND ITS RELEVANCE TO PERIPHERAL NEUROPATHY

14.30 - 15.30  
Oral Abstracts

14.30  
ATP1A1 REPRESENTS A SIGNIFICANT NOVEL DOMINANT CMT2 GENE

O6_1  
Stephan Zuchner
35264

(1) Lassuthova, P, (2) Rebelo, A, (3) Ravenscroft, G, (3) Lamont, P, (3) Baxter, M, (3) Ong, R, (8) Davis, M, (7) Manganelli, F, (2) Tao, F, (2) Saghira, C, (2) Abreu, L, (6) Bai, Y, (4) Isom, D, (3) Laing, N, (5) Choi, B-O, (1) Seeman, P, (6) Shy, M, (7) Santoro, L, (2) Zuchner S.  (1) DNA Laboratory, Department of Paediatric Neurology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic; (2) Dr. John T. Macdonald Foundation Department of Human Genetics, John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, USA; (3) Centre for Medical Research, University of Western Australia and Harry Perkins Institute of Medical Research, Nedlands, Australia; (4) Department of Pharmacology, Sylvester Comprehensive Cancer Center, and Center for Computational Sciences, University of Miami, Miami, USA; (5) Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; (6) Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, USA (7) Department of Neuroscience, Reproductive Sciences and Odontostomatology, Naples, Italy.

14.45  
PLASMA NEUROFILAMENT LIGHT CHAIN LEVELS ARE RAISED IN PATIENTS WITH INHERITED PERIPHERAL NEUROPATHY AND CORRELATE WITH DISEASE SEVERITY

O6_2  
Alexander Rossor
35092

(1) Fisgun, A, (1) Luan X and (1) Hoke A  (1) Johns Hopkins University, Baltimore, USA

15.00  
SARM1 DELETION AND WLDS ARE NEUROPROTECTIVE IN THREE MODELS OF CHEMOTHERAY INDUCED PERIPHERAL NEUROPATHY

O6_3  
Ahmet Hoke
34838

(1) Fisgun, A, (1) Luan X and (1) Hoke A (1) Johns Hopkins University, Baltimore, USA
15.15

PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY: IMPORTANCE OF PATIENT REPORTED OUTCOMES

Susanna Park

1,2) Park SB, (3) Kwok JB, (4) Asher R, (4) Lee CK, (5) Beale P, (6) Selle F, (2) Freidlander M. (1) Brain and Mind Centre, University of Sydney, Sydney, Australia; (2) Prince of Wales Clinical School, University of New South Wales, Sydney, Australia; (3) Neuroscience Research Australia, University of New South Wales, Sydney, Australia; (4) National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia; (5) Concord Cancer Centre, Concord Repatriation General Hospital, Sydney, Australia; (6) Department of Medical Oncology, Alliance For Cancer Research, Hôpital Tenon, Paris, France

15.30 - 17.00
Oral Posters

OP5_1
Peripheral Neuropathy Research Registry (PNRR)

Simone Thomas

Simone Thomas (1), Senda Ajroud-Driss (2), Mazen Dimachkie (3), Roy Freeman (4), David Simpson (5), Gordon Smith (6) and Ahmet Hoke (1). (1) Johns Hopkins School of Medicine (2) Northwestern University Medical Center, (3) Kansas University Medical Center, (4) Beth Israel Deaconess Medical Center, (5) Icahn School of Medicine at Mount Sinai Medical Center, (6) University of Utah Medical Center

OP5_2
POLYNEUROPATHY RELATES TO IMPAIRMENT IN DAILY ACTIVITIES, WORSE GAIT AND FALL-RELATED INJURIES

Rens Hanewinckel

1, 2) Hanewinckel R, (2, 3) Drenthen J, (1) Verlinden VJA, (1) Darweesh SKL, (3) van der Geest JN, (1, 5) Hofman A, (2) van Doorn PA, (1) Ikram MA. (1) Department of Epidemiology; (2) Department of Neurology; (3) Department of Neuroscience; (4) Department of Clinical Neurophysiology, Erasmus University Medical Center, Rotterdam, the Netherlands; (5) Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.

OP5_3
IENF AND MC ARE EARLY MARKERS OF PERIPHERAL INVOLVEMENT IN PD AND ARE DIFFERENTLY AFFECTED BY LIDOPA TREATMENT

Maria Nolano

(1) Nolano M, (1) Provitera V, (1) Stancanelli A, (1) Caporaso G, (1) Saltalamacchia AM, (1) Borreca I, (1) Lullo F, (1) Califano F, (1) Lanzillo B, (2) Iodice R, (2) Manganelli F, (3) Barone P, (2) Santoro L. (1) IRCCS "Salvatore Maugeri" Foundation, Institute, of Telese Terme (BN), Italy; (2) "Maugeri" Clinical and Scientific Institutes IRCCS, Institute of Telese Terme (BN), Italy; (3) Center for Neurodegenerative Diseases (CEMAND), Department of Medicine and Surgery, Neuroscience Section, University of Salerno, Italy.

OP5_4
A RANDOMIZED TRIAL OF AN AUTOMATED CIPN SYMPTOM MANAGEMENT SYSTEM

Noah Kolb

(1) Kolb, N, (2) Smith, A.G., (2) Singleton J.R., (3) Beck, S., (4) Howard, D. (5) Dittus, K., (2) Karafiath, S., (3) Mooney, K. (1) Department of Neuroscience, University of Vermont, Burlington, VT, USA, (2) Department of Neurology, University of Utah Health, SLC, UT, USA, (3) College of Nursing, University of Utah Health, SLC, UT, USA (4) Clinical Research Center, University of Vermont, Burlington, VT, USA, (5) Department of Medicine, Hematology/Oncology, University of Vermont, Burlington, VT, USA.
ROLE OF THE ALPHA SECRETASE TACE DURING WALLERIAN DEGENERATION

Marta Pellegatta
Pellegatta M1, Canevazzi P1, Forese MG1, Podini P2, Quattrini A2 and Taveggia C1 1Division of Neuroscience and INSPE, A xo-Glia Interaction Unit, San Raffaele Scientific Institute, Milan, Italy; 2 Division of Neuroscience and INSPE, Experimental Neuropathology Unit, San Raffaele Scientific Institute, Milan, Italy

SELECTIVE MUSCARINIC RECEPTOR ANTAGONISM ACTIVATES THE ERK/MAPK PATHWAY IN ADULT SENSORY NEURONS

Mohammad Golam Sabbir
Sabbir MG1, Calcutt NA2 and Fernyhough P1, 3. 1Division of Neurodegenerative Disorders, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada, 2Department of Pathology, University of California San Diego, California USA and 3Dept of Pharmacology & Therapeutics, University of Manitoba, MB, Canada.

CARPAL TUNNEL SYNDROME AS A HUMAN IN VIVO MODEL TO STUDY LARGE FIBER REGENERATION

Vincenzo Provitera

CMAP SCAN ANALYSIS IN MULTIFOCAL MOTOR NEUROPATHY

Boudewijn Sleutjes
Sleutjes BTHM, Kovalchuk M, van Schelven LJ, van den Berg L, Franssen, H.

CUTANEOUS NERVE FIBER ANALYSIS AS A BIOMARKER IN TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY

Gigi Ebenezer
(1) Gigi J Ebenezer, (1) Ying Liu, (2) Daniel P. Judge, (1) Kelly Cunningham, (3) Shaun True love, (1) Noel D. Carter, (1) Blessan Sebastian, (1) Kelly Byrnes, (1) Michael Polydefkis. (1) Department of Neurology, Johns Hopkins University, Baltimore, MD, USA; (2) Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA; (3) Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

A KNOCK-IN / KNOCK-OUT MOUSE MODEL FOR SMALL HEAT SHOCK PROTEIN HSPB8 MIMICKING DISTAL HEREDITARY MOTOR NEUROPATHY AND MYOFIBRILLAR MYOPATHY

Vincent Timmerman

PATHOGENESIS OF CHARCOT-MARIE-TOOTH DISEASE TYPE 2C DUE TO MUTATIONS IN TRPV4

Brett McCray
Johns Hopkins University, Baltimore, USA

NOVEL PHE210LEO MISSENSE MUTATION IN AIFM1 GENE IS ASSOCIATED WITH AN AXONAL POLYNEUROPATHY

Ryan Castoro
NOVEL NEFH MUTATIONS AS A CAUSE OF AN AUTOSOMAL AXONAL FORM OF CHARCOT-MARIE-TOOTH DISEASE WITH PROXIMAL MUSCLE INVOLVEMENT

Cécile Delorme
(1) Département de Neurologie, Hôpital Pitié-Salpêtrière, Paris, France
(2) Institut NeuroMyoGène, Université Lyon 1 - CNRS UMR 5310 - INSERM U1217, Lyon, France
(3) Unité fonctionnelle de neurogénétique moléculaire, CHU de Lyon - HCL groupement Est, Bron, France
(4) Clinique du motoneurone et pathologies neuromusculaires, CHRU de Montpellier, Montpellier, France
(5) Dr John T. MacDonald Foundation Department of Human Genetics, Institute of Human Genomics, University of Miami, Miller School of Medicine, Miami, USA
(6) Centre de références des maladies neuromusculaires, CHU de Bordeaux, Bordeaux, France
(7) Centre de Biotechnologie Cellulaire, CBC Biotec, CHU de Lyon - HCL groupement Est, Faculté de médecine Lyon Est, Bron, France
(8) Institut de Myologie, Hôpital Pitié-Salpêtrière, Paris, France

ALTERED NEUROFILAMENT DISTRIBUTION IN HUMAN CMT2E MOTOR NEURON AXONS

Mario Saporta
(1,2) de Moraes Maciel R, (1) Cutrupi AN, (2) Rebelo A, (2) Zuchner S, (1,2) Saporta MA
(1) Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA;
(2) Department of Human Genetics, Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.

MODELLING BROWN-VIALETTO-VAN LAERE SYNDROME IN C. ELEGANS

Megan Brewer
(1,2) Brewer MH, (2) Attrill G, (1) Ellis M, (1) Ly C, (1,2,3) Nicholson GA, (4,5) Menezes MP*, (1,2,3) Kennerson ML*
(1) Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia;
(2) Sydney Medical School, University of Sydney, Sydney, Australia;
(3) Molecular Medicine, Concord Repatriation General Hospital, Sydney Australia;
(4) The Institute for Neuroscience and Muscle Research, The Children’s Hospital at Westmead, Sydney, Australia;
(5) Pediatrics and Child Health, University of Sydney, Sydney, Australia;
*Equal last author

17.00 - 18.00 Coffee + Poster Viewing

18.00 - 19.00 Presidential Talk + Prizes

Presidential Lecture
HUMANS - THE ULTIMATE ANIMAL MODEL
Mary Reilly

19.00 PNS Closing Dinner
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3_1</td>
<td>SUBACUTE COMBINED DEGENERATION CAUSED BY CHRONIC ATROPHIC GASTRITIS WITH SPURIOUS ELEVATION OF VITAMIN B12 LEVEL</td>
<td>Min Su Park, Park JG, Park MS. Yeungnam University College of Medicine.</td>
</tr>
<tr>
<td>P3_3</td>
<td>ARSENIC TRIOXIDE INDUCED PERIPHERAL NEUROPATHY: PROSPECTIVE EVALUATION OF TWO PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA.</td>
<td>Marta Ruiz, Ruiz M, Lessi F, Cacciavillani M, Riva M, Salvalaggio A, Campagnolo M, Briani C. Neurology, Department of Neuroscience, University of Padova. Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova; 3CEMES, Data Medica Group, Padova, Italy.</td>
</tr>
<tr>
<td>P3_4</td>
<td>PERONEAL NERVE LESION DUE TO HERPES ZOSTER</td>
<td>Refah Sayin, Odabasi Z, Sayin R, Rota DD. Losante Hospital, Ankara, TURKEY; Ufuk University, Ankara, TURKEY; Ufuk University-Losante Hospital, Ankara, TURKEY</td>
</tr>
<tr>
<td>P3_5</td>
<td>IMPAIRMENT OF MITOCHONDRIAL TRAFFICKING IN DORSAL ROOT GANGLION NEURONS IS DEPENDENT ON HYDROCARBON CHAIN LENGTH OF SATURATED FATTY ACIDS</td>
<td>Maegan Tabbey, Rumora AE, Tabbey MA, LoGrasso G, Dolkowski J, Haidar J, Lentz SI, and Feldman EL. Department of Neurology, University of Michigan, Ann Arbor, MI 48109 USA; Department of Internal Medicine, Division on Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48105 USA</td>
</tr>
<tr>
<td>P3_6</td>
<td>THE ASSOCIATION BETWEEN THE METABOLIC SYNDROME AND NEUROLOGIC OUTCOMES IN A BARIATRIC SURGERY POPULATION</td>
<td>Emily Villegas-Umana, Callaghan BC, Villegas-Umana E, Reynolds E, Averill S, Feldman EL</td>
</tr>
<tr>
<td>P3_7</td>
<td>INCIDENCE OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY AND LONG TERM DISEASE BURDEN ON CANCER SURVIVORS IN A POPULATION-BASED COHORT</td>
<td>Nathan Staff, Shah A, Hoffman EM, Klein CJ, Staff NP. Mayo Clinic, Rochester, USA.</td>
</tr>
</tbody>
</table>
TREATMENT INDUCED NEUROPATHY OF DIABETES IN PATIENTS WHO HAVE UNDERGONE BARIATRIC SURGERY

Joel Wong
(1) Wong SHJ, (2) Koh SJ, (1) Lee BJH, (3) Chng YSK, (4) Pawa C, (4) Subramaniam T, (4) Cheng KSA, (2) T. Umapathi. (1) Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; (2) National Neuroscience Institute, Singapore; (3) Yong Loo Lin School of Medicine, National University Singapore, Singapore; (4) Khoo Teck Puat Hospital, Singapore.

PREVALENCE OF PERIPHERAL NEUROPATHY AMONG FREQUENT FLYERS – IS THERE A LINK TO “AEROTOXIC SYNDROME”?

Maryam Balke
(1) BALKE M, (1) SPRENGER A, (1) WUNDERLICH G, (3) STETTNER M, (1,2) FINK GR, (1) LEHMANN HC. (1) University Hospital of Cologne, Germany (2) INM-3 Research Centre Jülich, Jülich, Germany (3) University Hospital of Essen, Germany

ESTABLISHMENT OF THE COCULTURE SYSTEM OF IMMORTALIZED SCHWANN CELLS IFRS1 AND MOTOR NEURON-LIKE CELLS NSC-34

Kazunori Sango
Sango K, Takaku S, Niimi N, Yako H. Diabetic Neuropathy Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

THE EFFECT OF CURCUMIN ON PERIPHERAL NERVE REGENERATION

Özgür Demir
(1) Kilinç M, (1) Oksuz E, (1) Demir O, (1) Ersay FD, (2) Cevik B. Affiliations: (1) Gaziosmanpaşa University, Department of Neurosurgery, Tokat, Turkey (2) Gaziosmanpaşa University, Department of Neurology, Tokat, Turkey

TIME-COURSE CHARACTERIZATION OF FOREIGN BODY REACTION TO IMPLANTED DEVICES IN RAT PERIPHERAL NERVE

Natalia de la Oliva
De la Oliva N1, Del Valle J1, Navarro X1. 1Institute of Neurosciences, Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Bellaterra, Spain

ALTERNATIVES TO TRADITIONAL NERVE AUTOGRRAFTS FOR THE RECONSTRUCTION OF PERIPHERAL NERVE DISCONTINUITIES

Erick DeVinney
(1) DeVinney E, (2) Ducic I. (1) AxoGen Clinical Sciences, Alachua, FL USA; (2) Washington Nerve Institute, McLean, VA USA

IMPLICATIONS OF SKIN BIOPSY TISSUE THICKNESS ON STUDY OUTCOMES

Christopher Gibbons
(1) Gibbons C, (1) Wang N, (1) McCormick M, (1) Freeman R. (1)Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.

RECURRENT PERIPHERAL AND CENTRAL DEMYELINATION IN A SERONEGATIVE PATIENT

Can Ebru Bekircan-Kurt
(1,2) Bekircan-Kurt CE, (1) Yildiz G, (1) Temuçin Ç, (1) Kurne AT, (1,2) Tan E, (1,2) Erdem-Ozdamar SE Hacettepe University (1) Department of Neurology, (2) Neuromuscular Disease Research Laboratory Ankara, TURKEY
P3.16 OPTIMIZING ELECTRODIAGNOSTICS FOR GUILLAIN-BARRE SYNDROME: CLUES FROM CLINICAL PRACTICE
Fu Liong Hiew
(1) Fu Liong Hiew, (2) Yusuf A. Rajabally, (1) Regional Neuromuscular Clinic, Queen Elizabeth Hospital, University Hospitals of Birmingham, Birmingham, United Kingdom; (2) School of Life and Health Sciences, Aston Brain Centre, Aston University, Birmingham, United Kingdom.

P3.17 INFLUENCE OF IVIG ON NERVE EXCITABILITY IN MULTIFOCAL MOTOR NEUROPATHY
Maria Kovalchuk
Maria Kovalchuk 1, Hessel Franssen1, Leonard J van Schelven2, Leonard van den Berg1, Boudewijn Sleutjes1. 1Department of Neuro muscular Disorders, University Medical Center Utrecht, the Netherlands. 2Department of Medical Technology and Clinical Physics, University Medical Centre Utrecht, the Netherlands.

P3.18 HEMOLYTIC SIDE EFFECTS OF IVIG: MODELING PREDICTS RISK REDUCTION WITH ANTI-A/B IMMUNOAFFINITY CHROMATOGRAPHY AND TO A LESSER EXTEND WITH ANTI-A DONOR SCREENING.
Alphonse Hubsch
(1) Mallik R, (2) Hubsch A, (2) Gaida A, (3) Barnes D. (1) CSL Behring, KOP, US; (2) CSL Behring, Bern, Switzerland, (3) CSL Behring, Ottawa, Canada.

P3.19 THE VALUE OF ELECTROPHYSIOLOGICAL TYPING AND CONDUCTION BLOCK FOR PREDICTION OF FUNCTIONAL OUTCOME IN GUILLAIN-BARRE SYNDROME
Jingwen Niu
Niu JW, Cui LY, Guan YZ, Liu MS. The Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

P3.20 CLINICAL AND ELECTRODIAGNOSTIC FEATURES OF GANGLIONOPATHIES WITH SPECIAL REFERENCE TO ULNAR SENSORY-MOTOR AMPLITUDE RATIO(USMAR) FROM A TERTIARY CARE CENTER IN INDIA
Anjan Pyal
(1)Pyal A, (2)Sireesha Y,(3)Neeharika ML,(4) Meena AK . (1) Senior resident , (2) Assistant professor, (3) Assistant professor, (4) Professor. Department of Neurology, Nizam’s Institute of Medical Sciences.

P3.21 DOES ELECTROPHYSIOLOGY AND TREATMENT RESPONSE DIFFER IN IDIOPATHIC VS DIABETIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)?
Anza Memon
Anza Memon, Sarah Madani, BK. Ahmad, Lonni Schultz, Kavita Grover, Ximena Arcila-londono, Naganand Sripathi. Neuromuscular Division, Department of Neurology, Henry Ford Hospital, Detroit, MI.

P3.22 ASSESSMENT OF INDIVIDUAL RESPONSE TO INTRAVENOUS IMMUNOGLOBULIN USING DAILY HOME MONITORING OF HAND GRIP STRENGTH IN CHRONIC INFLAMMATORY NEUROPATHIES
Pietro Emiliano Doneddu
(1) Doneddu PE, (1) Hadden RDM (1) Department of Neurology, King’s College Hospital, London, UK.

P3.23 A RETROSPECTIVE AUDIT OF IVIG INFUSION RATES IN THE TREATMENT OF AUTOIMMUNE NEUROLOGICAL DISEASE
Michael Cumberbatch
P3_24 SWEATING DISTURBANCES IN SENSORY NEURONOPATHY

Rodrigo Conde
(1) Conde RM, (1) Fusco T, (2) Martinez AR, (1) França MC Jr, (1) Marques Jr W, (1) Barreira AA. (1) Department of Neuroscience, University of São Paulo, Medical School of Ribeirão Preto, SP, Brazil; (2) Department of Neurology, Faculty of Medical Sciences, University of Campinas, SP, Brazil

P3_25 PURE NEURAL LEPROSY MIMIKING BRACHIAL AND LUMBOSACRAL PLEXOPATHY

Pedro José Tomaselli Pj (1), Marques VD (1), dos Santos AJC (1), Lavigne CM (1), Toscano PO (1), Barreira AA (1), Foss N (2), Frade MA (2), Marques W Jr (1, 3) (1) Division of Neuromuscular Diseases, Department of Neurosciences and Behaviour Sciences, Clinical Hospital of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. (2) Dermatology, Department of Internal Medicine, Clinical Hospital of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. (3) Neurogenetics, Department of Neurosciences and Behaviour Sciences, University of São Paulo, Ribeirão Preto, Brazil.

P3_26 CORTICOSTEROID TREATMENT IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY – A MULTICENTER, RETROSPECTIVE STUDY.

Gwen van Lieverloo
(1) van Lieverloo G, (2) Basta I, (1) Verhamme C, (3) Gallia F, (2) Stevic S, (2) Nikolic A, (3) Liberatore G, (3) Bianco M, (3) Doneddu P, (1) van Schaik I, (3) Nobile-Orazio E, (1) Eftimov F (1) Academic Medical Center (AMC), Amsterdam, the Netherlands (2) Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia (3) Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Center, Department of Medical Biotechnology and Translational Medicine, Milan University, Rozzano, Milan, Italy

P3_27 DOES INTRAVENOUS IMMUNOGLOBULIN SERVE AS AN EFFECTIVE TREATMENT FOR GUILLAIN-BARRÉ SYNDROME IN DEVELOPING COUNTRIES? A CONTROLLED MATCHED PAIR ANALYSIS

Nowshin Papri
(1) Islam Z, (1) Papri N, (1) Ara G, (1,2) Islam MB, (3) Mohammad QD (1) International Centre for Diarrhoeal Disease Research, (icddr,b), Dhaka, Bangladesh; (2) Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands; (3) National Institute of Neurosciences and Hospital, Sher-e-Bangla Nagar, Agargaon, Dhaka, Bangladesh

P3_28 NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY

Elena Alvarez-Baron
(1) Gertz M, (2) Comenzo RL, (3) Landau H, (4) Sanchorawala V, (5) Weiss BM, (6) Zonder JA, (7) Walling J, (8) Kinney GG, (8) Koller M, (8) Schenk DB, (8) Guthrie SD, (8) Liu E, (8) Alvarez-Baron E, (9) Liedtke M. (1) Mayo Clinic, Rochester, USA; (2) Tufts Medical Center, Boston, USA; (3) Memorial Sloan Kettering Cancer Center, New York, USA; (4) Boston University School of Medicine, Boston, USA; (5) University of Pennsylvania, Philadelphia, USA; (6) Karmanos Cancer Institute, Detroit, USA; (7) JW Consulting, Hillsborough, USA; (8) Prothena Biosciences Inc, South San Francisco, USA; (9) Stanford University School of Medicine, Stanford, USA.

P3_29 RABBIT ANTI-FGFR3 ANTIBODIES INDUCE NEURON CELL DEATH AND MODULATE FGFR3 AND NMDA AND AMPA RECEPTORS THROUGH THE P38-MAP KINASE PATHWAY.

Jean-Christophe Antoine
Boutahar N,1 Reynaud E,1 Nasser Y,1 Camdessanché JP,1 Antoine JC.1 1 University Hospital, Saint-Etienne, France.
INTERNATIONAL CIDP OUTCOME STUDY (ICOS): A PROSPECTIVE STUDY ON CLINICAL AND BIOLOGICAL PREDICTORS OF DISEASE COURSE AND OUTCOME

P3_30
Merel Broers
(1) Bunschoten C, (2) van Lieverloo GGA, (2) Adrichem MA, (1) Broers MC, (3) van der Pol WL, (2) Eftimov F, (1,4) Jacobs BC, for the ICOS Consortium. (1) Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands; (2) Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands; (3) Department of Neurology, University Medical Center, Utrecht, The Netherlands; (4) Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.

EFFECTIVE THERAPEUTIC EFFECT OF HUMAN IMMUNOGLOBULIN AND A RECOMBINANT Fc PORTION ON A RAT MODEL FOR CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)

P3_31
Susana Brun
(1) Brun S, (1,2) Kremer L, (3) Mondon P, (3) Jacque E, (3) Chtourou S, (4) Masiello NC, (1,2) De Seze J. (1) UMR_S INSERM U1119 Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques. University of Strasbourg. Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; (2) Departement of Neurology, University Hospital of Strasbourg, Strasbourg, France; (3) Direction of Innovative Therapeutic, LFB Biotechnologies, Loos, France; (4) LFB USA, Framingham, MA.

MRI OF THE BRACHIAL PLEXUS AND CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY: ASSESSMENT OF DTI-DERIVED MEASUREMENTS AT 3.0-T

P3_32
Eve Chanson
Chanson E (1,2), Barriol M. (1,3), Taithe F (1,2), Zerroug A (1,3), Lhoste A.(1,3), Pereira B. (4), Boyer L.(1,3), Jean B. (1,3), Clavelou P. (1,2) (1) Clermont Université, Université d’Auvergne, EA7283 CREaT, Clermont-Ferrand, France ; (2) CHU Clermont Ferrand, Service de neurologie et unité de neurophysiologie clinique CHU Gabriel Montpied, Clermont Ferrand F-63000, France ; (3) CHU Clermont Ferrand, Service de radiologie, CHU Gabriel Montpied, Clermont Ferrand F-63000, France ; (4) CHU Clermont-Ferrand, Biostatistics unit (DRCI), Clermont-Ferrand, France.

EGOS DID NOT HAVE A GOOD CAPACITY TO PROGNOSIS IN GBS IN RIO GRANDE DO NORTE, BRAZIL

P3_33
Mário Emílio Dourado

INTERNATIONAL STANDARD FOR CIDP REGISTRY AND BIOBANK, RESULTS OF THE 231ST ENMC CONSENSUS MEETING

P3_34
Filip Eftimov
(1) Eftimov F, (2) Querol L, (3) Rajabally YA on behalf of all participants of the 231st ENMC Workshop. (1) Academic Medical Center, Amsterdam, the Netherlands ; (2) Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; (3) Aston University, Birmingham, United Kingdom

VALUE OF ANTI-HNK1 ANTIBODIES IN ANTI-MAG NEUROPATHIES: AN ANALYSE OF 144 SERA.

P3_35
Emilien Delmont
(1)Delmont E, (2)Antoine JC, (3)Paul S, (4)Boucraut J, (1)Attarian S (1) Referral centre for ALS and neuromuscular diseases, Marseille, France (2) Referral centre for neuromuscular diseases, Saint Etienne, France (3) Immunology laboratory, Saint Etienne, France (4) Immunology laboratory, Marseille, France
2017 PNS Annual Meeting
Sitges-Barcelona (Spain)
8 - 12 July

GBS CLASSIFICATION ACCORDING TO TWO-SETS OF EMG EXAMINATION IN A SAMPLE OF THE BRAZILIAN POPULATION

Caroline Germano
Germano CSB, Moreira CL, Marques VD, Santos ACJ, Onofre PTBN, Barreira AA, Marques W Jr.

AUTOIMMUNE T CELLS IN AN EX VIVO MODEL OF THE PERIPHERAL NERVOUS SYSTEM

Lea Grümme
(1) Lea Grümme, (2) Sandra T Hattenhauer, (2) Kathleen Wolffram (1) Christoph Kleinschnitz, (1) Anne K. Mausberg, (1) Mark Stettner (1) Department of Neurology, University Hospital Essen, Essen, Germany; (2) Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany

RANDOMIZED CONTROLLED TRIAL OF ORAL FINGOLIMOD IN CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (FORCIDP TRIAL): SUBGROUP ANALYSES

Richard Hughes
(1) Hughes R, (2) Comblath D, (3) Dalakas M, (4) Merkies ISJ, (5) Latov N, (6) Léger J-M, (7) Nobile-Orazio E, (8) Sobue G, (9) Genge A, (10) Merschhemke M, (10) Ervin C, (10) Agoropoulou C, (11) Hartung H-P (1) National Hospital for Neurology and Neurosurgery, London, UK; (2) Johns Hopkins Medical School, Baltimore, MD, USA; (3) University of Athens Medical School, Athens, Greece; (4) Maastricht University Medical Center, Maastricht, The Netherlands; St. Elisabeth Hospital, Willemstad, Curacao, Netherlands Antilles; (5) Well Cornell Medical College, NY, USA; (6) National Referral Center for Neuromuscular Diseases, University Hospital Pitié-Salpêtrière, Paris, France; (7) Milan University, Humanitas Clinical and Research Center, Rozzano, Milan, Italy; (8) Nagoya University Hospital, Nagoya, Japan; (9) Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada; (10) Novartis Pharma AG, Basel, Switzerland; (11) Department of Neurology, Universitätsklinikum Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany

EFFICACY OF IMMUNOGLOBULINS FOR NOD B7-2 KO MICE

Masahiro Iijima

SMALL VOLUME PLASMA EXCHANGE FOR GUILLAIN-BARRE SYNDROME IN LOW INCOME COUNTRIES: A SAFETY AND FEASIBILITY STUDY

M Badrul Islam
(1) Islam MB, (2) Islam Z, (3) Rahman S, (4) Endtz HP, (5) Vos MC, (6) vanDoom PA, (8) Jacobs BC, (9) Mohammad OD. (1) Laboratory Sciences and Services Division, International Centre for Diarrhoeal Disease Research, (icddr,b) Dhaka, Bangladesh and Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands; (2) Laboratory Sciences and Services Division, International Centre for Diarrhoeal Disease Research, (icddr,b) Dhaka, Bangladesh; (3) Department of Anesthesia and Intensive Care, Uttara Adhunik Medical College Hospital, Dhaka, Bangladesh; (4) Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands and Fondation Mérieux, Lyon, France; (5) Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands; (6) Department of Intensive Care, Erasmus MC, Rotterdam, The Netherlands; (7) Department of Neurology, Erasmus MC, Rotterdam, The Netherlands; (8) Department of Neurology and Immunology, Erasmus MC, Rotterdam, The Netherlands; (9) National Institute of Neurosciences, Dhaka, Bangladesh

THE SUCCESSFUL USE OF VERY HIGH DOSE IVIG IN ACQUIRED, DEMYELINATING NEUROPATHIES- 3 CASES

Mahima Kapoor
Kapoor M1, Catania S2, Sarri-Gonzales S1, Lunn MP1, Manji H1, Reilly MM1, Carr AS1 1)Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK 2)Department of Neurophysiology, National Hospital for Neurology and Neurosurgery, London, UK
AUTOPHAGOLYSOSOME-MEDIATED MYELIN CORPSE FORMATION BY SCHWANN CELLS IN SEGMENTAL DEMYELINATION

Byeola Yoon

ANTIBODIES AGAINST CELL ADHESION MOLECULES AND NEURAL STRUCTURES IN PARANEOPLASTIC NEUROPATHIES.

Ana Maria Siles
Siles AM 1,2, Martínez-Hernández E3, Diaz-Manera J1,2, Rojas-Garcia R1,2, Gallardo E1,2, Illa I1,2, Graus F3, Querol L1,2. 1 Neuromuscular Diseases Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Univeristat Autònoma de Barcelona, Barcelona (Spain); 2 Centro para la Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid (Spain); 3 Neuroimmunology Program, August Pi Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clinic, University of Barcelona (Spain).

UPDATE ON THE INTERNATIONAL GBS OUTCOME STUDY IN CHILDREN (IGOS-KIDS)

Alexandra Doets
Roodbol J 1,2, Yiu E 4, Doets A 1,2, de Wit MCY 2, Monges MS 5, van Nes S 6, Catsman-Berrevoets CE 2, van den Berg B 1,3, Jacobs BC 1,3, on behalf of the IGOS-Kids Consortium.
1 Department of Neurology, 2 Paediatric Neurology, 3 Immunology, Erasmus MC – Sophia Children’s Hospital, University Medical Center Rotterdam, The Netherlands.
4 Department of Paediatric Neurology, Royal Children’s Hospital Melbourne, Australia.
5 Department of Paediatric Neurology, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.
6 Department of Neurology, Havenziekenhuis Rotterdam, the Netherlands.

HEAD AND VOICE TREMOR IMPROVING WITH IMMUNOTHERAPY IN AN ANTI-NF155 POSITIVE CIDP PATIENT

Cèlia Painous Martí
Painous C, López-Pérez MA, Illa I, Querol L. Neuromuscular Diseases Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona (Spain). Centro para la Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid (Spain).
THE FRANCOPHONE ANTI-MAG COHORT: ANALYSIS OF THERAPEUTIC MANAGEMENT IN 202 PATIENTS

Jean-Philippe Camdessanche
(1) Department of Neurology, University Hospital of Saint-Etienne, 42055 Saint-Étienne Cedex 2 – France
(2) Department of Neurology, Croix-Rousse Hospital, Hospices Civils de Lyon, 103 grande rue de la Croix-Rousse, 69004 Lyon – France
(3) Electroneuromyography and Neuromuscular Department, GHE Neurologic Hospital, 69677 Lyon, Bron Cedex – France
(4) Department of Neurology, Timone Hospital, Marseille Teaching Hospital, Marseille – France
(5) Department of Neurophysiology and Neuropathology, AP-HP, GHU Pitié-Salpêtrière, Paris – France
(6) Neuromuscular Reference Center, CHU Nantes, 44093 Nantes Cedex 1
(7) Department of Neurology, Bicêtre Hospital, APHP, Le Kremlin Bicêtre, France
(8) Neuromuscular Competence Center, CHU Rouen, 73031 Rouen Cedex, France
(9) Reference Center of Neuromuscular Disorders, Neurology Department, Haute-pierre Hospital, Strasbourg, France
(10) Electroneuromyography and Neuromuscular Disorders Unit, Department of Clinical Neurosciences, Geneva University Hospital, 1211 Geneva, Switzerland
(11) Department of Neurology, Fondation Ophtalmologique A. de Rothschild, Paris, France
(12) Department of Neurology, Centre de Référence "Neuropathies Périphériques Rares", University Hospital of Limoges, 2 Avenue Martin Luther King, 87042 Limoges, France
(13) Department of Neurology, National Referral Center for Rare Neuromuscular Diseases, University Hospital Pitié-Salpêtrière and University Paris VI, Paris, France
(14) Nerve-Muscle Unit, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
(15) Department of Neurology, Basel University Hospital, Basel, Switzerland.

Members of the Francophone anti-MAG cohort Group are listed in “Appendix”.

Appendix: The Francophone anti-MAG cohort Group: Other members of the Francophone anti-MAG cohort Group who provided cases for the study are, in alphabetical order: David Adams, Hôpital Bicêtre; Sharam Attarian, CHU de Marseille; Anne-Laure Bedat-Millet, CHU de Rouen; Françoise Bouhour, CHU de Lyon; Célia Boutte, CHU de Grenoble; Guy Chauplannaz, CHU de Lyon; Raquel Costa, Hôpital Pitié-Salpêtrière; Perrine Devic, CHU de Lyon; Chantal Grand, CHU de Lyon; Guillenmette Jousserand, CHU de Lyon; Timothée Lenglet, Hôpital Pitié-Salpêtrière; Pierre Lozeron, Hôpital Bicêtre; Thierry Maisonobe, Hôpital Pitié-Salpêtrière; Cristina Muntean, Hôpital Pitié-Salpêtrière; Yann Pereon, CHU de Nantes; Jean Pouget, CHU de Marseille.

Inhibition of Complement in Guillain-Barré Syndrome: The ICA-GBS Study

Amy Davidson
Davidson AI 1 , Halstead SK 2 , Goodfellow JA 1 , Chavada G 1 , Mallik A 3 , Overell J 1 , Lunn MP 4 , McConnachie A 5 , van Doorn P 6 , Willison HJ 1 . (1) Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, 1345 Govan Road, Glasgow. (2) Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow. (3) Department of Clinical Neurophysiology, Institute of Neurological Sciences, Southern General Hospital, 1345 Govan Road, Glasgow. (4) Department of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London. (5.) Robertson Centre for Biostatistics, Boyd Orr Building, University of Glasgow. (6) Department of Neurology, Erasmus, MC, Rotterdam
P3_48 SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE FCRN INHIBITOR UCB7665: A PHASE I STUDY
Peter Kiessling
(1) Kiessling P, (2) Lledo-Garcia R, (3) Watanabe S, (4) Langdon G, (2) Tran D, (2) Bari M, (2) Christodoulou L, (2) Price G, (2) Smith B, (5) Brosset AE, (6) Jolles S. (1) UCB Pharma, Monheim, Germany; (2) UCB Pharma, Slough, UK; (3) UCB Pharma, Braine-l’Alleud, Belgium; (4) PTx Solutions Ltd, London, UK; (5) UCB Pharma, Raleigh, Durham, USA; (6) University Hospital of Wales, Cardiff, UK.

P3_49 MR-NEUROGRAPHY DETECTS INVOLVEMENT OF THE PERIPHERAL NERVOUS SYSTEM IN MULTIPLE SCLEROSIS
Jennifer Kollmer

P3_50 IMMUNE CHECKPOINT INHIBITOR-INDUCED ACUTE NEUROPATHIES
Thierry Kuntzer
Tsouni P1, Devic P2, Moura B1, Planque E3, Bédart-Millet AL4, Devaux J5, Steck AJ1, Delmont E6, Hottinger AF1, Kuntzer T1. 1DCN, CHUV, Lausanne, Switzerland; 2Centre de Référence Maladies Neuromusculaires, Hospices Civils de Lyon, Lyon, France; 3Cabinet Médical, Epinal, France; 4Département de neurologie, CHU de Rouen, Rouen, France; 5CNRS, CRN2M-UMR 7286, Université Aix-Marseille, Marseille, France; 6Centre de Référence maladies neuromusculaires et SLA, Hôpital La Timone, Marseille, France.

P3_51 ATYPICAL CASE OF ACUTE MOTOR AND SENSORY AXONAL NEUROPATHY (AMSAN) IN A PATIENT CO-INFECTED WITH SYPHILIS
Tayla Romão
(1) Romão TT, (2) Aleixo BFL, (3) Wedemann DLM, (4) Herculano FGN, (5) Prado HJ, (6) Cal H, (7) Pupe C, (8) Bittar C, (9) Nascimento OJM. (1,2,3,4,5,6,7,8,9) Universidade Federal Fluminense (UFF), Rio de Janeiro, Brazil

P3_52 CLINICO-ELECTROPHYSIOLOGICAL CORRELATION WITH ANTI-NEUROFASCIN155 ANTIBODY LEVELS IN THE ANTIBODY-POSITIVE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY PATIENTS
Hidenori Ogata

P3_53 THE CHALLENGES OF ACCURATE DIAGNOSIS OF ZIKA VIRUS ASSOCIATED GUILLAIN-BARRÉ SYNDROME (GBS) IN A DENGUE ENDEMIC AREA
Ohnmar Ohnmar
(1) Ohnmar O, (2) KamYW, (2) Ng LF, (3) T Umapathi (1) University of Medicine 1, Yangon, Myanmar, (2) Singapore Immunology Network, A*STAR, Singapore. (3) National Neuroscience Institute, Singapore.
P3_54  IGM ANTI-MAG PERIPHERAL NEUROPATHY: FROM PROPER ASSESSMENT TO TRIAL NEEDS (IMAGINE STUDY)
Mariëlle Pruppers
Pruppers MHJ(1,2) Merkies ISJ(1), Faber CG(1), Lunn MPT(3), Léger J-M(4), Nobile-Orazio E(5), Notermans NC (2), on behalf of the IMAGiNe study group. (1)Maastricht University Medical Centre, Maastricht, the Netherlands; (2) University Medical Centre Utrecht, Utrecht, the Netherlands; (3) Centre for Neuromuscular disease/ National Hospital for Neurology and Neurosurgery Queen Square, London, United Kingdom; (4) Hopital de la Salpêtrière, Paris, France; (5) Milan University/ Humanitas Clinical Institute, Milan, Italy.

P3_55  THE CRYPTIC 68-104 REGION OF MYELIN BASIC PROTEIN (MBP) CAUSES PAIN FROM LIGHT TOUCH EXCLUSIVELY IN FEMALE RODENTS: AUTOIMMUNE MECHANISMS OF SEXUAL DIMORPHISM IN MECHANICAL ALLODYNIA
Veronica Shubayev
Hullugundi SK1,2, Chernov AV3, Remacle AG3, Eddinger KA1, Angert M1,2, Doikas J1,2, Jones III RCW1,2,4, Strongin AY3, Yaksh TL1, Shubayev VI1,2. 1Department of Anesthesiology, University of California, San Diego, La Jolla, California, USA; 2VA San Diego Healthcare System; La Jolla, California, USA; 3Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, California, USA; 4Center for Pain Medicine, University of California, San Diego, La Jolla, California, USA.

P3_56  GUILLAIN-BARRÉ SYNDROME – ACUTE DISEASE WITH CHRONIC CONSEQUENCES
Stojan Peric
(1) Peric S, (1) Bozovic I, (2) Martic V, (2) Komatina N, (3) Djuric V, (4) Petrovic M, (5) Vujovic B, (5) Cukic M, (3) Djordjevic G, (1) Stevic Z, (1) Basta I. (1) Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia, (2) Military Medical Academy, Belgrade, Serbia, (3) Neurology Clinic, Clinical Center Nis, Nis, Serbia, (4) Neurology Clinic, Clinical Center Kragujevac, Kragujevac, Serbia, (5) Neurology Clinic, Clinical Center of Montenegro, Podgorica, Montenegro

P3_57  MONITORING PREGNANCY IN CHARCOT-MARIE-TOOTH DISEASE: RESULTS OF A SURVEY
Mariola Skorupinska
MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London UK; Coombe Women and Infants University Hospital, Dublin

P3_58  MYASTHENIA GRAVIS? MYOPATHY? OR A NEUROPATHY?
Albert Teng
(1) Teng A, (2) Ohnmar, (2) Kalpana P, (2) Chai YH, (2) T. Umapathi. (1) Yong Loo Lin School of Medicine, National University of Singapore, Singapore; (2) Department of Neurology, National Neuroscience Institute, Singapore.

P3_59  THE GERMAN CHARCOT-MARIE-TOOTH DISEASE NETWORK (CMT-NET): FROM RISK FACTORS TO THERAPEUTIC ACTIONS
Michael W. Sereda
(1,2) Sereda MW, (3) Walter MC, (4) Martini R, (4) Young P  (1) University Medical Centre Göttingen, Germany; (2) Max-Planck-Institute for Experimental Medicine, Göttingen, Germany; (3) Friedrich-Baur-Institute, Ludwig Maximilians University Munich, Germany; (4) University Hospital Würzburg, Germany (4) University of Münster, Germany
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3_60</td>
<td>RELEVANCE AND FREQUENCY OF DIFFERENT TYPES OF CHARCOT-MARIE-TOOTH NEUROPATHY IN A LARGE POPULATION OF PATIENTS STUDIED AT A SINGLE CLINICAL SITE</td>
<td>Giulia Ursino, (1)C. Gemelli, (1)M. Grandis, (2)L. Reni, (1)E. Bellone, (1)A. Geroldi, (1)F. Gotta, (1)P. Mandich, (1)M. Ferrara, (1)A. Schenone</td>
<td>DINOGMI University of Genoa, IRCCS-AOU San Martino Hospital Genoa, Hospital Genoa, Italy</td>
</tr>
<tr>
<td>P3_61</td>
<td>THE INHERITED NEUROPATHY VARIANT BROWSER</td>
<td>Stephan Zuchner</td>
<td>University of Miami, DNA Laboratory, Department of Paediatric Neurology, Charles University in Prague, Czech Republic</td>
</tr>
<tr>
<td>P3_62</td>
<td>AN ONGOING PHASE 2 STUDY EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ACE-083 IN PATIENTS WITH CMT1 AND CMTX</td>
<td>Kenneth Attie</td>
<td>Acceleron Pharma, University of Minnesota, Hackensack University Medical Center, University of Iowa, Iowa City, USA</td>
</tr>
<tr>
<td>P3_63</td>
<td>AUTONOMIC SYMPTOMS IN TRANSTHYRETIN AMYLOIDOSIS: AN ANALYSIS OF SYMPTOMATIC SUBJECTS FROM THE THAOS REGISTRY</td>
<td>Fabio Barroso</td>
<td>Raúl Carrea Institute for Neurological Research, Universidad de Brasilia, Mexico City, Argentina; Hackensack University Medical Center, University of Iowa, Iowa City, USA</td>
</tr>
<tr>
<td>P3_64</td>
<td>NOVEL, LIKELY PATHOGENIC, SEQUENCE VARIANTS IN HEREDITARY NEUROPATHY GENES</td>
<td>Geir Julius Braathen</td>
<td>Department of Laboratory Medicine, Section of Medical Genetics, Telemark Hospital, Skien, Norway</td>
</tr>
<tr>
<td>P3_65</td>
<td>CMT2 WITH PYRAMIDAL TRACT INVOLVEMENT DUE TO ARG329HIS MUTATION IN ALANYL-TRNA SYNTHETASE (AARS)</td>
<td>Ilaria Callegari</td>
<td>Neuroscience Consortium, University of Pavia, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, London, UK; MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, Queen Square, London, UK</td>
</tr>
</tbody>
</table>
P3_66  UNRAVELLING THE DISEASE MECHANISMS UNDERLYING THE DHMN1 INSERTION
34726  Anthony Cutrupi
(1,2,3) Cutrupi A N, (1) Perez-Siles G, (1) Brewer M H, (6) de Moraes Maciel R, (1) Ly C, (1) Drew A, (5) Zuchner S, (1,2,4) Nicholson G, (6) Saporta M A*, (1,2,4) Kennerson M L*. (1) Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia; (2) Sydney Medical School, University of Sydney, Sydney, Australia; (3) Sydney Medical School Foundation, Sydney, Australia; (4) Molecular Medicine Laboratory, Concord Repatriation General Hospital, Sydney, Australia; (5) Department of Human Genetics, Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, USA; (6) Department of Neurology, University of Miami, Miller School of Medicine, Miami, USA. *Equal last author

P3_67  HUMAN MOTOR NEURON NEUROSPHERES AS A NEW PLATFORM TO STUDY AXONAL PHENOTYPES IN PERIPHERAL NEUROPATHIES
34872  Renata de Moraes Maciel dos Santos
(1,2) de Moraes Maciel Renata, (1,2) Saporta Mario A

P3_68  AXONAL NEUROPATHIES DUE TO MUTATIONS IN SMALL HEAT SHOCK PROTEINS: CLINICAL, GENETIC AND FUNCTIONAL INSIGHTS INTO NOVEL MUTATIONS.
34576  Andoni Echaniz-Laguna
(1) Echaniz-Laguna A, (2) Geuens T, (3) Petiot P, (4) Péreton Y, (2) Adriaenssens E, (2) Haidar M, (2) Capponi S, (5) Maisonneuve T, (5) Fournier E, (5) Dubourg O, (5) Degos B, (5) Salachas F, (5) Lenglet T, (5) Eymard B, (6) Delmont E, (7) Pouget J, (8) Morales Juntas R, (9) Goizet C, (3) Latour P, (2) Timmerman V, (5) Stojkovic T. (1) Strasbourg University Hospital, Strasbourg, France; (2) Peripheral Neuropathy Group, VIB Department of Molecular Genetics and Institute Born Bunge, University of Antwerp, Antwerpen, Belgium (3) Lyon University Hospital, Lyon, France; (4) Nantes University Hospital, Nantes, France; (5) Hôpital de la Pitié-Salpêtrière, Paris, France; (6) Nice University Hospital, Nice, France; (7) Marseille University Hospital, Marseille, France; (8) Montpellier University Hospital, Montpellier, France; (9) Bordeaux University Hospital, Bordeaux, France.

P3_69  MUTATIONS IN BAG3 CAUSE ADULT ONSET CHARCOT MARIE TOOTH DISEASE
34352  Shawna Feely
(1) Feely S, (2) Rebelo A, (2) Abreu L, (2) Tao F, (1) Bacon C, (2) Zuchner S, (1) Shy ME. (1) University of Iowa, Iowa City IA; (2) Dr. John T Macdonald Department of Human Genetics and Hussman Institute for Human Genetics, Miller School of Medicine, University of Miami, Miami FL.

P3_70  SCHWANN CELL AND ENDOTHELIAL CELL DAMAGE IN TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY
35023  Haruki Koike
Haruki Koike,1 Shohei Ikeda,1 Mie TakahashiD,1 Yuichi Kawagashira,1 Masahiro Iijima,1 Yohei Misumi,2 Yukio Ando,2 Shu-ichi Ikeda,3 Masahisa Katsuno,1 and Gen Sobue 1,4 1Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan 2Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan 3Intractable Disease Care Center, Shinshu University Hospital, Matsumoto, Japan 4Research Division of Dementia and Neurodegenerative Disease, Nagoya University Graduate School of Medicine, Nagoya, Japan

P3_71  MOTOR AXON EXCITABILITY IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1B WITH A NULL MUTATION IN THE P0 GENE – INSIGHTS FORM A MOUSE MODEL.
35227  Christian Krarup
(1,2) Krarup C, (1,2) Moldovan M, (1) Alvarez S, (3) Ciano C, (3) Pisciotta C, (3) Pareyson D. (1) Univ. of Copenhagen, Copenhagen, Denmark; (2) Rigshospitalet, Copenhagen, Denmark; (3) Fondazione IRCCS Istituto Neurologico C.Besta, (INCB), Milan, Italy
ACE-083, A LOCALLY-ACTING GDF/ACTIVIN LIGAND TRAP, AUGMENTS DORSIFLEXOR MUSCLE FUNCTION IN A MURINE MODEL OF CHARCOT-MARIE-TOOTH (CMT) DISEASE

Jia Li
Jia Li1, Marishka Cannell1, Rajasekhar NVS Suragani1, R Scott Pearsall1, Ravindra Kumar1. 1Acceleron Pharma Inc, Cambridge, USA.

SENSITIVITY OF THE CMT INFANT SCALE: PRELIMINARY ANALYSIS OF CMT SUBTYPES AND COMPARISON TO CONTROLS

Melissa Mandarakas

(1) University of Sydney, Sydney, Australia; (2) Sydney Children's Hospitals Network (Randwick and Westmead), New South Wales, Australia; (3) University of Iowa Hospitals and Clinics, Iowa City, USA; (4) The Royal Children's Hospital and University of Melbourne, Victoria, Australia; (5) The Children's Hospital of Philadelphia, Philadelphia, USA; (6) Istituto Neurologico Carlo Besta, Milan, Italy; (7) Nemours Children's Hospital, Orlando, USA; (8) Connecticut Children's Medical Center, Hartford, USA; (9) University of Rochester, Rochester, USA; (10) MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, UK; (11) Great Ormond Street Hospital, London, UK; (12) Siriraj Hospital, Mahidol University, Bangkok, Thailand.

CLINICAL AND NEUROPHYSIOLOGICAL PROFILE OF CMTX3 IN CHILDHOOD

Manoj Menezes
(1) Kanhangad M, (2,3) Cornett K, (2,4) Brewer MH, (2,4,5) Nicholson GA, (1,2,3) Ouvrier RA, (6,7,8) Ryan MM, (9) Smith RL, (9) Subramanian GM, (2,10) Young HK, (2,4,5) Kennerson ML, (2,3) Menezes MP. (1) T.Y. Nelson Department of Neurology and Neurosurgery, The Children's Hospital at Westmead, Westmead, Australia; (2) University of Sydney, Camperdown, Australia; (3) Institute for Neuroscience and Muscle Research, The Children's Hospital at Westmead, Westmead, Australia; (4) Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, Australia; (5) Molecular Medicine Laboratory, Concord Repatriation General Hospital, Concord, Australia; (6) Department of Neurology, Royal Children's Hospital, Parkville, Australia; (7) Murdoch Childrens Research Institute, Parkville, Victoria, Australia; (8) Department of Paediatrics, University of Melbourne, Parkville, Australia; (9) Department of Neurology, John Hunter Children's Hospital, and University Faculty of Health, Newcastle, Australia; (10) Department of Paediatrics, Royal North Shore Hospital, St Leonards, Australia; (11) Paediatric Gait Analysis Service of New South Wales, Sydney Children's Hospitals Network (Randwick and Westmead), Australia.

CMT1B AND SENSORY ABNORMALITIES ASSOCIATED WITH A MPZ NULL MUTATION

Giuseppe Piscosquito
(1) Piscosquito G, (2) Saveri P, (1) Provitera V, (1) Stancanelli A, (3) Ciano C, (4) Magri S, (4) Taroni F, (5) Fabrizi GM (1) Nolano M, (2) Pareyson D. (1) Neurorehabilitation Unit, "Mauger" Scientific Clinical Institutes, Scientific Institute of Telese Terme (BN), Italy; (2) Unit of Rare Neurological Diseases of Adulthood, Department of Clinical Neurosciences, IRCCS Foundation, "C. Besta" Neurological Institute, Milan, Italy; (3) Neurophysiopathology and Epilepsy Centre, Department of Diagnostics and Applied Technology, IRCCS Foundation, C. Besta Neurological Institute, Milan, Italy; (4) Unit of Genetics of Neurodegenerative and Metabolic Disease, Department of Diagnostic and Applied Technology, IRCCS Foundation, "C. Besta" Neurological Institute, Milan, Italy; (3) Section of Neurology, Department of Neurological and Movement Sciences, University of Verona, Verona, Italy.
P3_76  EVALUATING THE BENEFITS OF COMMUNITY BASED AEROBIC TRAINING ON THE PHYSICAL HEALTH AND WELL-BEING OF PEOPLE WITH CHARCOT-MARIE-TOOTH DISEASE TYPE 1A: A PILOT RANDOMISED CONTROLLED TRIAL.

Gita Ramdharry
Wallace A (1), Pietrusz A (1), Dewar E (1), Dudziec M (1,2), Jones K (1), Hennis P (3), Sterr A (4), Baio G (5), Butcher K (6), Laura M (1), Skorupinska I (1), Skorupinska M (1), Trenell M (7), Hanna MG (1), Reilly MM (1), Ramdharry GM (1,2). 1MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK 2Faculty of Health, Social Care & Education, Kingston University/St George’s University of London, UK 3Institute of Sport, Exercise and Health, UCL, UK 4Department of Psychology, University of Surrey, Guildford, UK 5Department of Statistical Science, UCL, London. UK 6Charcot Marie Tooth United Kingdom, Registered charity number 1112370, UK 7Moveland, Newcastle University, UK

P3_77  RECESSIVE SH3TC1 VARIANTS IN A CASE WITH PROGRESSIVE AND LETHAL PERIPHERAL DEMYELINATION

Adriana Rebelo
(1) Rebelo A, (2) Feely, SM, (1) Bis D, (1) Tao F, (2) Shy, R, (1) Zuchner, S, (2) Shy, M. (1) Dr. John T. Macdonald Foundation Department of Human Genetics, John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, USA; (2) Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, USA

P3_78  CHARCOT-MARIE-TOOTH DISEASE TYPE-1A (CMT1A) PLUS

Megan Simmons
(1) Simmons M, (2) Tao F, (2) Abreu L, (2) Zuchner S, (1) Li J. (1) Department of Neurology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA; (2) Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.

P3_79  MOTOR UNIT NUMBER INDEX CORRELATES WITH DISABILITY IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A.

Joachim Bas
(1) Bas J, (1, 2) Delmont E, (1) Fatehi F, (3) Boulay C, (3) Chapr b, (1, 5) Salort-Campana E, (1) Sévy A, (1) Verschueren A, (1, 5) Pouget J, (4) Lefebvre MN, (1) Grapperon AM, (1, 5) Attarian S. (1) Reference Center for Neuromuscular Diseases and ALS, La Timone University, Aix-Marseille University, Marseille, France (2) Aix-Marseille University, UMR 7286, Medicine Faculty, Marseille, France (3) Reference Center for Pediatric Neuromuscular Disorders, La Timone University Hospital, Aix-Marseille University, Marseille, France (4) CIC- CPCET, La Timone University Hospital, Aix-Marseille University, Marseille, France (5) Aix-Marseille University, Inserm, GMGF, Marseille, France

P3_80  PHENOTYPICAL AND GENOTYPICAL CROSSROADS BETWEEN INHERITED DISEASES OF NERVE AND MUSCLE: TWO EXAMPLES OF VCP AND GNE –RELATED DISORDERS

Gian Maria Fabrizi
(1) Fabrizi GM, (1) Testi S, (2) Høyer H, (2) Braathen Gj, (3) Squintani G, (1) Bertolasi L, (1) Ferrari M, (1) Taioli F, (1) Cabrini I, (1) Panceri E, (1) Cavallaro T, (1) Tonin P. (1) Department of Neuroscience, Biomedicine and Movement, University of Verona and Department of Neuroscience, AOUI Verona, Italy; (2) Section of Medical Genetics, Department of Laboratory Medicine, Telemark Hospital, Skien, Norway.
P3_81  PMP22 EXON 4 DELETION CAUSES ER RETENTION OF PMP22 AND A GAIN-OF-FUNCTION ALLELE IN CMT1E

Tiffany Grider
(1) Department of Neurology, Neuro muscular Division, University of Iowa Hospitals and Clinics, Iowa City, Iowa (2) Department of Neurology, Neuro genetics Division, University of Iowa Hospitals and Clinics, Iowa City, Iowa (3) Departments of Neurology and Pediatrics, Washington University School of Medicine, Neuromuscular Division, St. Louis MO (4) Department of Pediatrics, Baylor College of Medicine, Houston, Texas  * The two authors contributed equally

P3_82  TAFAMIDIS DELAYS DISEASE PROGRESSION COMPARABLY ACROSS VAL30MET AND NON-VAL30MET GENOTYPES IN TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY

Balarama Gundapaneni
(1) Gundapaneni B, (2) Sultan MB, (2) Keohane DJ, (2) Schwartz J. (1) inVentiv Health Inc., Burlington, MA, USA; (2) Pfizer Inc, New York, NY, USA.

P3_83  THE DEVELOPMENT OF NEUROPATHY IN A MOUSE MODEL OF CMT2E - SEQUENTIAL NERVE CONDUCTIONS

Eunjoo Lancaster
(1) Lancaster E, (1) Li J, (2) Liem R (1) Scherer SS. (1) Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; (2) Columbia University School of Medicine, New York, NY, USA

P3_84  MOLECULAR DIAGNOSIS OF INHERITED PERIPHERAL NEUROPATHIES: GENE PANEL VS. EXOME SEQUENCING

Vincenzo Lupo
Lupo V1.2, Frasquet M3.4, Sánchez-Monteagudo A1.2, Barreiro M3, García-Romero M5, Alberti MA6, Márquez-Infante C7, Pascual S15, Casasnovas C6, Quintans B8.9, Camacho A10, Domínguez C10, Sedano MJ11, Pelayo AL11, Pardo J12, Sobrino T12, Sobrido MJ8.9, Sevilla T3.4, Espinós C1.2. 1Centro de Investigación Príncipe Felipe, Valencia, Spain; 2INCLIVA & IIS La Fe Rare Diseases Joint Units, Valencia, Spain; 3Hospital Universitari i Politècnic La Fe, Valencia, Spain; 4CIBER of Rare Diseases (CIBERER); 5Hospital La Paz, Madrid, Spain; 6Hospital Bellvitge, Barcelona, Spain; 7Hospital Virgen del Rocio, Sevilla, Spain; 8Instituto de Investigaciones Sanitarias (IDIS), Santiago de Compostela, Spain; 9Fundación Pública Galega de Medicina Xenómica, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain; 10Hospital 12 de Octubre, Madrid, Spain; 11Hospital Universitario Marqués de Valdecilla, Santander, Spain; 12Hospital Clínic Universitario Santiago de Compostela, Santiago de Compostela, Spain.

P3_85  CLINICAL SIGNIFICANCE OF CONDUCTION BLOCK IN CMT1A PATIENTS WITH PMP22 DUPLICATION

Jihyung Park
(1) Park J, (2) Choi MS, (3) Seok JM, (4) Min JH, (5) Kim BJ, (6) Choi BO. (1) Samsung Medical Center, Seoul, Korea, Republic of; (2) Samsung Medical Center, Seoul, Korea, Republic of; (3) Samsung Medical Center, Seoul, Korea, Republic of; (4) Samsung Medical Center, Seoul, Korea, Republic of; (5) Samsung Medical Center, Seoul, Korea, Republic of; (6) Samsung Medical Center, Seoul, Korea, Republic of.
CHARCOT MARIE TOOTH DISEASE TYPE 2 (CMT2P) DUE TO LRSAM1 MUTATIONS: CLINICAL AND GENETIC FINDINGS

Andrea Cortese
Cortese A (1), Laura M (1), Polke H (2), Poh R (2), Rossor AM(1), Tomaselli P (1), Blake J (1), Lunn M (1), Houlden H (3), Reilly MM (1). (1) MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, Queen Square, London, UK (2) Department of Neurogenetics, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, London, UK (3) Department of Molecular Neuroscience, UCL Institute of Neurology and the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

WEDNESDAY 12 JULY 2017

7.30 - 8.30  Clinical Trial Updates
Coffee + Poster Viewing

Clinical Trial Updates

Poster Session 4 (see end of Wednesday for poster titles)

8.30 - 9.00  Plenary 6: Jim Sejvar
NEURO-EPIEMIOLOGY AND ITS RELEVANCE TO PERIPHERAL NEUROPATHY
INTERNATIONAL GUILLAIN-BARRÉ SYNDROME OUTCOME STUDY (IGOS): DESCRIPTION OF THE FIRST 1000 PATIENTS

Bianca van den Berg


(1) Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
(2) Department of Neurology, University of Glasgow, Glasgow, UK
(3) Department of Neurology, Aarhus University Hospital, Aarhus, Denmark
(4) Department of Neurology, Tufts University School of Medicine, Boston, USA
(5) Department of Neurology, University of Düsseldorf, Düsseldorf, Germany
(6) Department of Neurology, University Hospital of Cologne, Köln, Germany
(7) Department of Neurology, Kindai University Faculty of Medicine, Osaka, Japan
(8) Department of Neurology, Hospital Sant Pau, UAB, Ciberer, Barcelona, Spain
(9) Department of Neurology, Milan University, Humanitas Institute, Milan, Italy
(10) Department of Neurology, Hospital Britanico, Buenos Aires, Argentina
(11) Department of Neurology, Concord Repatriation General Hospital, Sydney, Australia
(12) Department of Neurology, ICDDR,B, Dhaka, Bangladesh
(13) Laboratory Sciences and Services Division, ICDDR,B, Dhaka, Bangladesh
(14) National Institute of Neuroscience and Hospital, Dhaka, Bangladesh
(15) Department of Neurology, University Hospital St. Luc, Brussels, Belgium
(16) Department of Clinical Neuroscience, University of Calgary, Calgary, Canada
(17) Reference Centre for Neuromuscular Diseases, Nantes University Hospital, Nantes, France
(18) Department of Neurology, University of Malaya, Kuala Lumpur, Malaysia
(19) Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan
(20) Department of Neurology, University of Cape Town, Cape Town, South Africa
(21) Department of Neurology, University of Thessaly, Larissa Thessaly, Greece
(22) Department of Neurology, Affiliated Hospital of Jining Medical College, Jining, China
(23) Department of Neurology, Institute of Neurology, University College, London, UK
(24) Department of Neurology, Johns Hopkins University, Baltimore, USA
(25) Department of Immunology, Erasmus Medical Centre, Rotterdam, The Netherlands
9.15  REFINEMENT OF DIAGNOSTIC CRITERIA FOR CIDP BEYOND ELECTROPHYSIOLOGY: DATA FROM THE ITALIAN DATABASE FOR THE DIAGNOSIS AND THERAPY OF CIDP AND VARIANTS

O7_2  Giuseppe Liberatore
34972

9.30  THE ROLE OF IMMUNE CELLS IN NERVE DEGENERATION AND REGENERATION: A NEW PERSPECTIVE

O7_3  Richard Zigmond
35111
Lindborg JA, Niemi, JP, DeFrancesco A, Zigmond RE,

9.45  PREDICTORS OF SEVERITY AND OUTCOME OF GUILLAIN-BARRÉ SYNDROME IN CHILDREN

O7_4  Joyce Roodbol
35105
(1,2) Roodbol J, (5) Korinthenberg R, (2) de Wit MCY, (4) Lingsma H, (2) Catsman-Berrevoets CE, (1,3) Jacobs BC. (1) Department of Neurology, (2) Paediatric Neurology, (3) Immunology, (4) Public health, Erasmus MC–Sophia Children’s Hospital, University Medical Center Rotterdam, The Netherlands. (5) Division of Neuropaediatrics and Muscular Disorders, Department of paediatrics and Adolescent Medicine, University Hospital Freiburg, Freiburg, Germany.

10.00 - 10.30  Coffee

10.30 - 12.00  Oral Posters

OP6_1  IMMUNOGLOBULIN TREATMENT FOR PATIENTS WITH MILD GUILLAIN-BARRÉ SYNDROME: AN INTERNATIONAL PROSPECTIVE OBSERVATIONAL STUDY

Christine Verboon
34556
(1,2) Verboon C and (1, 2) Jacobs BC, the IGOS Consortium, (1) Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands, (2) Department of Immunology, Erasmus Medical Centre, Rotterdam, The Netherlands
OP6_2  MUTIPLE SITES NERVE ULTRASOUND OF CHARCOT-MARIE-TOOTH TYPE 1A AND CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY

Jingwen Niu
Niu JW, Cui LY, Liu MS. The Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

OP6_3  CIDP DIAGNOSTIC CRITERIA AND TREATMENT RESPONSE

Mamatha Pasnoor
Pasnoor M, Roach C, Barohn RJ, Statland J, Jawdat O, Dick A, Glenn M, Dimachkie MM. Department of Neurology, Neuromuscular Division, The University of Kansas Medical Center, Kansas City, KS, USA

OP6_4  PROPOSAL OF DIAGNOSTIC CRITERIA FOR POEMS SYNDROME WITH THE HIGH SENSITIVITY/SPECIFICITY

Tomoki Suichi
(1) Suichi T, (1) Misawa S, (2) Sato Y, (1) Beppu M, (1) Sekiguchi Y, (1) Shibuya K, (1) Watanabe K, (1) Amino H, (1) Kuwabara S. (1) Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan; (2) Clinical Research Center, Chiba University Hospital, Chiba, Japan.

OP6_5  BLINK R1 LATENCY UTILITY IN DIAGNOSIS AND TREATMENT ASSESSMENT OF POEMS AND CIDP

Wei Wang
(1, 2) Wang W, (1) Litchy WJ, (1) Mauermann ML, (1) Dyck PJB, (3) Dispenzieri A, (4) Mandrekar J, (1) Dyck PJ, (1) Klein CJ. (1) Department of Neurology, Mayo Clinic, Rochester MN, USA; (2) Department of Neurology, China-Japan Friendship Hospital, Beijing, China; (3) Department of Hematology, Mayo Clinic, Rochester MN, USA; (4) Biomedical Statistics and Informatics, Mayo Clinic, Rochester MN, USA.

OP6_6  ITG2A-EXPRESSING SCHWANN CELLS UPREGULATE A MACROPHAGE RECRUITMENT FACTOR PERIOSTIN DURING SPONTANEOUS AUTOIMMUNE PERIPHERAL NEUROPATHY

Denise Elena Allard

OP6_7  HIGH INCIDENCE OF GUILLAIN-BARRÉ SYNDROME AFTER ZIKA VIRUS INFECTION IN THE STATE RIO GRANDE DO NORTE, IN NORTHEAST BRAZIL

Mário Emílio Dourado

OP6_8  DIFFERENCES OF ANTIBODY REACTIVITIES AGAINST GLYCOLIPID COMPLEXES AMONG GUILLAIN-BARRÉ SYNDROME, MILLER FISHER SYNDROME AND BICKERSTAFF BRAINSTEM ENCEPHALITIS

Yoshikawa Keisuke
(1) Keisuke Y, Miyuki M, Motoi K, Susumu K. (1) Department of Neurology, Kindai University Faculty of Medicine, Osaka, Japan.
INTERNATIONAL ZIKA VIRUS RELATED GUILLAIN-BARRÉ SYNDROME OUTCOME STUDY (IGOS-ZIKA): A CASE-CONTROLLED STUDY

Sonia Leonhard
(1) S.E. Leonhard, (2) M. Amorelli, (3) A.A. Barreira, (4) D.R. Comblath, (5) M. Deen Mohammed, (1) P.A. van Doorn, (6) Z. Islam, (3) W. Marques Jr., (4) C.A. Pardo, (7) N. Shahrizaila, (8) T. Umapathi, (9) H.J. Willison, (1,10) B.C. Jacobs, the IGOS-Zika Consortium. (1) Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands, (2) Department of Infectious Diseases, Secretary of State for Health of the Federal District, Brasilia, Brazil, (3) Department of Neuroscience Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil, (4) Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, The United States (5) National Institute of Neurosciences and Hospital (NINS), Dhaka, Bangladesh, (6) Laboratory Sciences and Services Division, icddr,b, Dhaka, Bangladesh, (7) Department of Neurology, University of Malaya, Kuala Lumpur, Malaysia, (8) National Neuroscience Institute, Singapore, Singapore, (9) Department of Neurology, University of Glasgow, Glasgow, The United Kingdom, (10) Department of Immunology, Erasmus Medical Centre, Rotterdam, The Netherlands.

THE DIAGNOSTIC YIELD OF PCR-BASED CLONALITY TESTING ON NERVE BIOPSY IN THE DIAGNOSIS OF NEUROLYMPHOMATOSIS

Laurent Magy

INTRAVENOUS IMMUNOGLOBULIN (IVIG) FOR RESTABILIZATION TREATMENT AFTER IVIG WITHDRAWAL IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP). RESULTS FROM THE PRE-RANDOMIZATION PHASE OF THE PATH STUDY

Orell Mielke
(1) Mielke O, (2) Bril V, (3) van Geloven N, (4) Hartung H-P, (5) Lewis RA, (6) Sobue G, (1) Lawo J-P, (1) Durn BL, (7) Comblath DR, (8) Merkies ISJ, (9) van Schaik IN, on behalf of the PATH study group. (1) CSL Behring, Marburg, Germany and King of Prussia, PA, USA; (2) Department of Medicine (Neurology), University Health Network, University of Toronto, Toronto, Canada; (3) Department of Biostatistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands; (4) Department of Neurology, Heinrich Heine University, Düsseldorf, Germany; (5) Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; (6) Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan; (7) Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; (8) Department of Neurology, Maastricht University Medical Centre, Maastricht, The Netherlands; (9) Department of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
ELECTROPHYSIOLOGICAL CRITERIA FOR GBS SUBTYPE DIAGNOSIS: A PROSPECTIVE MULTICENTRIC EUROPEAN STUDY

Peter Van den Bergh
(1) Van den Bergh PYK, (2) Attarian S, (2) Grapperon AM, (3) Nicolas G, (4) Cassereau J, (5) Rajabally YA, (2) Delmont E, (6) Woodard JL, (7) Piéret F; the University of Louvain GBS Electrodiagnosis Study Group* (1) Neuromuscular Reference Centre, University Hospital St-Luc, Brussels, Belgium; (2) Centre de référence des maladies Neuromusculaires et la SLA, Hôpital de la Timone, Marseille, France; (3) Service de neurologie, Hôpital Raymond Poincaré, Garches, France; (4) Centre de Recherche Maladies Neuromusculaires de l’Enfant et de l’Adulte Nantes-Angers, Centre Hospitalier Universitaire d’Angers, Angers, France; (5) Regional Neuromuscular Service, Neurology, University Hospitals Birmingham, Birmingham, UK; (6) Department of Psychology, Wayne State University, Detroit, Michigan, USA; (7) St Elisabeth Hospital, Brussels, Belgium; *The University of Louvain GBS Electrodiagnosis Study Group: P. Y. K. Van den Bergh, V. Van Parijs (University Hospital St-Luc, Brussels); F. Piéret (St Elisabeth Hospital, Brussels); D. Verougstraete (Parc Leopold Hospital, Brussels); Ph. Jacquerye, J. M. Raymackers (St-Pierre Hospital, Ottignies); C. Redant (St-Luc Hospital, Bouge); C. Michel (Jolimont Hospital, Mons)

LARGE COVERAGE MR NEUROGRAPHY IN CIDP – DIAGNOSTIC ACCURACY AND ELECTROPHYSIOLOGICAL CORRELATION

Min-Suk Yoon
(1) Kronlage M, Baeumer P, (2) Pitarokoili K, (1) Schwarz D, (1) Schwehr V, (1) Godel T, (1) Heiland S, (2) Gold R, (1) Bendszus M, (2) Yoon MS. (1) Heidelberg University Hospital, Department of Neuroradiology, Germany (2) St. Josef. Hospital, Ruhr University of Bochum, Department of Neurology, Germany

MODELLING THE PHARMACOKINETICS OF INTRAVENOUS IMMUNOGLOBULIN IN GUILLAIN-BARRÉ SYNDROME

Willem Jan Fokkink
(1,2) Fokkink WJR, (3) de Winter BCM, (3) van Gelder T, (3) Koch BCP, (1,2) Jacobs BC. (1) Department of Immunology; (2) Neurology; (3) Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

ANTIBODIES AGAINST THE NODE OF RANVIER, A FLOW CYTOMETRY ANALYSIS

Emilien Delmont
12.00 - 14.00
Lunch + Poster Viewing

14.00 - 20.00
Individual Meetings

Poster Session 4

P4_1 PATIENT ASSISTED INTERVENTION FOR NEUROPATHY: COMPARISON OF TREATMENT IN REAL LIFE SITUATIONS (PAIN-CONTRoLS)
35108
Richard Barohn

P4_2 DIGIT WRINKLE SCAN©: FROM NORMATIVE VALUES TO ITS CLINICAL APPLICABILITY IN SMALL FIBER NEUROPATHY
32667
Isis Joosten
(1) Joosten IBT, (1) Sopacua M, (1) Bovenkerk DSH, (1) Potten RMM, (1) Faber CG, (2) Merkies ISJ, (1) Hoeijmakers JGJ. (1) Maastricht University Medical Center, Maastricht, The Netherlands; (2) St. Elisabeth Hospitaaal, Willemstad, Curaçao.

P4_3 COMPARISON BETWEEN COMPLEX REGIONAL PAIN SYNDROME TYPE 1 AND 2 BASED ON ELECTROPHYSIOLOGIC, IMAGING AND CLINICAL FINDINGS
35231
Je-Young Shin
(1) Shin JY, (2) Moon JY. (3) Sung JJ. (1) Seoul National University Hospital, Seoul, Republic of Korea; (2) Seoul National University Hospital, Seoul, Republic of Korea; (3) Seoul National University Hospital, Seoul, Republic of Korea.

P4_4 PERIPHERAL ANTINOCICEPTIVE EFFECT OF VENLAFAXINE IN RATS
34971
Gülay Sezer
Sezer G1, Teköl Y2, Sezer Z. 2,3 1Erciyes University, Betül Ziya Eren GenKok Genome and Stem Cell Centre, Kayseri, Turkey, 2 Erciyes University, School of Medicine, Pharmacology Department, Kayseri, Turkey. 3 Erciyes University, Good Clinical Practice and Research Centre, Kayseri, Turkey.
P4_5 34922

NEUROPHYSIOLOGICAL MEASURES CORRELATE WITH PATIENT REPORTED SYMPTOMS OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY

Hannah Timmins
(1) Brain and Mind Centre, University of Sydney; (2) Chris O'Brien Lifehouse, Sydney, NSW, Australia; (3) Sydney Medical School, University of Sydney, Sydney, NSW, Australia; (4) Department of Oncology, Royal Prince Alfred Hospital, NSW, Australia; (5) Patricia Ritchie Centre for Cancer Care and Research, The Mater Hospital, NSW Australia; (6) Sydney Nursing School, University of Sydney, NSW, Australia; (7) Prince of Wales Clinical School, UNSW, NSW, Australia; (8) Department of Medical Oncology at Prince of Wales Hospital, Sydney, NSW, Australia.

P4_6 35035

IVIg EFFECT IN A WISTAR RAT MODEL OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY

Elisa Ballarini
Ballarini E1, Meregalli C1, Carozzi V1, Chiorazzi A1, Canta A1, Monza L2, Fumagalli G3, Pozzi E3, Alberti P1,3, Rodriguez V1, Bossi M1, Marjanovic I4, Scali C4, Marmiroli P1, Cavaletti G1.  
1School of Medicine, Experimental Neurology Unit, University of Milano-Bicocca, Monza, Italy. 2PhD program in Translational and Molecular Medicine, DIMET, University of Milano-Bicocca, Milan, Italy. 3PhD program in Neuroscience, University of Milano-Bicocca, Monza, Italy. 4Kedrion S.p.A., Loc. Ai Conti, Castelvecchio Pascoli (Barga) Lucca, Italy

P4_7 34940

CHARACTERIZATION OF A TRANSGENIC MOUSE MODEL OVEREXPRESSING TNF ALPHA IN MYELINATING SCHWANN CELLS

Belén García-Lareu
Belén Garcia-Lareu1,2,3, Lorena Ariza2, Stephano Cobianchi1,4, Miguel Chilón1,2,5,6, Xavier Navarro1,3,4, Assumpció Bosch1,2,3 1Institut de Neurociències, UAB (INc), 2Departament de Bioquímica i Biologia Molecular, UAB 3Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CiberNed), Insituto de Salud Carlos III  4Departament Biologia Cel·lular, Fisiologia i Immunologia, UAB, 5Institut Català de Recerca i Estudis Avançats (ICREA) 6Unitat Mixta UAB-VHIR, Vall d'Hebron Institut de Recerca (VHIR)

P4_8 31107

DIAGNOSTIC VALUE OF SYMPTOMS IN CHRONIC POLYNEUROPATHY: THE ERASMUS POLYNEUROPATHY SYMPTOM SCORE (E-PSS)

Rens Hanewincke
(1, 2) Hanewinckel R, (1) van Oijen M, (3, 4) Merkies ISJ, (5) Notermans NC, (5) Vrancken AFJE, (2) Ikram MA, (1) van Doorn PA. (1) Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands; (2) Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands; (3) Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands; (4) Department of neurology, St. Elisabeth Hospital, Willemstad, Curaçao; (5) Department of Neurology, University Medical Center Utrecht, the Netherlands.

P4_9 35110

LONG-TERM OUTCOME OF INTRAEPIDERMAL NERVE FIBER REGENERATION IS IMPAIRED IN DIABETIC PATIENTS, BUT IS INDEPENDENT OF AXON LENGTH OR BLOOD GLUCOSE LEVEL.

Mohammad Khoshnoodi
Khoshnoodi M, Truelove S, Polydefkis M. The Johns Hopkins University, Baltimore, MD

P4_10 32746

A NOVEL PROTEIN, MAJOR URINARY PROTEIN (MUP) CONTRIBUTES TO THE BEHAVIOUR OF DIABETIC AND NONDIABETIC SENSORY NEURONS

Trevor Poitras
Poitras T, Chandrasekhar A, Singh V, Martinez J, Zochodne DW. Neuroscience Mental Health Institute, and Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2R3
INHIBITION OF HISTONE DEACETYLASE 6 (HDAC6) PROTECTS AGAINST VINCRIStINE-INDUCED PERIPHERAL NEUROPATHIES AND INHIBITS TUMOR GROWTH

Lawrence Van Helleputte
Van Helleputte L 1,2, Kater M 1,2, Cook D 3, Haeck W 1,2, Jaspers T 1,2, Geens N 1,2, Vanden Berghe P 4, Geysemans C 3, Robberecht W 1,2, Van Damme P 1,2,5, Cavaletti G 6, Jarpe M 7 and Van Den Bosch L 1,2 1 KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium 2 VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium 3 KU Leuven - University of Leuven, Clinical and Experimental Endocrinology, Leuven, Belgium 4 KU Leuven - University of Leuven, Laboratory for Enteric Neuroscience, TARGID, Leuven, Belgium 5 University Hospitals Leuven, Department of Neurology, Leuven, Belgium 6 Experimental Neurology Unit and Milan Center for Neuroscience, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. 7 Acetylon Pharmaceuticals Inc., Boston, MA, USA

PERIPHERAL NEUROTOXICITY IN OXALIPLATIN RETREATMENT IN COLORECTAL CANCER PATIENTS

ROSER VELASCO
(1,2) Gonçalves NP, (3) Murray SS, (2,4) Jensen TS, (1,2) Vaegter CB. (1) Danish Research Institute of Translational Neuroscience DANDRITE Nordic-EMBL Partnership, Department of Biomedicine, Aarhus University, Aarhus, Denmark; (2) The International Diabetic Neuropathy Consortium, Aarhus University, Aarhus, Denmark; (3) Department of Anatomy and Neuroscience, The University of Melbourne, Victoria, Australia; (4) Department of Neurology and Danish Pain Research Center, Aarhus University, Aarhus, Denmark.

SCHWANN CELL p75NTR EXPRESSION AND DIABETIC NEUROPATHY

Nadia Gonçalves
(1,2) Gonçalves NP, (3) Murray SS, (2,4) Jensen TS, (1,2) Vaegter CB. (1) Danish Research Institute of Translational Neuroscience DANDRITE Nordic-EMBL Partnership, Department of Biomedicine, Aarhus University, Aarhus, Denmark; (2) The International Diabetic Neuropathy Consortium, Aarhus University, Aarhus, Denmark; (3) Department of Anatomy and Neuroscience, The University of Melbourne, Victoria, Australia; (4) Department of Neurology and Danish Pain Research Center, Aarhus University, Aarhus, Denmark.

ROLE OF L-PGDS IN SCIATIC NERVE REGENERATION AFTER INJURY

Maria Grazia Forese
Forese MG 1, Pellegatta M 1, Rivellini C 2, Podini P 3, Quattrini A 3, Previtali SC 2, Tavaglia C 1. 1 Division of Neuroscience and INSPE, Axo-Glia Interaction Unit, San Raffaele Scientific Institute, Milan, Italy; 2 Division of Neuroscience and INSPE, Neuromuscular Repair Unit, San Raffaele Scientific Institute, Milan, Italy; 3 Division of Neuroscience and INSPE, Experimental Neuropathology Unit, San Raffaele Scientific Institute, Milan, Italy.

LOCAL INFUSION OF A LOW DOSE OF CURCUMIN IMPROVES NERVE REGENERATION AND FUNCTIONAL RECOVERY IN RATS SUBMITTED TO SCIATIC NERVE CRUSH INJURY

Martial Caillaud
(1) CAILLAUD M, (1,2) RICHARD L, (1) VIGNAUD L, (1,2) VALLAT JM, (1) DESMOULIERE A, (1) BILLET F. (1) EA 6309 - Myelin Maintenance & Peripheral Neuropathies, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France; (2) Department of Neurology, Reference Center for Rare Peripheral Neuropathies, University Hospital of Limoges, Limoges, France.
P4_16  MECHANOSENSING AT THE NANOSCALE: THE INFLUENCE OF THERMOPLASTIC NANOSTRUCTURES ON NEURAL CELLS.

Cecilia Masciullo
(1) Masciullo Cecilia, (1,2)Tonazzini Ilaria, (3) Dell’Anna Rossana, (4) Sonato Agnese, (5) Böttger Roman, (3) Pepponi Giancarlo, (4) Romanato Filippo, (1) Cecchini Marco.(1) NEST, Scuola Normale Superiore and Istituto Nanoscienze-CNR, Piazza San Silvestro 12, 56127 Pisa, Italy; (2) Fondazione Umberto Veronesi; Piazza Velasca 5, Milano, Italy; (3) Fondazione Bruno Kessler, Centre for Materials and Microsystems, Micro Nano Facility, Via Sommarive 18, 38123 Trento, Italy; (4) Laboratorio Nazionale IOM-CNR, Edificio MM, S.S. 14, km 163.5 in Area Science Park, Basovizza, Italy; (5) Helmholtz-Zentrum Dresden-Rossendorf, Institute of Ion Beam Physics and Materials Research, Bautzner Landstraße 400, 01328 Dresden, Germany.

P4_17  VOLUNTARY EXERCISE MODULATES MACROPHAGE POLARIZATION FOLLOWING SCIATIC NERVE INJURY AND IMPROVES FUNCTIONAL RECOVERY IN MICE

Megan Jack
Jack MM1, Wright DE1. 1The University of Kansas Medical Center, Kansas City, USA.

P4_18  RESTORATION OF NEUROMUSCULAR FUNCTION IN A MOUSE MODEL OF CHARCOT-MARIE-TOOTH TYPE 1A BY DIFFERENTIATED HUMAN TONSIL-DERIVED MESENCHYMAL STEM CELLS

Sung-Chul Jung
(1) Jung SC, (1) Park S, (1) Choi Y, (2) Kwak G, (2) Hong YB, (1) Jung N, (3) Chung KW, (2) Choi BO (1) Ewha Womans University, Seoul, Republic of Korea; (2) Sungkyunkwan University, Seoul, Korea; (3) Kongju National University, Gungju, Republic of Korea.

P4_19  IN VITRO MORPHOLOGICAL STUDY OF BORTEZOMIB-INDUCED PERIPHERAL NEUROTOXICITY

Alessio Malacrida
(1) Rodriguez-Menendez V, (1) Ballarini E, (1,2) Malacrida A, (1) Ceresa C, (1,2) Semperboni S, (1) Meregalli C, (1), Cavaletti G, (1) Nicolini G. (1) School of Medicine and Surgery, Experimental Neurology Unit, University of Milano-Bicocca, Monza, Italy; (2) PhD program in Neuroscience, University of Milano-Bicocca, Monza, Italy.

P4_20  TRPV1 ACTIVATION BY CAPSAICIN ENHANCES THE REGENERATION OF SENSORY NEURONS

Trevor Poitras
Poitras T, Chandrasekhar A, McCoy L, Webber C, Zochodne DW. Institute of Neuroscience, Mental Health and Addiction, Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2R3.

P4_21  FASCICULAR NERVE STIMULATION AND RECORDING USING A NOVEL DOUBLE-AISLE REGENERATIVE ELECTRODE

Jaume del Valle
Del Valle J1,2, Delgado-Martínez I1, Righi M3, Santos D1,2, Cutrone A3, Bossi S4, D’Amico S3, Micera S3,5, Navarro X1,2. 1Institute of Neurosciences, Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain; 2Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Bellaterra, Spain; 3The Biorobotics Institute, Scuola Superiore Sant’Anna, Viale Rinaldo Piaggio 34, Pontedera (PI), Italy; 4Robotics Laboratory, ENEA, Casaccia Research Center, Via Anguillaresi 301, Roma, Italy; 5Bertarelli Chair in Translational NeuroEngineering, Center for Neuroprosthetics, and Institute of Bioengineering, School of Engineering, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland.
P4_22  INTRAVENOUS IMMUNOGLOBULIN THERAPY FOR CHRONIC INFLAMMATORY Demyelinating Polyneuropathy in Pediatric Patients: An Observational Study

Alphonse Hubsch

(1) Watson DJ, (2) Martinez C, (2) Wallenhorst C, (3) Hubsch A, (4) Shebl A, (1) Simon TL, (1) CSL Behring LLC, King of Prussia, USA; (2) Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany; (3) CSL Behring AG, Bern, Switzerland; (4) CSL Behring GmbH, Marburg, Germany.

P4_23  Malignancy in Guillain-Barre Syndrome: A Twelve-Year Single-Center Study

Fu Liong Hiew

(1) Fu Liong Hiew, (2) Yusuf A. Rajabally (1) Regional Neuromuscular Clinic, Queen Elizabeth Hospital, University Hospitals of Birmingham, Birmingham, United Kingdom; (2) School of Life and Health Sciences, Aston Brain Centre, Aston University, Birmingham, United Kingdom

P4_24  The Francophone Anti-MAG Cohort: Lessons Learned from the Analysis of 202 Patients

Jean-Philippe Camdessanche


The Francophone anti-MAG cohort Group: Other members of the Francophone anti-MAG cohort Group who provided cases for the study are, in alphabetical order: David Adams, Hôpital Bicêtre; Sharam Attarian, CHU de Marseille; Anne-Laure Bedat-Millet, CHU de Rouen; Françoise Bouhour, CHU de Lyon; Célia Boutte, CHU de Grenoble; Guy Chauplannaz, CHU de Lyon; Raquel Costa, Hôpital Pitié-Salpêtrière; Perrine Devic, CHU de Lyon; Chantal Grand, CHU de Lyon; Guillaume Joubert, CHU de Lyon; Timothée Lenglet, Hôpital Pitié-Salpêtrière; Pierre Lozeron, Hôpital Bicêtre; Thierry Maisonobe, Hôpital Pitié-Salpêtrière; Cristina Muntean, Hôpital Pitié-Salpêtrière; Yann Pereon, CHU de Nantes; Jean Pouget, CHU de Marseille.
P4_25
DISRUPTION OF BLOOD-NERVE BARRIER AT ENTRAPMENT SITES RATHER THAN NERVE ENDINGS IS THE LIKELY CAUSE OF SURAL-SPARING PATTERN IN GUILLAIN-BARRE SYNDROME

Yong Jian Cheng
(1) Cheng YJ, (1) Teng A, (1) Goh EJH, (2) T. Umapathi. (1) Yong Loo Lin School of Medicine, National University of Singapore, Singapore; (2) Department of Neurology, National Neuroscience Institute, Singapore.

P4_26
CILOSTAZOL MODULATES SEQUENTIAL EXPRESSION OF MATRIX METALLOPROTEINASES AND THEIR INTRINSIC INHIBITOR WITHIN PERIPHERAL NERVOUS TISSUE DURING EXPERIMENTAL AUTOIMMUNE NEURITIS

Toshiki Fujioka
Hagiwara W, Konno S, Kihara, Inoue M, Fujioka T. Toho University, Tokyo, Japan

P4_27
LIFESTYLE AND DIETARY HABITS AS PREDISPOSING FACTORS FOR THE ONSET AND PROGRESSION OF CIDP: A CASE-CONTROL STUDY FROM THE ITALIAN CIDP DATABASE

Pietro Emiliano Doneddu
Doneddu PE(1), Cocito D(2), Santoro L(3), Fazio R(4), Filosto M(5), Mazzeo A(6), Jann S(7), Cortese A(8), Beghi E (9), Carpo M(10), Clerici M(11), Luigetti M(12), Lauria G(13), Fierro B(14), Antonini G(15), Briani C(16), Cavaletti G(17), Rosso T(18), Benedetti L(19), Martia G(20), Liberatore G(1), Peci E(2), Manganelli F(3), Velardo D(4), Todeschini A(5), Toscano A(6), Verrengia EP(7), Piccolo L(8), Nobile-Orazio E(1)(1)Milan University, IRCCS Humanitas Clinical and Research Center, Milan, Italy; (2)Città della Salute e della Scienza Hospital, Torino, Italy; (3)Università degli Studi di Napoli "Federico II", Napoli, Italy; (4)IRCCS San Raffaele Hospital, Milan, Italy; (5) University of Brescia, Spedali Civili Hospital, Brescia, Italy; (6)Azienda Ospedaliera Universitaria "G. Martino," Messina, Italy; (7)Niguarda Ca Granda Hospital, Milan, Italy; (8)IRCCS Fondazione Mondino, Pavia, Italy; (9) IRCCS Mario Negri Institute, Milan,(10)Treviglio Hospital, Treviglio, Italy; (11)Fondazione Macchi Hospital, Varese, ITA; (12)Università Cattolica del Sacro Cuore, Roma, Italy; (13)IRCCS Carlo Besta Neurological Institute, Milan, Italy; (14)Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy; (15)Sant'Andrea Hospital, University of Rome, Rome, Italy; (16)Università di Padova, Padova, Italy (17)Milano Bicocca University, Monza, Italy; (18)Azienda UL.SS. 8 Asolo, Castelfranco Veneto, Italy; (19)Ospedale Sant'Andrea, La Spezia, Italy; (20) Policlinico Tor Vergata, Roma, Italy;

P4_28
MRI BIOMARKERS TO ASSESS PROXIMAL NERVE INJURY IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)

Alina Sprenger
Sprenger A(1), Lichtenstein T(2), Henning T(2), Lehmann HC(3). (1)Department of Neurology, University Hospital of Cologne, Germany; (2)Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Germany; (3) Department of Neurology, University Hospital of Cologne, Germany

P4_29
THROMBOEMBOLIC EVENTS IN INFLAMMATORY NEUROPATHY PATIENTS ON IVIG

Aisling Carr

P4_30
CAN NK CELLS HELP DISCRIMINATE IVIG TREATMENT RESPONSE IN PATIENTS WITH CIDP?

Anne K. Mausberg
(1) Mausberg AK, (2) Heininger MK, (3) Meyer zu Horste G, (4) Cordes S, (1) Kleinschnitz C, (2) Kieseier BC, (1) Stettner M. (1) Department of Neurology, University Hospital Essen, Essen, Germany; (2) Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany; (3) Department of Neurology, University of Münster, Münster, Germany; (4) Department of Hematology, Oncology & Tumor Immunology, Charite Berlin, Berlin, Germany
P4_31  THE FOREARM/UPPER ARM RATIOS OF CROSS-SECTIONAL AREA ADD THE DIAGNOSTIC VALUE IN AMYOTROPHIC LATERAL SCLEROSIS

Yu-ichi Noto
(1) Noto Y, (1) Garg N, (1) Tiffany Li (1), Hannah Timmins (1), Susanna B. Park (1), Shibuya K, (1) Kiernan M. (1)
Brain and Mind Centre, The University of Sydney, Sydney, Australia.

P4_32  HEREDITARY OR INFLAMMATORY CHILDHOOD NEUROPATHY – ELECTROPHYSIOLOGICAL ABNORMALITIES HELPFUL IN THE DIFFERENTIATION

Anna Potulska-Chromik
(2) Neuromuscular Unit, Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland

P4_33  ULTRA HIGH FREQUENCY ULTRASOUND (UHFUS) NERVE IMAGING IN CIDP PATIENTS

Angela Puma
Puma A1, Cambieri C1,2, Panicucci E1, Desnuelle C1, Raffaelli C3 and Sacconi S1 1 Université de Nice et de la Côte d’Azur (UCA), Peripheral Nervous System, Muscle & ALS Department, Pasteur 2 Hospital, Nice, France 2 Department of Neurology and Psychiatry, «Sapienza» University of Rome, Rome, Italy 3 Department of Radiology, Pasteur 2 Hospital, Nice, France

P4_34  DIFFERENT AXONAL DYSFUNCTION PATTERN IN SEROPOSITIVE AND SERONEGATIVE SJÖGREN’S SYNDROME

Jowy Tani
(1) Department of Neurology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; (2) Ph.D. Program for Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes; (3) Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; (4) Division of Allergy, Immunology and Rheumatology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; (5) Translational Neuroscience, Department of Physiology, School of Medicine Science, Faculty of Medicine, University of New South Wales, Sydney, Australia; (6) Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

P4_35  SUBCUTANEOUS IMMUNOGLOBULIN IN CIDP: A TWO-YEAR EXPERIENCE

Antonietta Topa

P4_36  Ca(2+)-DEPENDENT ANTI-GANGLIOSIDE ANTIBODY IN SERONEGATIVE GUILLAIN-BARRÉ SYNDROME.

Ayumi Uchibori
Uchibori A, Gyohda A, Chiba A
PARANODAL ANTIBODIES IN AUSTRIAN PATIENTS WITH ACUTE ONSET INFLAMMATORY NEUROPATHY

Desiree De Simoni
De Simoni D1,2, Hagen H1, Löschter W1, Lindeck-Pozza E4, Breu M2,5, Lang J2, Varga T1, Rath J3, Zimprich F2, Höftberger R2, Wanschitz J1. 1Department of Neurology, Medical University of Innsbruck, Austria; 2Institute of Neurology, Medical University of Vienna, Austria; 3Department of Neurology, Medical University of Vienna, Austria; 4Department of Neurology SMZ Süd, Vienna, Austria; 5Department of Pediatric and Adolescent Medicine, Medical University of Vienna, Austria

ACUTE-ONSET OF CIDP WITH IGG4 ANTI-NF155 ANTIBODIES RESISTANT TO CONVENTIONAL THERAPIES AND RESPONSIVE TO RITUXIMAB

Chiara Demichelis
(1) Demichelis C, (1) Garnero M, (2) Franciotta D, (2) Cortese A, (2) Callegari I, (1) Mancardi GL, (1) Schenone A, (3) Leonard R, (1) Benedetti L (1) Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova and IRCCS AOU San Martino-IST, Genova, Italy (2) Laboratory of Neuroimmunology, IRCCS, "C. Mondino" National Neurological Institute, University of Pavia, Pavia, Italy (3) U.O. Neurology, ASL1 Imperiese, Imperia, Italy

TWO CASES OF IVIG RESPONSIVE INFANTILE ONSET AXONAL POLYNEUROPATHY

Ozgur Duman
(1) Duman O, (1) Saracoglu M, (1) Haspolat S, (1) Bozkurt O.

GLOBAL TRANSCRIPTOME ANALYSES REVEAL A KEY ROLE FOR MORC2 IN THE AXONAL METABOLISM

Paula Sancho
Sancho P1,2, Lupo V1,2,3, García-García F4, Ramírez-Jiménez L3, Sevilla T5,6, Chrust R7, Espínós C1,2,3. 1Unit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain; 2INCLIVA & IIS La Fe Rare Diseases Joint Units, Valencia, Spain; 3Department of Genomics and Translational Genetics, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain. 4Computational Genomics Department, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain. 5Department of Neurology, Hospital Universitari i Politécnic La Fe, Valencia, Spain. 6CIBER of Rare Diseases (CIBERER), Spain. 7Department of Neurosciences, Karolinska Institutet, Stockholm, Sweden.

CMT1A PATIENTS GET OLD WORSE THAN HEALTHY PEOPLE

Stefano Tozza

PXT3003, A FIXED COMBINATION OF BACLOFEN, NALTREXONE AND SORBITOL, FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE TYPE 1A (CMT1A): STATUS OF A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PIVOTAL PHASE III STUDY (PLEO-CMT)

Peter Young
(1) Attarian S, (2) Sevilla T, (3) Van Damme P, (4) De Visser M, (5) Thomas FP (6) Roberts M, (7) Young P. For the PLEO-CMT Study Group (1) University Hospital La Timone, Marseille, France; (2) Hospital Universitari i Politècnic La Fe, Valencia, Spain; (3) University Hospital, Leuven, Belgium; (4) Academic Medical Centre, Amsterdam, The Netherlands; (5) Hackensack University Medical Center, Hackensack, USA; (6) Salford Royal NHS Foundation Trust, Manchester, UK; (7) University Hospital, Munster, Germany
P4_43 WILD-TYPE TRANSTHYRETIN AMYLOIDOSIS (ATTR-WT) AND PERIPHERAL NEUROPATHY
34892 Merrill D. Benson
(1,2) Benson MD, (1) Kluve-Beckerman B, (3) Dasgupta NR. (1) Indiana University School of Medicine, Department of Pathology and Laboratory Medicine, Indianapolis, Indiana, USA

P4_44 PILOT STUDY OF CLINICAL SEVERITY SCORE FOR HEREDITARY NEUROPATHY WITH LIABILITY TO PRESSURE PALSIES
35043 Vera Fridman
(1) Fridman V, (2) Skorupinska M, (2) Laura M, (1) Sillau S, (3) Shy ME, (2) Reilly M M. (1) University of Colorado Hospital, Aurora, CO, USA, (2) MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, UK, (3) University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

P4_45 IDENTIFICATION OF COMMON MOLECULAR PLAYERS INVOLVED IN THE PROGNOSIS AND PATHOGENESIS OF AXONAL CMT SUBTYPES
35176 Manisha Juneja
(1) Juneja M, (2) Azmi A, (3) Emmerson I, (3) Bansagi B, (4) Saveri P, (4) Pisciotta C, (2) Maudsley S, (3) Horvath R, (4) Pareyson D, (1) Timmerman V. (1) Peripheral Neuropathy Research Group, University of Antwerp, Belgium; (2) Translational Neurobiology Group, VIB and University of Antwerp, Belgium; (3) Institute of Genetic Medicine, Newcastle University, United Kingdom. (4) Department of Clinical Neurosciences, C. Besta Neurological Institute, Milan, Italy.

P4_46 NATURAL HISTORY STUDY IN HEREDITARY SENSORY NEUROPATHY TYPE 1 (HSN1): IMPROVING THE RESPONSIVENESS OF OUTCOME MEASURES
34741 Umaiyal Kugathasan
Kugathasan U1, Evans M1,2 , Laurá M1, Sinclair C1,2, Homemann T3, Suriyanarayanan S3, Phadke R4, Miller K4, Lauria G5, Lombardi R5, Polke J6, Bennett D7 , Houliden H1, Blake J8 and Reilly MM1 . 1MRC Centre for Neuromuscular Diseases, London, UK; 2Academic Neuroradiological Unit, UCL Institute of Neurology, UK; 3Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; 4Division of Neuropathology, National Hospital for Neurology and Neurosurgery, London, UK; 5IRCCS Foundation “Carlo Besta” Neurological Institute, Milan, Italy; 6Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London, UK; 7Nuffield Department of Clinical Neurosciences, Oxford, UK ; 8Department of Clinical Neurophysiology, Norfolk and Norwich University Hospital, UK

P4_47 ABSENCE OF NEUROFILAMENT LIGHT CHAIN IN PATIENT-SPECIFIC MOTOR NEURONS IN AUTOSOMAL RECESSIVE CHARCOT-MARIE-TOOTH DISEASE
34763 Markus Sainio
Sainio M.T1, Ylikallio E1,2, Auranen M1,2, Palmio J3, Tynynmaa H1 1Reseach Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland; 2Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; 3Neuromuscular Research Center, University of Tampere and Tampere University Hospital, Tampere, Finland
MODELING THE PATHOGENESIS OF CHARCOT-MARIE-TOOTH DISEASE TYPE 1A USING PATIENT-SPECIFIC IPSCs

Lei Shi
Lei Shi1, 2, 6, Ruojie He1, 6, Lihua Huang3, 6, Minying Zheng1, Xilin Lu1, Zhong Pei1, Huanxing Su4, Weijun Huang3, Qiong Ke3, Xingqiang Lai3, Andy Peng Xiang3, 5, Weiqiang Li3, 5, Xiaoli Yao1
1 Department of Neurology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
2 Division of Neurosurgical Intensive Care Unit, Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
3 Center for Stem Cell Biology and Tissue Engineering, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-Sen University, Guangzhou, China.
4 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
5 Department of Biochemistry, Zhongshan Medical School, Sun Yat-sen University, Guangzhou, China.
6 These authors made equal contributions to this work.

MITOCHONDRIAL DYSFUNCTION AND ABNORMAL CALCIUM HANDLING IN CELLULAR MODELS OF HEREDITARY SENSORY NEUROPATHY TYPE 1

Emma Wilson
Wilson ER (1,2), Kalmar B (1), Kugathasan U (1,2), Clark AJ (4), Bennett DLH (4), Abramov AY (3), Reilly MM (2), Greensmith L (1,2) 1 Sobell Department of Motor Neuroscience and Movement Disorders, 2 MRC Centre for Neuromuscular Diseases, 3 Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, United Kingdom, 4 Neural Injury Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom

A COMBINATION OF THREE REPURPOSED DRUGS (PXT3003) SYNERGISTICALLY INCREASES MYELINATION IN CO-CULTURES OF SCHWANN CELLS AND NEURONS DERIVED FROM CMT1A RATS.

Nathalie Cholet
Cholet N, Laffaire J, Guedj M, Murphy PN, Chumakov I, Nabirotchkin S, Hajj R, Cohen D.

RATE OF PROGRESSION IN PEDIATRIC CHARCOT-MARIE-TOOTH DISEASE

Kayla Cornett
(1) Cornett KMD, (2) Menezes MP, (3) Shy RR, (4) Moroni I, (5) Pagliano E, (6) Pareyson D, (7) Estilow T, (8) Yum SW, (9) Bhandari T, (10) Muntoni F, (11) Laura M, (12) Reilly MM, (13) Finkel RS, (14) Eichinger K, (15) Herrmann DN, (16) Bray P, (17) Halaki M, (18) Shy ME, (19) Burns J for the CMTPedS Study Group (1) Sydney Children’s Hospitals Network, University of Sydney, Sydney, Australia; (2) Paediatrics and Child Health, University of Sydney, Sydney, Australia; (3) Carver College of Medicine, Dept of Pediatrics, University of Iowa, Iowa City, USA; (4) IRCCS Foundation, Carlo Besta Neurological Institute, Milan, Italy; (5) IRCCS Foundation, Carlo Besta Neurological Institute, Milan, Italy; (6) IRCCS Foundation, Carlo Besta Neurological Institute, Milan, Italy; (7) Neuromuscular Program, The Children’s Hospital of Philadelphia, USA; (8) Division of Neurology, The Children’s Hospital of Philadelphia, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, USA; (9) UCL Institute of Child Health & Great Ormond Street Hospital, London, UK; (10) UCL Institute of Child Health & Great Ormond Street Hospital, London, UK; (11) MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, UK; (12) MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, UK; (13) Neuromuscular Program, Division of Neurology, Nemours Children’s Hospital, Orlando, USA; (14) Department of Neurology, University of Rochester, Rochester, USA; (15) Department of Neurology, University of Rochester, Rochester, USA; (16) Sydney Children’s Hospitals Network, University of Sydney, Sydney, Australia; (17) Paediatrics and Child Health, University of Sydney, Sydney, Australia; (18) Carver College of Medicine, Dept of Neurology, University of Iowa, Iowa City, USA; (19) Sydney Children’s Hospitals Network, University of Sydney, Sydney, Australia.
CHARCOT-MARIE-TOOTH DISEASE TYPE 1A: INFLUENCE OF BODY MASS INDEX ON NERVE CONDUCTION STUDIES AND ON THE CHARCOT MARIE TOOTH EXAM SCORE

Nivedita Jerath MD MS 1, Michael E. Shy MD 1 1 Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, IA

DIAGNOSTIC YIELD OF A 6,000 DISEASE-ASSOCIATED GENE FOCUSED EXOME IN CMT AND COMPLEX NEUROPATHY CASES: AN EXPLORATORY STUDY

Andrea Cortese A (1), Bugiardini E (1), Hughes D (2), Pittmann A (2), Laura M (1), Rossor AM (1), Houlden H (2), Reilly MM (1) (1) MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, Queen Square, London, UK (2) Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

BIOMARKERS OF SMALL FIBER NEUROPATHY IN AMYLOID NEUROPATHY

Sung-Tsang Hsieh
(1) Hsieh S-T, (2) Chao, C-C.

AEROBIC EXERCISE FOR SUBJECTS AFFECTED BY CHARCOT MARIE TOOTH (CMT) NEUROPATHY: RESULTS OF A MULTICENTER, PROSPECTIVE, RANDOMIZED, SINGLE BLIND, CONTROLLED CLINICAL TRIAL

Angelo Schenone
Mori L1, Francini L1, Prada V1, Signori A2, Pareyson D3, Padua L4,5, Fabrizi G5, Schenone A1. 1Department of Neurosciences, Rehabilitation, Ophthamology, Genetics, Maternal and Child Health, University of Genoa, Italy; 2Department of Health Science, Biostatistics section, University of Genoa, Italy; 3IRCCS Foundation, Carlo Besta Neurologic Institute, Milan, Italy; 4Don Carlo Gnocchi Foundation Onlus – Centro Santa Maria della Pace, Rome, Italy; 5 Catholic University of the Sacred Heart, Rome, Italy; 6GB Rossi Policlinic, Department of Neurologic and Visual Science, University of Verona, Italy

DYSREGULATED LIPID METABOLISM IN THE ABSENCE OF PERIPHERAL MYELIN PROTEIN 22 (PMP22)

Lucia Notterpek
(1) Zhou Y, (2) Tavori H, (1) Lee S, (1) Al Salih M, (2) Fazio S, (1) Notterpek L. McKnight Brain Institute, University of Florida, Gainesville, Florida, USA; (2) Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon, USA.

INVESTIGATION OF SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS AS A TREATMENT FOR CHARCOT-MARIE-TOOTH DISEASE TYPE 1A USING A CO-CULTURE SYSTEM.

Robert Prior
Prior R, Benoy V, Vanden Berghe P, and Van Den Bosch L.

THE COMBINATIONAL DRUG PXT3003 IMPROVES NEUROMUSCULAR FUNCTION IN AN ANIMAL MODEL OF CHARCOT-MARIE-TOOTH DISEASE TYPE 1A DISEASE

Thomas Prukop
Prukop T1,2,4, Wernick S1, Adam J1, Zschüntzsch J5, Schmidt J5, Brureau A3, Fouquier J3, Guedj M3, Cholet N3, Nave KA1, Nabirotchkin S3, Hajj R3, Cohen D3 and Sereda MW1,4. 1Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany; 2University Medical Center Göttingen, Institute of Clinical Pharmacology, Göttingen, Germany; 3Pharnext, Issy-Les-Moulineaux, France; 4University Medical Center Göttingen, Department of Clinical Neuropsychology, Göttingen, Germany.5University Medical Center Göttingen, Department of Neurology, Göttingen, Germany.
P4_59  A GENE THERAPY APPROACH FOR TREATING CMT4C NEUROPATHY
35211  Natasa Schiza
Schiza N1, Markoullis K1, Richter J2, Tryfonos C2, Kagiava A1, Sargiannidou I1, Christodoulou C2, Kleopa KA1,3
1Neuroscience Laboratory, 2Department of Molecular Virology, and 3Neurology Clinics, Cyprus Institute of
Neurology and Genetics and Cyprus School of Molecular Medicine, Nicosia, Cyprus.

P4_60  A COMPLEX HOMOZYGOUS MUTATION IN ABHD12 RESPONSIBLE FOR PHARC SYNDROME
34239  Anne-Sophie Lia
(1) Lerat J, (2) Cintas P, (1,3) Dzugan H, (1,3) Magdelaine C, (1,3) Sturtz F, (1,3) Lia AS. (1) Service de Biochimie
et Génétique Moléculaire - CHU de Limoges, Limoges, France ; (2) Service de Neurologie et d’explorations
fonctionnelles - CHU de Toulouse, Toulouse, France ; (3) EA6309 - Université de Limoges, Limoges, France

P4_61  GAIT PATTERNS OF CHILDREN WITH CMT TO INFORM THE DESIGN OF 3D PRINTED
34920  Orthoses
Elizabeth Wojciechowski
(1,2) Wojciechowski E, (1,2) Little D, (1,2) Menezes MP, (2) Hogan S, (1,2) Burns J. (1) University of Sydney, New
South Wales, Australia; (2) Sydney Children’s Hospital Network (Randwick and Westmead), New South Wales,
Australia.

P4_62  DO ORTHOSES IMPROVE GAIT IN CHILDREN AND ADOLESCENTS WITH CHARCOT-MARIE-
31142  TOOTH?
Sylvia Ounpuu
1, 2) Ounpuu S, (1) Pogemiller K, (1, 2, 3) Pierz K, and (2, 4) Acsadi G. (1) Center for Motion Analysis, Connecticut
Children’s Medical Center, Farmington, CT, USA, (2) School of Medicine, University of Connecticut, Farmington,
CT, USA, (3) Division of Orthopaedics, Connecticut Children’s Medical Center, Farmington, CT, USA, (4) Division
of Neurology, Connecticut Children’s Medical Center, Farmington, CT, USA.

P4_63  A PATIENT WITH ATAXIA WITH OCULOMOTOR APRAXIA TYPE 1 AND SLOW CONDUCTION
35119  VELOCITIES
Pedro Jose Tomaselli
Tomaselli PJ (1), Lourenço CM (1), Cintra VP (2), Barreira AA (1), Marques W Jr (1, 2, 3) (1) Division of
Neuromuscular Diseases, Department of Neurosciences and Behaviour Sciences, Clinical Hospital of Ribeirão
Preto, University of São Paulo, Ribeirão Preto, Brazil. (2) Neurogenetics, Department of Neurosciences and
Behaviour Sciences, University of São Paulo, Ribeirão Preto, Brazil.

P4_64  EMG PATTERNS IN FAMILIAL AMYLOIDOTIC POLINEUROPATHY (FAP) DUE TO TTR MUTATIONS
35287  Wilson Marques Júnior
Lavigne-Moreira C1, Oliveira M F1, Marques V D1, Onofre P T B N1, Dos Santos A C J1, Nascimento O J M2,
Barreira A A1, Marques W Jr1. 1Division of Neuromuscular Diseases and Neurogenetics, Department of
Neurosciences and Behaviour Sciences, Clinical Hospital of Ribeirão Preto, University of São Paulo, Ribeirão
Preto, Brazil; 2Department of Neurology, Fluminense Federal University, Rio de Janeiro, Brazil.
TRANSTHYRETIN-RELATED FAMILIAL AMYLOID POLYNEUROPATHY IN POLAND- GENOTYPIC AND CLINICAL PRESENTATION

Marta Lipowska
Lipowska M (1), Drac H (1), Rowczenio D (2), Gilbertson J (2), Philip N Hawkins PN (2), Ptasińska-Perkowska A (3), Lasek-Ball A (4), Brydak-Godowska J (5), Chandoga J (6), Kostera-Pruszczyk A (1). (1)Department of Neurology, Medical University of Warsaw, Poland, (2) National Amyloidosis Centre, University College London, Rowland Hill Street, London, UK, (3) Transplantation Institute, Medical University of Warsaw, Poland, (4) Department of Neurology, Medical University of Silesia, Katowice, Poland; (5) Department of Ophthalmology, Medical University of Warsaw, Poland; (6) Centrum Lekarskej Genetiky, Bratislava, Slovakia

A NEW AUTOSOMAL RECESSIVE AMYELINATING CAUSE OF CHARCOT MARIE TOOTH DISEASE WITH CNS FEATURES AND RESPIRATORY DISTRESS

Carly Siskind
Siskind CE, Tesi Rocha C. (1) Stanford Health Care, Palo Alto, CA, USA; (2) Stanford University, Stanford, CA, USA.

ATYPICAL CASE OF ACUTE MOTOR SENSORY AXONAL NEUROPATHY (AMSAN) AT HIV-POSITIVE YOUNG WOMAN

Tayla Romão
Romão T, Lima B, Wedemann D, Nogueira F, Prado H, Cal H, Nascimento O, Pupe C. (1, 2, 3, 4, 5, 6, 7) Universidade Federal Fluminense (UFF), Niterói, Rio de Janeiro, Brazil

CONUCTION BLOCK OF LEWIS-SUMNER SYNDROME AND MULTIPLE MOTOR NEURON DISEASE IN CHINA

Li Yi
Li Yi, Mingsheng Liu. Department of Neurology, Peking Union Medical College Hospital, Beijing, China; Chinese Academy of Medical Sciences, Beijing, China

CHALLENGES IN NEUROLOGICAL PRACTICE IN LAO P.D.R

Keovilayhong Southanalinh
Southanalinh K, University of Health Sciences, Vientiane capital, Lao P.D.R.